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SCOPE OF THE THESIS 
This thesis focuses on NE differentiation in prostate cancer, especially in 
prostate cancer models. We studied the effects of androgen depletion on the NE 
differentiated status of in vivo and in vitro prostatic tumor models. Knowledge 
concerning the function of NE cells in the normal human prostate and in prostate cancer 
is limited. A number of groups have studied NE differentiation in different epithelial 
systems. NE cells were found to be present in most prostatic adenocarcinomas (Oi-
Sant'Agnese, 1994). There is accumulating evidence that NE cells and tumors with NE 
cells are related to the androgen independent and poorly differentiated types of prostate 
cancer. There are indications that at least some secretion products of prostatic NE cells, 
like GRP and 5-HT, affect both prostate cancer growth and possibly also tumor 
differentiation. However, the growth modulating effects of neuropeptides and their relation 
to circulating androgen levels and androgen sensitivity of prostate cancer need to be 
further assessed. Studies directed towards identifying the role of NE cells in hormonally 
treated prostate cancer may contribute to the understanding of the transition of androgen 
dependent to androgen independent prostate cancer. There are still unanswered 
questions that need to be answered: How is the process of neuroendocrine 
differentiation regulated and can this process be influenced? Are the NE cells 
necessary for the regulation of growth and differentiation of the prostate or do they play 
a role in the maintenance of prostatic homeostasis? Can these cells induce (androgen 
independent) growth of surrounding cells, for instance by ligand independent activation 
of the androgen receptor (AR) through neuropeptides secreted by NE cells? 
The role of NE cells in the progression to androgen independent growth is still 
unclear and there are not many representative prostate cancer models with NE 
differentiation. Several groups have been developing prostate tumor models both in 
vitro cell lines (Romijn, 1996) and in vivo xenografts, like CWR-22 (Nagabhushan, 
1996), LuCap (Liu, 1996) and the PC model systems developed at our instituton (van 
Weerden, 1996). The generally available prostate cancer cell lines, LNCaP, OU-145, 
PC-3 and TSU-Pr1 lack the potency to differentiate into NE cells. NE differentiation was 
studied in the panel of in vivo human prostate cancer xenografts available at our 
Institution. The androgen dependent PC-295 and PC-310 models constitutively have 
the NE phenotype and these models regress after androgen deprivation. Therefore, 
they are very suitable for studying the process of NE differentiation in prostate cancer 
and the role that NE cells may play in progression of prostate cancer. In both the PC-
295 and PC-310 models, androgen deprivation induces an increase of the numbers of 
NE cells. The kinetics of NE differentiation was intensively studied after short-term 
hormone deprivation in both the PC-295 (Chapter 2) and the PC-310 model (Chapter 
4). The process of NE differentiation of androgen dependent cells to NE cells and the 
consecutive maturation of these NE cells after long-term hormone deprivation in the 
PC-310 model are described in Chapter 5. In these studies, CgA, AR, PSA and MIB-1 
were used as cellular differentiation and proliferation markers, with Sglll, PC-1, PAM 
and 7B2 as alternative NE markers associated with the regulated secretory pathway 
(RSP). In addition, the expression of different growth factors like 5-HT, GRP, VIP and 
VEGF were analyzed before and after androgen deprivation. 
The production of a variety of secretory products of NE differentiated cells, such 
as GRP, CT, VIP, NGF, parathyroid hormone-related protein (PTHrP), neurotensin 
(NT), IGF-1, may result in paracrine and/or autocrine interactions between the NE and 
non-NE epithelial cells and the stromal cells in prostate cancer. Therapies that 
antagonize effects of autocrine or paracrine stimulations of tumor cell growth are 
currently being developed for small cell lung cancer patients. Such an approach may 
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also be relevant for the treatment of hormone refractory prostate cancer. A detailed 
study of the in vitro growth modulating effects of neuropeptides on four prostate cancer 
cell lines is described in Chapter 3, together with the development of an androgen 
independent subline of LNCaP cell line which shows an autocrine growth pattern after 
long-term androgen deprivation. 
In Chapter 6, data are presented of clinical and experimental studies on the 
expression of pro-adrenomedullin N-terminal peptide (PAMP) and peptidyl-alpha 
amidating-mono-oxygenase (PAM) in prostate cancer. The expression patterns of these 
NE factors were correlated to patient tumor grade and clinical progression. The 
expression levels after induction by long-term hormone deprivation were studied in the 
human prostate cancer xenograft model PC-310. 
In the general discussion (Chapter 7), the initial working hypothesis is evaluated 
that NE cells in a prostatic adenocarcinoma form a subset of primarily androgen 
independent cells which modulate the growth of neighbouring non-NE tumor cells by the 
secretion of neuropeptides. This hypothesis will be tested on the basis of our present 
data on NE differentiation in experimental hormone deprived prostate cancer. Recent 
publications by others as well as the current rate of developing hormone refractory 
prostate cancer were included. Finally, new directions and perspectives for future 
research in the field of NE differentiation and prostate cancer progression are 
presented. 

CHAPTER 1 
INTRODUCTION 
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1.1 The prostate 
The normal prostate surrounds the proximal part of the human male urethra just 
below the urinary bladder and functions as a male accessory exocrine sex gland. The 
prostate is composed of an epilhelial and a stromal part which together form branching 
secretory tubules and acini. The prostate secretes its producls into the urethra. 
Prostatic development depends on an interaclion between epithelial cells and the 
stroma in the presence of androgens (Cunha, 1994; Lee, 1996; Kooistra, 
1997).Testosterone is the major circulating androgen, whereas its metabolite 
dihydrotestosteron (DHT) regulates prostatic growth and function and the production of 
seminal plasma. The withdrawal of androgens reduces the expression of prostate-
specific genes and induces programmed cell death in exocrine cells which results in a 
decrease of prostate volume. The human male testes are not the only source of 
androgens, as the human adrenal glands produce low amounts of androgen precursors 
like dehydroepiandrosterone (DHEA). Less than 1 % of male testosterone levels are 
derived from these adrenal androgens. The complex process of prostate growth 
regulation is not yet sufficiently understood. In the prostate several abnormalities are 
found, including benign prostatic hyperplasia (BPH) and prostatitis as benign prostatic 
diseases, whereas adenocarcinoma of the prostate, small cell prostatic carcinoma 
(SCPG), and the very rare prostatic carcinoid are malignant diseases. 
1.2 Prostate cancer 
1.2.1 Epidemiology and pathogenesis 
In the western world, prostate cancer is the most commonly diagnosed malignant 
tumor and the second cause of cancer deaths in males (Schroder, 1995; Pienta, 1996; 
Schroder, 1996). The percentage of patients presenting with locally advanced or 
metastatic disease is still high, despite recent improvements in early diagnosis (Pienta, 
1996; Hankey, 1999; Masuda, 1999). Refinements of diagnostic tools, such as plasma 
prostate specific antigen (PSA), and an increased number of screening protocols has 
lead to high increases in identification of prostate cancer in the early ninetees. This 
increase has levelled of to a still high number of new cases identified each year due to 
the use of PSA as diagnostic marker in an aging population. When prostate cancer is 
diagnosed earlier, the type of cancer is less advanced and is associated with belter 
prognosis and survival rates for the patients. 
According to Pienta et al , both molecular and environmental factors influence 
the course of each individual prostatic tumor. Genetic instability of prostatic tissues can 
be induced at higher age, through race differences and by differences in diet. Fat 
content, intake of vitamin A (Aboseif, 1997; Pienta, 1997; Olson, 1998; Smith, 1998) or 
Iycopene, family history of cancer, and hormone levels (testosterone, DHT) have been 
identified to be related with prostate cancer oncogenesis (Montie, 1994; Pienta, 1996). 
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1.2.2 Diagnosis and prognostic markers 
The early detection of prostate cancer is of high relevance for implementing 
curative therapeutical options. Given the variable biological behaviour of prostate 
cancer it has become pertinent to identify those cancers which can be potentially cured 
by radical surgery or radiotherapy. For this purpose diagnostic and prognostic markers 
are necessary as different combinations of tumor markers may better predict the final 
outcome of therapy for the patient (Gao, 1997) .. Relevant prognostic markers are 
considered clinically of significance when tested statistically significant in both univariate 
and multivariate analysis (Noordzij, thesis). 
Nowadays, different grading systems are available of which the Gleason grading 
system is most commonly used as the prognostic marker for prostate cancer (Gleason, 
1966; Gleason, 1992). Gleason grading is based on the main histological features of a 
tumor. There are five Gleason growth patterns ranging from poorly differentiated 
prostatic acini to undifferentiated, irregular and scattered growth of prostatic tumor cells. 
Most often, the Gleason Sum Score is used as prognostic marker, being the sum of the 
two most observed Gleason growth patterns. Other conventional prognostic markers 
are pathological stage and tumor volume (Epstein, 1993). The most commonly used 
diagnostic marker is PSA, and the most commonly used secondary tools are digital 
rectal examination (ORE) and transrectal ultrasonography (TRUS) (Gao, 1997; Gau, 
1997; Polito, 1997). PSA has particular prognostic value as a follow-up marker, and 
together with ORE it is used for large screening protocols. Recently, several other tissue 
markers have been studied in prostate cancer. The Ki-67 -based proliferative index 
(Bonkhoff, 1991; Bonkhoff, 1994b; Noordzij, 1995b; Glynne-Jones, 1996; Kyprianou, 
1996; Bubendorf, 1998; Stapleton, 1998) in combination with i) apoptotic index, ii) tumor 
suppressor gene p53, iii) the relation with members of the anti-apoptotic bcl-2 family 
(Segal, 1994; Bubendorf, 1996; Krajewska, 1996; Bonkhoff, 1998) and iv) AR status 
(Bonkhoff, 1998) has been shown to be of prognostic significance to some extent for 
clinical progression of the disease. Molecular markers for prostate cancer metastasis 
are extensively studied like the cell adhesion molecules CD44 (Noordzij, 1997; Noordzij, 
1999), E-cadherin (Umbas, 1992; Bussemakers, 1996) located on chromosome 11p 
and KAI1 on chromosome 16q (Cheng, 1996; Pienta, 1996; Dong, 1997; Isaacs, 1997). 
The PTEN/MMAC1 tumor suppressor gene, located on chromosome 10, is of particular 
interest, because it is frequently lost in prostate cancer (lttmann, 1996; Murakami, 1996; 
Vlietstra, 1998; Whang, 1998). 
Other prognostic markers of which the relevance has not been assessed 
definitely could be the expression of epidermal growth factor receptor and its ligands 
(Glynne-Jones, 1996), altered expression of nuclear proteins like pp32 or NF-KP (Keller, 
1996; Epstein, 1997; Kadkol, 1998) and cell differentiation markers like prostate stem 
cell antigen (PSCA) (Isaacs, 1989; Mason, 1997; De Marzo, 1998; Reiter, 1998) and 
the cell cyle arrest marker, p27k;P1 (Yang, 1998). Chromogranin A, the marker for 
neuroendocrine differentiated cells has also been studied as a possible prognosticator 
(Noordzij, 1995a; Noordzij, 1995c; Krijnen, 1997; McWilliam, 1997; Abrahamsson, 
1998; Deftos, 1998a; Deftos, 1998b). Finally, intratumoral vascularity or tumor 
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angiogenesis have been correlated to prostate tumor formation and progression 
(Fregene, 1993; Weidner, 1996; Lissbrant, 1997; Silberman, 1997). The vascular 
endothelial growth factor (VEGF) (Ferrara, 1996) is expressed in both prostate cancer 
patients (Harper, 1996; Jackson, 1997) and in prostate cancer models (Ferrer, 1997; 
Connolly, 1998; Ferrer, 1998; Muhkerjee, 1999). VEGF is the central growth factor for 
the formation of novel blood vessels, a process also known as the . angiogenic switch' 
during tumorigenesis (Hanahan, 1996a; Hanahan, 1996b; Hanahan, 1997). 
1.2.3 Therapy of prostate cancer 
Resection of organ-confined prostatic tumors by radical prostatectomy or cryo-
surgery is the most commonly used strategy for prostate cancer patients, and pending 
the stage of disease, . watchful waiting' is also a serious option. There are many 
potential targets for therapeutic intervention of androgen induced growth of the prostate 
(Coffey, 1987; Galbraith, 1997). Patients with obstructed urinary outflow due to non-
organ-confined prostatic tumors are mostly surgically treated by trans-urethral resection 
of the prostate (TURP). Surgical castration, or orchidectomy, is often performed as 
therapy to directly infiuence the serum testoterone levels. The majority of the patients 
are chemically castrated by administration of luteinizing hormone releasing hormone 
(LHRH) agonists or by indirect hormone ablation therapy. This is performed by using 
anti-androgens like fiutamide, zoladex and casodex. Oral estrogens (DES) are very 
rarely used for this purpose, because of their severe cardiovascular side effects. The 
human adrenal androgens dehydroepiandrosterone (DHEA) and 
dehydroepiandrosterone-sulphate (DHEAS) have been shown to activate mutant 
androgen receptors expressed in androgen dependent prostate cancer (Tan, 1997). 
Combinations of LHRH analogues and orchidectomy with an anti-androgen are 
considered to result in very low androgen levels by their blockade of both testosterone 
and the adrenal androgens, DHEA and DHEAS (Galbraith, 1997). Hormone therapy can 
be given prior to radiotherapy, TURP or radical prostatectomy to induce regression of 
the primary tumor. 
The effects of androgen deprivation therapy on prostate cancer, i.e. preoperative 
hormonal therapy and anti-androgen (withdrawal) therapy have been widely studied in 
prostate cancer patients, using e.g bicalutamide (Casodex), flutamide or Estramustine-
phosphate (EMP) (Van de Voorde, 1994; Civantos, 1995; Scher, 1996). Effects of 
androgen deprivation observed in clinical patients were induction of apoptosis, atrophy, 
basal cell prominence, and vacuolated luminal cells in the benign non-neoplastic parts 
of the prostate (Van de Voorde, 1994; Civantos, 1995; Scher, 1996). In the neoplastic 
_prostate, small residual tumor glands surrounded by stroma with or without pyknosis 
and occasionally unaltered prostatic tumor areas were observed during androgen 
deprivation (Civantos, 1995). In addition, proliferative activity of the prostate cancers is 
reduced (Westin, 1995; van der Kwast, 1999). 
Almost all clinical prostate cancer will eventually develop hormone therapy 
resistance which creates a major problem for urologists and scientists. Scher et al 
(Scher, 1996) described two variants of relapsed hormone refractory disease. These 2 
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groups include patients with either androgen independent, but hormone sensitive 
prostate cancer and those suffering from androgen independent, and hormone 
insensitive disease that is not responding to anti-androgen withdrawal therapy at all. In 
both in vitro cell lines (Limonta, 1992; Egawa, 1996; Esquenet, 1997; Myers, 1997) and 
in vivo models (Isaacs, 1981) androgen independent tumor growth was induced after 
treatment by androgen deprivation. Isaacs and Coffey stated that hormone refractory 
prostatic tumor growth was a result of tumor heterogeneity. Clonal expansion of 
androgen independent cells during hormone therapy will eventually lead to tumor 
progression (Isaacs, 1981; Coffey, 1987). 
1.2.4 Hormone dependence and induction of apoptosis 
The difference in the response to anti-androgen hormonal therapy is dependent 
on the possibility to induce apoptosis in hormone sensitive prostate cancer cells, 
whereas this is not induced in androgen insensitive cells (Scher, 1996). Apoptosis is a 
complex process of different cascades, e.g. p53 dependent, caspase activated, 
Fas/Fas-ligand dependent, etc. These pathways have a number of checkpoints where 
this process is either induced, blocked or reversed. Some examples of proteins that 
inhibit induction of apoptosis are high expression levels of the anti-apoptotic BcI-2 
protein (Raffo, 1995) or overexpression of the mutated p53 protein which can determine 
the status of androgen dependence (Isaacs, 1991; Martikainen, 1991; Denmeade, 
1996; Liu, 1996; Lu, 1996; Dorai, 1997; McDonnel, 1997; Rokhlin, 1997; Saeed, 1997). 
Another observation done after hormone deprivation involves the down regulation of 
VEGF expression and rapid reduction of blood flow in prostate cancer tissue (Joseph, 
1997; Levine, 1998; Shabsigh, 1998). However, this is not a uniform response, as in the 
Dunning rat R3327 prostate cancer progression model, the levels of VEGF mRNA were 
elevated after androgen withdrawal (Haggstrom, 1998). 
1.3 Prostate cancer progression 
In spite of initial succesful hormonal treatment, many if not all prostatic cancers 
eventually progress to a hormone therapy-refractory stage after prolonged treatment. 
Various molecular mechanisms responsible for this escape after treatment of the 
disease are under extensive study. Effective therapies for these hormone refractory 
patients are not yet available. With respect to AR involvement in androgen independent 
growth of advanced prostate cancer several mechanisms may be involved (figure 1). 
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Figure 1: Schematic presentation of different ways of advanced prostate cancer 
formation after hormonal therapy. 
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Altered preferences or cross reactivity with other growth factors due to either AR 
mutations or AR gene amplification, paracrine growth factor induced or ligand-
independent activation of the androgen receptor are possible escape mechanisms of 
hormone refractory prostatic tumors (Ruizeveld de Winter, 1994; Culig, 1998; Koivisto, 
1998). Likewise, the inability to induce apoptosis during anti-androgen treatment, i.e. a 
form of apoptosis resistance, could be a possible escape mechanism. Androgen 
receptor expression in prostatic carcinoma is modulated by androgen blockade or 
hormone deprivation (van der Kwast, 1991; Ruizeveld de Winter, 1992; Van der Kwast, 
1996). The expression levels of the androgen receptor in advanced hormone refractory 
tumors differs from patient to patient as the expression levels can be heterogeneous, 
depending on initial tumor stage, length of therapy and the occurrence of AR gene 
mutations or amplification (van der Kwast, 1991; de Vere White, 1997; Stanford, 1997; 
Gil-Diez de Medina, 1998; Gregory, 1998). One study in the PC-82 human prostate 
xenograft model clearly showed down-regulation of nuclear AR expression shortly after 
androgen deprivation (Ruizeveld de Winter, 1992) and re-expression after androgen re-
supplementation. In the PC-310 human xenograft model spontaneous re-expression of 
the AR occurs after initial down-regulation following androgen deprivation (Chapter 4 & 
5). This temporal down regulation of AR expression in prostate cancer could imply a 
way to circumvent androgen deprivation induced apoptosis. The cells expressing the 
AR in high amounts might be more prone to undergo apoptosis than cells that express 
relatively low levels of the AR. AR expression is probably down-regulated because no 
more DHT is formed to stabilize the protein, due to the rapidly decreasing serum 
testosterone levels after androgen deprivation. 
The proliferation of prostatic cells has been shown to be regulated by a number 
of growth factors, mitogens, which are probably produced by the prostatic epithelium 
itself, e.g. neuroendocrine cells, or by the surrounding stromal tissue (Coffey, 1987; 
Byrne, 1996; Culig, 1996; Peehl, 1996a; Scher, 1996; Culig, 1997a). Androgen 
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independent growth of clinical prostate cancer is found by detection of elevated PSA 
levels (Polito, 1997; Smith, 1998). Androgen independent PSA expression can be 
induced through autocrine or paracrine mechanisms (Hsieh, 1993; Gkonos, 1996; 
Walls, 1996). Regulation of prostate cell growth has been reported for epidermal growth 
factor (EGF) and transforming growth factors TGF-a or-I> (Carruba, 1996; Jones, 1997), 
basic fibroblast growth factor (bFGF), heparin-binding growth factors, vitamins A and D 
and insulin-like growth factors (IGF). TGF-I> is a growth factor which can both stimulate 
and inhibit proliferation (Martikainen, 1990; Desruisseau, 1996; Lamm, 1998). 
Enhanced expression of TGF-I> or decreased expression of its receptors may therefore 
be potentially involved in prostate cancer progression (Culig, 1996). Insuline-like growth 
factors have gained interest in prostate cancer research as high plasma IGF-1 levels 
have been shown to be present in clinically advanced prostatic carcinoma, whereas IGF 
is normally found at very low plasma levels (Boudon, 1996; Peehl, 1996b; Quinn, 1996; 
Chan, 1998; Cohen, 1998; Wolk, 1998). Prostatic carcinogenesis in the Noble rat 
seems to be dependent on functional IGF and VEGF (Wang, 1998). Other factors that 
are important in IGF action, like the IGF binding proteins (IGFBP) have also been 
shown to be produced by androgen independent prostatic cell lines and its effects could 
be enhanced by LHRH agonists (Srinivasan, 1996; Marelli, 1999). 
1.3.2 Paracrine growth modulation in prostate cancer 
Different cytokines (Sokoloff, 1996) and neuropeptide growth factors have been 
implicated in paracrine growth modulation of prostate cancer. Interleukin-6 is an 
example of a cy10kine which has been found in plasma during prostate cancer 
progression and is produced by the prostatic cancer cell lines, LNCaP, DU-145 and PC-
3 (Siegall, 1990; Borsellino, 1995; Twillie, 1995; Hobisch, 1998). Other cytokines are 
tumor necrosis factor-a (TNF-a), interferon-a and -y (IFN-a and -y), interleukin-2 (IL-2) 
(Sokoloff, 1996), and leukemia-inhibitory factor (Kellokumpu-Lehtinen, 1996). 
Furthermore, several researchers have shown the growth modulating capacities of T-
lymphocy1e conditioned medium (Hsieh, 1995) and the bone conditioned medium both 
of which contain many cy10kines (Lang, 1995; Hullinger, 1998; Lang, 1998). Examples 
of neuropeptide growth modulatory factors are bombesinfgastrin releasing peptide, 
nerve growth factor, and somatostatin which can have both growth stimulating as well 
as inhibiting effects (Bogden, 1990; Milovanovic, 1992; Brevini, 1993; Geldof, 1997). 
The activity of these proteins is strongly dependent on the presence of bioactivating 
enzymes, like the amidating enzyme peptidyl-glycine-alpha-amidating-mono-oxygenase 
(PAM) (Treston, 1993; Vos, 1995; Saldise,1996; Vos, 1996; Prigge, 1997) (Chapter 6). 
Directly related to these growth factors is neutral endopeptidase 24.11 (NEP, 
CD1O), a peptidase that can abrogate the growth modulatory effect of neuropeptide 
growth factors (Cohen, 1996; Krongrad, 1997; Papandreou, 1998) by processing these 
peptides to smaller inactive peptides. 
Testosterone independent activation of androgen receptor can be achieved in 
different pathways. LHRH is able to synergistically activate the androgen receptor in the 
presence of low androgen concentrations (Culig, 1997b). IL-6 can activate androgen 
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receptor mediated prostate specific antigen expression in prostatic carcinoma either 
ligand-independent or synergistically with the synthetic androgen methyltrienolone 
(R1881) (Hobisch, 1998). More recently, the possible involvement of the mitogen-
activated protein (MAP) kinase pathway in steroid independent activation of the 
androgen receptor, e.g. through mitogens like EGF or IGF is being studied in advanced 
hormone refractory prostate cancer (Nazareth, 1996; Zhu, 1997; Chen, 1999; Jenster, 
1999; Putz, 1999). 
1.4 Prostate cancer models 
1.4.1 Model stUdies 
To study factors involved in development and progression of prostate cancer, the 
establishment and characterization of experimental human tumor model systems is 
necessary. For years the Dunning and Noble rat prostate cancer models have been 
used for numerous in vivo stUdies (Isaacs, 1981; Kadar, 1988; Wang, 1998). Human 
prostate cancer tissue culturing (Stone, 1978; Kaighn, 1979; Horoszewicz, 1983; 
Brower, 1986; Lizumi, 1987; Limon, 1990; Bright, 1997) as well as heterotransplantation 
(Pretlow, 1993; van Steenbrugge, 1994) of human prostate cancer into athymic nude 
mice, have an important place in prostatic cancer research. These models are applied 
to study various aspects of human prostatic cancer, such as androgen-regulated cell 
proliferation and cell death, the role of growth factors in growth and progression, 
molecular and cy1ogenetics, tumor metastasis, multidrug resistance, and more. 
Furthermore, prostate cancer model research focuses at molecular-biological studies on 
androgen regulated gene expression, DNA in situ hybridization studies to identify 
chromosomal aberrations in prostatic carcinoma tissues and clinicopathological studies 
on the phenotypic changes of human prostatic carcinomas during their progression to 
androgen independence. 
The induction of prostate specific tumor models in mice has gained recent 
interest since the discovery of Cre-mediated recombination dependent conditional 
knockout models (Akagi, 1997). The principle of this model is cloning of two 10xP siles 
in a gene of interest, e.g. PTEN, used in combination with prostate specific expression 
of Cre under control of the PSA promotor which might then lead to initiation of murine 
prostatic tumors. This technique gives many possibilities to investigate the involvemnet 
of different tumor suppressor genes in the oncogenesis of prostate cancer. 
1.4.2 In vitro prostate cancer cell lines 
The four most commonly used human prostatic cancer cell lines are LNCaP 
(Horoszewicz, 1983), PC-3 (Kaighn, 1979), DU-145 (Stone, 1978) and TSU-Pr1 
(Lizumi, 1987) which have also been used for the development of orthotopic and 
xenograft in vivo models; (Rembrink, 1997; Sato, 1997). Likewise, Baley et al used ras 
and myc transformed murine cell lines, RM-9, RM-1 and RM-2 to set up subsequent 
orthotopic in vivo models (Baley, 1995). More recently, Romijn et al (Romijn, 1996) 
established a new cell line, PC-346C from the PC-346 xenograft model. 
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1.4.3 Human prostate cancer xenograft models 
For many years our laboratory has put much effort into the establishment of in vivo 
human prostatic xenograft tumor models (van Steenbrugge, 1994). Clinical specimens of 
human prostate cancer were transplanted subcutaneously in athymic nude mice. 
Subsequent transplantation has finally resulted in 11 serially transplantable prostatic 
tumor models in athymic nude mice (Noordzij, 1996; van Weerden, 1996). The whole 
panel is of interest because of the great variety in phenotype and origin of both the AD 
and AID models. The 10 presently available androgen dependent (AD) and independent 
(AID) tumor models and their origin are listed below (Table I). Three models have been 
established over 10 years ago and have been studied extensively. In particular, the PC-
82 model is a well known model for studying androgen dependent prostate cancer 
(Hoehn, 1980; Ruizeveld de Winter, 1992; van Weerden, 1992). More recent research 
focuses on the AD models, PC-346, PC-295 and PC-310 which are interesting for 
studying different treatment strategies, e.g androgen deprivation or medical castration 
with Casodex or flutamide (5-FU) to observe the effects of androgen deprivation on 
prostatic tumors. The PC-346 model is of special interest for a number of reasons which 
are the existence of AID sublines, in vitro cultures and the spontaneous incidence of 
androgen independent tumors. The AID models PC-324 and PC-339 are of interest as 
progressive models because of the patient status, i.e. hormone refractory under hormonal 
treatment. 
The AD tumors are grown with supplementation of testosterone (T) via silastic 
implants. The models have different doubling times and lag phases and they have been 
characterized as reported in detail (van Weerden, 1996). The models represent 
prostatic tumors with moderately to poorly differentiated and very poorly differentiated 
growth patterns. 
Table I: Overview of the human prostate cancer xenograft models 
Model Established AD/AID Origin 
PC-82 1977 AD primary tumor 
PC-133 1981 AID soft tissue metastasis 
PC-135 1982 AID primary tumor 
PC-295 1990 AD lymph node 
PC-310 1990 AD primary tumor 
PC-324 1991 AID palliative TUR-P 
PC-329 1991 AD primary tumor 
PC-339 1991 AID palliative TUR-P 
PC-346 1991 AD paliiativeTUR-P (1 week androcur) 
PC-374 1992 AID skin metastasis 
TUR-P = trans urethral resection of the prostate 
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The xenograft models are homogeneous in their hormone responsiveness and 
they are therefore easy to manipulate, e.g.by removal of T implants or by transplantation 
of AD tumors to female mice. Tumor volume measurements can easily be performed and 
blood and tumor tissue can be easily sampled. These data give the researcher potential 
information about prostatic tumor behavior during androgen deprivation. 
More in vivo models have been developed by other groups representing both 
xenograft models, like UCRU-PR-2 (Haaften-Day, 1987; Jelbart, 1988; Jelbart, 1989), 
CWR22 and its sublines (Pretiow, 1993; Wainstein, 1994; Nagabhushan, 1996; Agus, 
1999) as well as transgenic mice models, like CR2-T-Ag (Garabedian, 1998) and GylT 
or lIh11T (Perez-Stable, 1996; Perez-Stable, 1997). 
Primary cultures from xenograft tissues (Limon, 1990), makes it possible to study 
effects both in vivo as well as in vitro. The in vitro cultures have the advantages that 
they are easier to manipulate and that a lot of cells can be generated without too much 
burden to living animals. Furthermore, the comparison with the in vivo situation is very 
well possible as we will show in Chapter 4. 
1.5. Neuroendocrine differentiation 
1.5.1 Neuroendocrine cells: characteristics and origin 
Most glandular epithelial systems, like the gastro-intestinal tract, bronchi and 
the prostate are constituted of a basal cell layer, which separates the luminal epithelial 
cells from the stromal cells. In the glands, the luminal cells are divided in two types, 
exocrine luminal cells and neuroendocrine (NE) cells, which both secrete into the 
lumen. Epithelial systems are initiated from a stem cell compartment (Mason, 1997; De 
Marzo, 1998; Reiter, 1998). The stem cells have several unique characteristics, like 
expression of 8c1-2, specific cytokeratins and the cell cyle arrest marker p27kiP1 • Xue et 
al studied neuroendocrine differentiated cells in the prostatic epithelium with respect to 
cytokeratins and Bcl-2 (Xue, 1997; Xue, 1998b). They found that there were different 
subgroups of serotonin (5-HT) positive NE cells that showed expression of cytokeratins 
specific for either stem cells, cq basal cells or luminal cells. This meant that prostatic NE 
cells may either differentiate directly from prostatic stem cells or after several cell 
divisions from luminal prostatic cells (Xue, 1998a). 
NE cells appear in two types, namely an open type reaching out to the lumen 
and a closed type which is captured in between the basal and exocrine luminal cells, 
but does not secrete into the lumen. NE cells can be identified by 
immunohistochemistry (Pearse, 1969; Azzopardi, 1971) through their affinity for silver 
(Argentaffin) or with specific antibodies against secreted NE products like serotonin (5-
HT) (Xue, 1997) and gastrin-releasing protein (GRP) or against secretion-associated 
granins, like Chromogranin A (CgA) (O'Connor, 1986; Abrahamsson, 1989; Schmid, 
1994; Hendy, 1995), which is the commonly used marker for NE differentiation. 
Most studies on human NE differentiation have been performed in NE 
differentiated systems, like lung, pancreas and intestine. In a few studies NE 
differentiation was induced by several methods (Mabry, 1989; Pfeiffer, 1989; de Bruine, 
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1993; Bang, 1994). In a colorectal cancer model (NCI-H716) showing NE differentiation in 
vivo, NE differentiation could be induced by culturing the non-NE tumor cells in the 
presence of native extracellular matrix, fibroblast layers or in a defined medium wilh basic 
fibroblast growth factor (de Bruine, 1993). Transfeclion of v-rasH into DMS-53 small cell 
lung cancer cells resulted in a cell line with increased NE features (Mabry, 1989). 
Transfeclion of both c-raf-1 and c-myc oncogenes into SV-40 immortalized bronchial 
epithelial cells revealed a large cell carcinoma wilh a NE phenotype (Pfeiffer, 1989). 
Subsequently, these investigators were able to establish heterotransplantable xenografts 
from these carcinoma cell lines with a comparable phenotype (Pfeiffer, 1991). Thus, on 
the one hand stromal-epithelial interactions are essential and on the other hand 
expression of certain (proto) oncogenes are associated with the induced level of NE 
differentiation. These experiments might be important in the study of prostate cancer 
since no prostate cancer models are available at the moment which show NE 
differentiation in vitro. 
1.5.2 Neuroendocrine cells: the regulated secretory pathway 
In principle, the NE cells synthesize, store and release peptide signaling molecules 
in accordance with the physiological demands of an organism. For this purpose the NE 
cells have a unique regulated secretory pathway (RSP) (Holthuis, 1995; Huttner, 1995; 
Holthuis, 1996b; Shennan, 1996; Kaether, 1997). Many features of this pathway are still 
poorly understood, but the RSP has been carefully characterized in the South-African 
clawed toads, Xenopus laevis which were used for their capacity to adapt their skin 
colour to a black background (Holthuis, 1995; Van Horssen, 1995; Braks, 1996; Holthuis, 
1996b). This has led to a better understanding of the process of regulated secretion in NE 
cells. The central protein produced by the RSP in Xenopus laevis is called 
proopiomelanocortin (POMC) which also plays an important role in the hypothalamo-
pituitary-adrenal axis. The POMC peptide hormone production starts at the level of the 
endoplasmatic reticulum (ER), where the protein is translocated, N-glycosylated, 
phophorylated and folded. The proteins are transported from the ER to the Golgi 
complex, where they will traverse the cis-, medial-, and trans-cisternae. Post-translational 
modifications, a.o. the remodelling of N-linked oligosaccharide side chains and the 
stepwise biosynthesis of O-linked glycans. Furthermore, protein sulphation at tyrosine 
residues takes place at the trans-Golgi network. The trans-Golgi network is involved in 
the correct distribution of all secretable proteins over the different pathways. For the RSP, 
the peptide precursor proteins are sorted and packaged into secretory granules which is 
followed by subsequent proteolytic maturation. Next to CgA, the secretory granules can 
be identified by different granins, like Secretogranin III (Sglll) and Secretogranin V (7B2) 
(Martens, 1989; Sigafoos, 1993; Braks, 1996). Enzymes involved in this maturation are 
the prohormone convertases PC1 and PC2, carboxypeptidase H and the amidating 
enzyme PAM. Final secretion of bioactive peptides is dependent on an as yet unknown 
extracellular stimulus. During the whole RSP procedure, POMC is clipped C-terminally to 
form endorphins, melanocyte stimulating hormone (a-, ~-MSH) and adrenocorticotropic 
hormone (ACTH). a-MSH is responsible for initiating the Xenopus laevis skin colour 
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transformation. Evaluation of markers of the RSP is ongoing in X. laevis, human lung 
and prostate cancer (Huttner, 1995; Eib, 1996). Markers of NE differentiation, a.o. those 
of the RSP or the PAM marker are currently being evaluated for additional prognostic 
value in prostate cancer. 
1.5.3 Neuroendocrine celis: neuropeptides 
A number of neurosecretory products of NE prostatic tumor cells, like serotonin (5-
HT), gastrin releasing peptide/bombesin (GRP), calcitonin (CT), vasoactive intestinal 
peptide (VIP) (Mack, 1997) and somatostatin (SMS) exhibit growth factor activity 
mediated by a membrane receptor. This may represent a way of paracrine growth 
modulation (Willey, 1984; Dalsgaard, 1989; Seuwen, 1990). Most of the prostatic 
adenocarcinoma cells surrounding NE cells contain the AR. It was found in COS cells 
transfected with steroid hormone receptors that dopamine activated several steroid 
hormone receptors (progesteron, estrogen, vitamin D and thyroid hormone-l\ receptors) 
in a ligand-independent fashion (Power, 1991). In this way NE tumor cells might stimulate 
the growth of neighbouring non NE tumor cells by androgen independent activation of the 
AR in a paracrine manner. Bonkhoff et al. studied the relation between proliferation and 
NE differentiation at the immunohistochemical level and found in normal, hyperplastic and 
cancerous prostatic tissues that proliferating cells were usually, but not necessarily, 
located in proximity of NE cells (Bonkhoff, 1991) suggesting paracrine growth regulation 
(Hoose in, 1996). This is supported by results of Aprikian et ai, who think that NE cells 
may promote progression and androgen independence of prostate cancer through the 
action of secreted gastrin releasing peptide (GRP) (Aprikian, 1996; Aprikian, 1997; Han, 
1997; Aprikian, 1998). 
Serotonin (5-HT) 
Serotonin is well known as neurotransmitter and vasoactive substance. Some 
recent reports indicate that serotonin has growth factor activity (Seuwen, 1988; Abdul, 
1994; Abdul, 1995). Serotonin can stimulate DNA synthesis in hamster fibroblasts which 
is mediated by activation of the 5-HT'b receptor (Seuwen, 1988). This receptor is only 
expressed in rodents. Growth experiments with antagonists or uptake inhibitors of 
serotonin showed direct inhibition of the growth of prostatic tumor cells lines (Abdul, 1994; 
Abdul, 1995; Hoosein, 1996). Serotonin might also influence tumor growth indirectly by 
changing the local blood flow in a tumor due to its vasoactive action. The fact that 
serotonin is expressed and secreted by most if not all prostatic NE cells makes it an 
interesting neuropeptide to study in prostatic cancer NE cells, although it is as yet not 
known if non-NE prostatic tumor cells contain 5-HT receptors. 
Gastrin releasing peptide (GRP) 
Gastrin releasing peptide (GRP) or bombesin stimulated the growth of cultured 
gastric carcinoma cells (Bold, 1994) and normal bronchial epithelial cells (Willey, 1984) 
and in vivo small cell lung cancer (SCLC) models (Alexander, 1988; Chu, 1996; Rogers, 
1997) in a dose dependent manner. In vitro studies with cultured pulmonary NE cells 
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demonstrated that treatment with GRP increased the number of NE cells and stimulated 
their serotonin expression, while treatment with serotonin did not (Speirs, 1993). This 
effect could be blocked by antibodies against GRP. It has also been shown that GRP 
stimulated growth of small cell lung cancer cells (Cuttitta, 1985). This effect could be 
blocked in vivo by monoclonal antibody 2A 11 (Moab 2A 11), an antibody against GRP 
(Avis, 1991; Kelley, 1997) and in vitro by GRP analogues which prevented binding of 
GRP to its receptor (Cuttitta, 1985; Mahmoud, 1991). In vitro studies with the androgen 
independent prostatic cancer cell line PC-3 similarly showed a growth stimulatory action 
of GRP which could be blocked by an anti-GRP antibody (Bologna, 1989). Saturable 
GRP binding sites were demonstrated on PC-3 cell membranes, but in this case no 
immunoreactivity against GRP was demonstrated (Bologna, 1989). However, GRP 
immunoreactivity was demonstrated in PC-3 cells in other studies (Kaighn, 1979; 
Hoosein, 1993). The bombesin/GRP antagonist RC-3095 was able to inhibit the growth of 
the androgen dependent PC-82 in vivo and the androgen independent DU-145 in vitro or 
in vivo as xenograft (Milovanovic, 1992; Pinski, 1993). In both models, saturable GRP 
binding sites were demonstrated (Milovanovic, 1992; Pinski, 1993). Furthermore, the 
signal transducing mechanism of the interaction of GRP and GRP-like peptides with 
prostatic cancer cells has well been studied (Zachary, 1993; Aprikian, 1996; Aprikian, 
1997; Han, 1997; Wasilenko, 1997). This has resulted in either a Ca2+ or a tyrosine 
phophorylation dependent signal transduction pathway leading to differences in cell 
motility (Aprikian, 1997). All together, evidence exists that GRP can playa potential role 
in androgen independent growth of prostate cancer (Siegfried, 1994; Aprikian, 1998). 
Catcitonin (CT) 
Calcitonin was demonstrated in a subset of normal and neoplastic prostatic cells 
(Abrahamsson, 1987; Davis, 1989; di-Sant'Agnese, 1989; Aprikian, 1993; Deftos, 1998a). 
In conditioned medium of cultures of prostate cancer cells immunoreactive CT was found 
in 4-fold concentration compared to cultures of BPH cells (Shah, 1992). In vivo 
administration of salmon CT to rats induced ornithine decarboxylase (a key enzyme 
associated with cell cycle progression and growth) in a number of organs (Nakhla, 1987). 
It should be realized that serum CT also decreases the pituitary secretion of luteinizing 
hormone which is an important mediatior of androgen secretion (Leicht, 1974). In 
addition, the secretion of prolactin, which is thought to mediate the action of androgens 
on the prostate, was also found to be decreased by CT (Bloom, 1979). Therefore, 
pituitary mediated growth inhibitory effect of CT on prostate cancer growth might be 
possible. The direct growth modulating effects of CT have been studied in a few tumor 
systems. In vitro growth of T 47D breast cancer cells was dose dependently inhibited by 
CT (Iwasaki, 1983; Ng, 1983) by inducing increased intracellular cAMP levels. 
Comparable results were found in KA TO III cells, a human gastric carcinoma cell line 
(Nakamura, 1992). In a study with six human renal adenocarcinoma cell lines four 
showed increased cAMP levels upon CT administration (Kinoshita, 1985). These four 
lines were also growth inhibited by CT, while the two lines that did not show a cAMP 
response displayed no growth inhibition. In a study on a panel of small cell lung cancer 
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cell lines, two out of 13 expressed CT and one other cell line was able to bind CT (Be pier, 
1988). In this study no growth effect of CT was observed. Recently, a few experimental 
studies on CT in prostate cancer showed that CT was able to stimulate growth of prostate 
cancer cell lines through cAMP signal tranduction and induced Ca2' levels (Shah, 1994; 
Ritchie, 1997). 
Somatostatin (SMS) 
Abrahamsson et al found somatostatin immunoreactivity in 12 out of 40 prostatic 
adenocarcinomas (Abrahamsson, 1987), a result that could not be confirmed in another 
study, however (Aprikian, 1993). In a study of Reubi etal, neither in 17 prostatic 
carcinomas, nor in 2 BPH specimens SMS receptors were found (Reubi, 1987). A 
number of experimental studies concerning the growth modulating effects of SMS in 
prostate cancer have been published. The androgen sensitive in vivo Dunning R-3327 rat 
prostate cancer model or its subline R-3327H were studied for the effects of SMS 
analogues. In two studies two different SMS analogues (sandostatin and somatuline) 
were injected in R-3327H tumor bearing mice resulting in growth inhibiting effects of both 
SMS analogues (Siegel, 1988; Bogden, 1990). In one of these studies this potentiated 
the castration induced growth inhibition even after the tumors became androgen 
independent (Bogden, 1990). In another study this extra growth inhibiting effect was not 
confirmed, however (Siegel, 1988). Treatment of R-3327H bearing mice with the SMS 
ilnalogue, RC-160, a luteinizing hormone-releasing hormone (LH-RH) analogue (0-TRp6 
LH-RH) or a combination of both resulted in growth inhibition, with the strongest inhibition 
found in the combined treatment (Kadar, 1988). This was associated with down-
regulation of both the SMS and prolactin receptors, the strongest down-regulation being 
found after the RC-160/D-TRp6 LH-RH combined treatment. As prolactin probably has a 
stimulating effect on prostate cancer, down regulation of the prolactin receptor by SMS 
might explain the growth inhibiting effects. In the PC-82 xenograft model the combination 
of SMS analogues (RC-121, RC-160) with an LH-RH analogue (D-TRp6) gave a stronger 
growth inhibition than treatment with a single analogue (Milovanovic, 1992). In addition, 
PSA, insulin like growth factor I, and growth hormone serum levels were greatly reduced 
in the PC-82 tumors following treatment. SMS receptor positive prostatic adenocarcinoma 
were succesfully treated with 188Re_RC_160, a directly-radio labeled somatostatin 
analogue (Zamora, 1996). In vivo experiments with the SMS receptor positive DU-145 
(Stone, 1978) tumor also demonstrated a growth inhibiting effect of SMS analogue RC-
160 (pinski, 1993). Following treatment, serum levels of growth hormone and gastrin 
decreased and the epidermal growth factor receptor was down regulated. In vitro 
experiments with the androgen dependent LNCaP (Horoszewicz, 1983) demonstrated a 
direct proliferation and protein synthesis inhibiting effect of SMS (Brevini, 1993). This 
effect was dose dependent and reversible. All these results strongly suggest a growth 
modulating effect of somatostatin (analogues) in prostate cancer. 
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1.6 Neuroendocrine differentiation In the prostate 
1.6.1 Neuroendocrine differentiation in normal and neoplastic prostate 
NE cells are identified in normal prostate and prostate cancers (Azzopardi. 1971; 
Kazzaz, 1974), although the reported percentages of prostatic tumors with NE cells vary 
from 30% to almost 100% (Bono, 1985; Abrahamsson, 1987; Abrahamsson, 1989; 
Cohen, 1990; Aprikian, 1993). NE cells have been localized in nearly all clinical prostatic 
adenocarcinomas (Abrahamsson, 1986; di-Sant'Agnese, 1992b; Aprikian, 1993; 
Bonkhoff, 1995; di-Sant'Agnese, 1995; Noordzij, 1995a; Noordzij, 1995c). NE cells have 
also been identified in neoplasia of many other epithelial organs like breast, lung, 
stomach, and pancreas (Grube, 1986; Gould, 1988; Helman, 1988; Lehrer, 1988; 
Linnoila, 1988; Nesland, 1988; Blumenfeld, 1996; Linnoila, 1996). 
According to di-Sant'Agnese, NE differentiation in prostate cancer may be found 
in adenocarcinoma, small cell prostate cancer (SCPC), the rarely found prostatic 
carcinoid, mixed tumors of these 3 types. It may also be evident in prostate cancer with 
ectopic or eutopic production of neuroendocrine hormones and in prostatic malignancies 
associated with paraneoplastic syndromes (di-Sant'Agnese, 1992a). Undifferentiated 
small cell cancers, or NE carcinomas, mostly occur in the lung. SCPC is a relatively rare 
disease accounting for ± 5% of all prostate cancers (Schron, 1984; Ro, 1987; Tetu, 1987; 
Oesterling, 1992). It is a highly malignant disease with a very short survival time of 7-17 
months. In about half of the SCPC patients the small cell component is preceded by a 
common adenocarcinoma and also mixed tumors were found (Tetu, 1987; Oesterling, 
1992). Not all SCPC showed the NE phenotype, however (Ro, 1987). 
NE cells in prostatic tumors are most often recognized by their immunoreactivity 
for NE markers (CgA, NSE) or eutopically expressed bioactive SUbstances (serotonin, 
gastrin releasing peptide or bombesin, calcitonin, and somatostatin). In addition to the 
eutopic neurosecretory products, a number of ectopic peptides have been found, e.g. 
adrenocorticotropic hormone (ACTH), leu-en kephalin and l1-endorphin (Abrahamsson, 
1987). Expression of these factors, especially ACTH, can cause Cushing's syndrome as 
found in some prostate cancer patients (Matzkin, 1987). 
The most common expression pattern of NE differentiation found in prostate 
cancer is prostatic adenocarcinoma with scattered NE cells. The number of NE cells 
within a tumor varies from patient to patient and the prognostic significance of their 
presence is still a matter of debate. In some studies a relation between the tumor grade 
and the number of NE cells was found (Abrahamsson, 1987; Abrahamsson, 1989; 
Cohen, 1991; Schmid, 1994; Cussenot, 1998). In other studies this could not be 
confirmed, however (Aprikian, 1993; Noordzij, 1995a; Noordzij, 1995c). NE cells were 
also identified in lymph node and bone metastases of prostatic adenocarcinomas 
(Aprikian, 1993; Aprikian, 1994). 
The possible correlation between tumor grade and the number of NE cells 
found in individual tumors may well account for part or all of the reported prognostic 
value of NE differentiation in prostate cancer (di-Sant'Agnese, 1998a; di-Sant'Agnese, 
1998b). Markers that show prognostic value in univariate statistical analysis also have 
28 
to be tested in multivariate analysis in order to be proven as an independent marker for 
prostate cancer (Noordzij, 1995a; Noordzij, 1995c). Clinical follow up studies have been 
performed that deal with the correlation using this multiple regression analysis. Most of 
these studies on the prognostic value of CgA for NE differentiation did not show a 
correlation between CgA expressing NE cells in prostatic adenocarcinomas and bad 
prognosis or clinical progression of prostate cancer (di-Sant'Agnese, 1992b; Aprikian, 
1993; Cohen, 1994; di-Sant'Agnese, 1995; Noordzij, 1995a; Noordzij, 1995c; Casella, 
1998). One study showed significant correlation of NE differentiation of prostatic tumors 
before treatment with progressive behavior in hormonally treated patients (Krijnen, 
1997). 
Kadmon et al demonstrated elevated CgA serum levels in 12 out of 25 patients 
with metastatic, hormone insensitive prostate cancer (Kadmon, 1991), although PSA 
levels were in the normal range in 4 of these 12 patients. Others found comparable 
results with respect to elevated CgA levels in serum of hormonally treated patients 
(Cussenot, 1996a; Theodorescu, 1997; Cussenot, 1998; Wu, 1998b) or in NE tumors 
(Kimura, 1997). Serum levels of another NE marker, neuron specific enolase (NSE), were 
found to be increased more often in patients with hormone refractory tumors than in 
patients with hormone sensitive tumors (Tarle, 1991). 
Abrahamsson et al studied NE differentiation in repeated biopsy specimens of 
patients treated with hormonal therapy or with radiotherapy (Abrahamsson, 1989; 
Abrahamsson, 1996). They generally observed increasing numbers of NE, i.e. CgA 
positive, cells during follow-up paralleled by cellular dedifferentiation and hormonal 
escape, i.e. progression, of the tumor. Other studies showed that androgen deprivation 
in clinical prostate cancer induced both NE differentiation and increased expression of 
the proliferative marker Ki-67 (Van de Voorde, 1994; Guate, 1997; Jiborn, 1998; 
Pruneri, 1998). One study showed growth arrested tumors with differential expression of 
the androgen receptor (AR), but no induction of NE differentiation was found upon 
androgen deprivation therapy (Reuter, 1997). These results raise the question whether 
NE cells in prostate tumors are androgen sensitive or not. 
Immunohistochemically defined NE cells in both normal and hyperplastic prostatic 
tissue did not show immunoreactivity against the AR (Bonkhoff, 1993; Krijnen, 1993). 
One of these studies reported that prostatic NE tumor cells very rarely contained the AR 
(Bonkhoff, 1993) while in the other study all NE tumor cells were AR negative (Krijnen, 
1993). It is generally believed that NE cells in normal or neoplastic prostate do not contain 
the AR. However, in one study prostatic NE cells as well as tumoral NE cells usually 
showed immunoreactivity against the AR (Nakada, 1993). In this latter study, as 
compared to the two former studies, a different antibody against the AR was applied. 
Although it has been shown that the AR content of a prostatic tumor does not predict 
androgen (in)sensitivity (van der Kwast, 1991; Van der Kwast, 1996), it is unlikely that AR 
negative tumor cells will respond to androgen withdrawal. 
Neuroendocrine (NE) cells are considered to be non-proliferating cells which do 
not express the androgen receptor (Krijnen, 1993) and therefore are assumed to be 
unaffected by androgen deprivation. NE cells show a heterogeneous cytokeratin 
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expression pattern as there are basal, luminal and intermediate NE cell types (Bonkhoff, 
1994a; Bonkhoff, 1994b; Xue, 1997; Xue, 1998a). Xue et al recently showed no co-
expression of 5-HT with the anti-apoptotic oncogene Bcl-2 (Xue, 1997), thus showing 
that NE cells are non-proliferating, androgen independent cells which do not have an 
active Bcl-2 pathway. In addition, NE cells are often found near BcI-2 positive prostate 
cancer cells (Colombel, 1992; Cohen, 1994). 
1.6.2 NE differentiation in human prostatic xenograft models 
Previously, the NE differentiation status of the human prostate cancer xenograft 
models and the initial patient material was studied for CgA by Noordzij et al (Noordzij, 
1996) (Table II). The number of NE cells found in the PC-295 and PC-310 xenograft 
models closely resembles the expression pattern of NE differentiation found in clinical 
prostatic tumors. The PC-295 prostate cancer xenograft model showed induced NE 
differentiation only after androgen deprivation. PC-295 showed fast regression and 
restimulation of grow1h by androgens failed already within 3 weeks after androgen 
withdrawal. The PC-310 model showed a similar pattern of induction of NE 
differentiation after androgen deprivation, but in contrast to PC-295 this tumor shows 
slower regression and formation of tumor residues, which can be restimulated by 
androgens even after longer periods of androgen deprivation (Noordzij, 1996; van 
Weerden, 1996). In PC-346, PC-374 and PC-324, NE differentiation had been found in 
the patient material and the first passages of the xenografted tissue in nude mice. No NE 
differentiation was observed in PC-82, PC-133, PC-135 PC-329 and PC-339. Evaluation 
of the complete panel of available xenografts with a more sensitive staining protocol, 
enabled us to detect CgA positivity in recent passages of PC-324, PC339, PC329, and 
only small numbers in PC-82 tumor tissue of both androgen supplemented as well as the 
androgen deprived status. We think that the PC-324 model is a small cell prostate cancer 
(SCPC) tumor model. Pathologically, the tumors showed features of SCPC, like poor 
differentiation, Gleason sum scores of 9-10 and expression of CgA. Furthermore, the 
tumor cells overexpresses p53 and Bcl-2, which are typical characteristics for SCPC. RT-
PCR analysis for CgA, Sglll and PC-1 mRNA confirmed that PC-324 is indeed a 
neuroendocrine tumor (unpublished results). 
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Table II: Human prostate cancer xenograft models 
Model Year Origin AD Neuroendocrine Differentiation 
Patient Xenograft 
PC-82 1977 Primary tumor + 
PC-EW 1981 Lymph node + +++ + 
PC-133 1981 Bone 
PC-135 1982 Primary tumor 
PC-295 1990 Lymph node + ++ + 
PC-310 1990 Primary tumor + + + 
PC-324 1991 TUR-P +++ - (LP +++) 
PC-329 1991 Primary tumor + 
PC-339 1991 TUR-P 
PC-346 1991 TUR-P + V - (LP V) 
PC-374 1992 Skin meta - (LP +orV) 
Neuroendocrine Differentiation (= immunoreactivity against Chromogranin A) 
TUR-P = trans urethral resection of the prostate, meta = metastasis, 
AD = androgen dependence, LP = low passage on nude NMRI mice 
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ABSTRACT 
It was previously shown in the PC-295 xenograft that the number of 
chromogranin A (CgA) positive neuroendocrine (NE) cells increased after androgen 
withdrawal. NE cells did not proliferate and differentiated from Go-phase arrested cells. 
Here we further characterized NE differentiation, androgen receptor status and 
apoptosis-associated Bcl-2 expression in the PC-295 model after androgen withdrawal 
to assess the origin of NE cells. 
PC-295 tumor volumes decreased by 50% in 4 days. Intraperitoneal BrdU 
incorporation and MIB-1 labeling decreased to 0% and the apoptosis was maximal at 
day 4. Androgen receptor expression and PSA serum levels decreased rapidly within 2 
days. The number of NE cells increased six-fold at day 4 and thirty-fold at day 7. Five 
and ten percent of the CgA positive cells were BrdU positive after continuous BrdU 
labeling for 2 and 4 days, respectively. However, no MIB-1 expression was observed in 
CgA positive cells. NE cells expressed the regulated secretory pathway marker 
secretogranin III, but were negative for androgen receptor and BcI-2. BcI-2 expression 
did increase in the non-NE tumor cells. 
In conclusion, androgen withdrawal leads to a rapid PC-295 tumor regression 
and a proliferation independent induction of NE differentiation. The strictly androgen 
independent NE cells that were still present after 21 days differentiated mainly from Go-
phase arrested cells. 
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INTRODUCTION 
Neuroendocrine (NE) cells form an androgen independent subfraction of the 
prostate(Abrahamsson, 1996). NE cells have been localized in nearly all clinical 
prostatic adenocarcinoma with different expression patterns(Abrahamsson, 1986; di-
Sant'Agnese, 1992b; Aprikian, 1993; Bonkhoff, 1995; di-Sant'Agnese, 1995; Noordzij, 
1995a; Noordzij, 1995c). These cells produce various growth modulating neuropeptides 
in a paracrine or autocrine way(Seuwen, 1990; Iwamura, 1994b; Abdul, 1995; Aprikian, 
1996; Solano, 1996; Zia, 1996; Mack, 1997). 
Possible roles for NE cells in the prostate may be regulation of homeostasis and 
secretion of prostatic fluid, either actively or passively. NE cells can be identified by 
routine electron microscopy (dense core granulas) or by immunohistochemistry with 
specific antibodies against secreted products for example serotonin(Xue, 1997) or 
secretion associated proteins, like Chromogranin A (CgA)(Abrahamsson, 1989; Schmid, 
1994; Hendy, 1995), which is a marker for neuroendocrine differentiation. NE cells are 
considered to be non-proliferating cells and do not express the androgen 
receptor(Krijnen, 1993) and are therefore probably unaffected by androgen deprivation. 
Consequently, they will not undergo apoptosis under such circumstances. Therefore, it 
is relevant to assess whether or not CgA positive cells co-express the anti-apoptotic 
oncogene Bcl-2(Cohen, 1995). Moreover, NE cells show a heterogeneous cytokeratin 
expression pattern as there are basal, luminal and intermediate NE cell types(Bonkhoff, 
1994b; Bonkhoff, 1994a; Xue, 1997) and are often found near BcI-2 positive prostate 
cancer cells(Colombel, 1992; Cohen, 1994). 
The single expression of CgA is not the only requisite for the determination of NE 
differentiated cells as there exists a regulated secretory pathway (RSP) in NE 
cells(Holthuis, 1996b) next to the lysosomal and an exocrine constitutive pathway. 
Along the RSP pathway secretion and processing of bioactive neuropeptides and 
growth hormones, like insulin and glucagon in the pancreas(Smeekens, 1992; Tucker, 
1996), are regulated. The RSP consists of a sequence of processes linked from 
transcription/translation of various factors to final secretion of neuropeptides at the 
plasma membrane from secretory granules(Holthuis, 1995). Different markers can be 
identified, such as granular markers Secretogranin III (SGIII) and Secretogranin V 
(7B2)(Martens, 1989; Sigafoos, 1993; Braks, 1996), peptidylglycine o:-amidating 
monooxygenase (PAM)(Vos, 1995; Vos, 1996), the processing enzymes prohomone 
convertase 1 and 2 (PC 1 & 2), carboxy peptidase E. Evaluation of these specific 
markers of the RSP is ongoing in X. Laevis, lung and prostate cancer(Huttner, 1995; 
Eib, 1996). 
The number of prostate cancer cases still increases and the search for a curative 
therapy for metastasized cancer continues. NE cells have been found in most prostatic 
adenocarcinomas and the role of NE cells in the progression to androgen independent 
growth is still unclear. Fundamental questions related to a possible role for NE 
differentiation in the progression of prostate cancer can only be solved by using 
representative prostate cancer models with NE differentiation. Several groups have 
recently been developing tumor models both in vitro cell Iines(Romijn, 1996) and in vivo 
xenografts(Liu, 1996; Nagabhushan, 1996; van Weerden, 1996). NE differentiation has 
been studied in a panel of 11 in vivo human prostate cancer xenograft models. Some 
models do not express the NE phenotype and PC-324 and PC-346 lost their NE 
phenotype after a few passages in nude mice(Noordzij, 1996). The PC-295 and PC-310 
models are androgen dependent models of which a part of the cells constitutively show 
the NE phenotype. Therefore, these two models are very suitable for studying NE 
differentiation in prostate cancer and the role that NE cells may play in the progression 
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of prostate cancer. In both the PC-295 and PC-310 models androgen deprivation leads 
to an increased number of NE cells. In a previous study with the androgen dependent 
PC-295 model(Noordzij, 1996), tumors continuously labeled with the S-phase marker 
BrdU for two days prior to castration showed no double labeling of NE cells after 
castration with BrdU. This shows that the increased NE phenotype is not induced prior 
to castration. Absence of BrdU and another proliferation marker, MIB-1, shows that NE 
cells are non proliferating and thus Go phase arrested cells prior to androgen 
withdrawal. However, it can not totally be excluded that proliferation occurring after 
androgen withdrawal is responsible for the increase in NE differentiation in the PC-295 
model. 
In this study, we further looked for the origin of NE cells by focusing on the 
kinetics of the process of NE differentiation. Furthermore, we characterized changes in 
apoptosis and subpopulations of prostatic epithelial cells as marked by their expression 
of CgA, Sglll, grow1h modulating neuropeptides, androgen receptor and Bcl-2 after 
androgen withdrawal in the PC-295 model both shortly after castration and after 
prolonged androgen deprivation. 
MATERIALS AND METHODS 
PC·295 xenograft model 
The nude mouse human prostate cancer xenograft model PC-295 was 
established from a pelvic lymph node metastasis(van Steenbrugge, 1994; van 
Weerden, 1996). The tumors usually grow with a doubling time of about 14 days and a 
lag phase of 2-3 months. The model represents a strictly androgen dependent and 
moderately differentiated tumor, histologically organized in solid sheets and microacini. 
In short, PC-295 tumors were implanted subcutanuously at both shoulders of intact 
nude NMRI males, obtained from the breeding colony of the Erasmus University Center 
for Animal Research. Optimal grow1h conditions were reached by supplementation of 
PC-295 transplanted mice with testosterone implants, as previously described (van 
Steenbrugge, 1984). The subcutaneous tumors developed within 2-3 months and were 
grown up to a maximum volume of 2000 mm3. Tumor volume changes were followed 
weekly by two perpendicular diameter measurements (01 and 02) after which the 
volume was calculated from the formula: V=(nJ6)(01 x 02)312. 
Castration experiments with the PC·295 human prostate cancer xenograft 
model 
Two consecutive castration experiments were performed with 39 testosterone-
supplemented PC-295 bearing male NMRI mice in total. Androgen withdrawal was 
performed by castrating the mice under hypnorm anaesthesia (Janssen 
Pharmaceuticals, Oxford, UK) and by removing the silastic implant. The mice received 
bromodeoxyuridine (BrdU) to check the effect of androgen withdrawal on the 
proliferative activities in the PC-295 tumor tissue. One group of mice received BrdU 
(1 mg/ml) intraperitoneally (IP) as standard labeling for one hour before sacrifice. The 
second group received BrdU (30mg/ml) via subcutanuously inserted osmotic Alzet 
micropumps (Alzet 10070, Alza Corp., Palo Alto, CAl having a flow rate of 0.5 ~l/hour 
as of the moment of castration until sacrifice. Three mice were sacrificed at each time 
point after castration. For the first experimental set-up, these time points were 0, 0.5, 1, 
1.5,2,4,7, 14 and 21 days, whereas in the second set-up, mice received BrdU for 0, 
1.5, 2, 4 and 7 days after castration. 
After blood samples were taken for determining serum prostate specific antigen 
levels, mice were sacrificed. Tumor volumes were measured and tumors were 
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removed. The tumors were cut into small pieces which were either fixed in 4% buffered 
formalin and paraffin embedded for immunohistochemical analysis or snap frozen in 
liquid nitrogen and stored at - ao'c for biochemical analysis. The paraffin embedded 
material was processed routinely for hematoxylin and eosin staining. 
Immunohistochemistry 
To identify the fraction of cells expressing the NE phenotype, paraffin embedded 
tissue sections of the PC-295 xenografts were stained immunohistochemically with 
antibodies against CgA (clone LK2H10; ICN Pharmaceuticals, Aurora Ohio) and SGIII 
(rabbit polyclonal antibody; Department of Animal physiology, University of Nijmegen) 
(Holthuis, 1996a). For identification of the proliferative capacity, tissue sections were 
stained with antibodies against BrdU (clone IIB5, Eurodiagnostics, Apeldoorn, The 
Netherlands) and against the proliferation associated Ki-67 antigen (MIB-1, 
Immunotech, Marseille, France). In addition, apoptotic cells were identified by the 
TUNEL-method (TdT-Kit, Boehringer Technologies Mannheim, Germany). Other 
antibodies used were directed against the androgen receptor (clone F39.4, kindly 
provided by Dr. A.O. Brinkmann, Department of Endocrinology and Reproduction, 
Erasmus University); the cytoplasmatic BcI-2 antigen (clone 124, Dako, Glostrup, OK) 
and against the neuropeptides bombesin (MoAb 2A11; kindly provided by Dr F. Cuttita, 
NCI, Bethesda, USA), serotonin (5HT; rabbit polyclonal antibody), vasoactive intestinal 
polypeptide (VIP, rabbit polyclonal) and Calcitonin (rabbit polyclonal). 
Paraffin embedded xenograft tissues were cut at 4 11m sections for single 
immunostaining and 2 11m for double immunostaining. The sections were mounted on 3-
amino-propyl-triethoxysilane coated glass slides and incubated overnight at 60'C. The 
slides were deparaffinized through xylene and 100 % ethanol and endogenous 
peroxidase activity was blocked with 3.3% hydrogen peroxide (H20 2) in methanol for 10 
minutes. After rinsing with tap water and demi, the slides were placed in 10 mmoliL 
citrate buffer (pH 6.0). Antigen retrieval was then performed in a microwave at 700 watt 
for an initial 12.5 minutes and a subsequent 5.5 minutes(Shi, 1991). The slides were 
allowed to cool down to room temperature and then rinsed with phosphate buffered 
saline (PBS). The tissue slides were then put into the sequenza immunostaining system 
(Shandon, Uncorn, UK). All slides were preincubated with normal goat serum (DAKO, 
Glostrup, OK) diluted 1:10 in PBS, which yields for all compounds used hereafter, for 15 
minutes. The primary antibody was incubated at the appropriate concentration for 2 
hours at room temperature or overnight at 4'C. The secondary antibody was incubated 
for 30 minutes, being either horseradishperoxidase conjugated goatamouse or 
goaturabbit (1 :50), or biotynilated goatamouse and goatarabbit (1 :400) for monoclonal 
and polyclonal antibodies, respectively. In case of biotinylated goatamouse and 
goatarabbit, a horseradishperoxidase streptavidin biotin complex diluted 1:1 :200 in 
PBS, prepared at least 30 minutes prior to use, was incubated for a subsequent 30 
minutes. Between the subsequent steps, the slides were rinsed four times with PBS. 
The bound horseradishperoxidase was visualized in 10 minutes with diaminobenzidine 
(Fluka, Neu-Ulm, Germany) in PBS containing 0.075% H20 2 as substrate. Slides were 
rinsed extensively in tap water and finally counterstained in Mayer's Haematoxylin, 
dehydrated through a series of alcohol and embedded in malinol. 
To assess the properties of the NE cells, double staining of CgA respectively with 
BrdU, MIB-1, androgen receptor and Bcl2 was performed on the PC-295 xenograft 
tumors. The double staining consists of two consecutive stainings with two primary 
antibodies. The first staining was always an horseradishperoxidase-related stable 
diaminobenzidine complex, whereas the second staining was performed with an 
alkaline phosphatase conjugated goatamouse secondary antibody. The alkaline 
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phosphatase was visualized in 30 minutes incubation of the slides with AS-MX-
phosphate (O.3mg/ml; Sigma) mixed with new fuchsin (2.5~l/ml; Sigma), NaNO, (1.45 
mmol/l; Sigma) and levamisole (0.5 mg/ml; Sigma) in the dark. All compounds were 
diluted in 0.2 molll TRIS buffer (Gibco) adjusted at pH 8.0. In between both stainings, 
the slides were rinsed with PBS for one hour and again boiled in a microwave in 10 
mmolll citrate buffer (pH 6.0) for 10 minutes. For immunostaining of incorporated BrdU, 
the slides were treated with 2N HCI at 37"C for 30 minutes to uncoil DNA and 
subsequently neutralized with a 0.1 mmol/l sodium tetra borate buffer (pH 8.5). As 
negative control, PBS replaced the primary antibody in all stainings. Radical 
prostatectomies, containing normal prostatic tissue were used as positive control for 
CgA, Sglll, androgen receptor, Bcl2 and Ki-67 expression. 
For all markers, except androgen receptor, the number of positive cells were 
determined by quantitative counts of all cells in tumor squares at 310x magnification 
from which the number of positive cells per square mm was calculated. In total, positive 
cells were scored as percentage of the total cell number, in <: 25 squares. For the 
androgen receptor, the level of immunostaining was assessed semi-quantitatively. 
Western Analysis 
We further confirmed the expression patterns of immunohistochemically 
determined CgA, SGIII and androgen receptor in our castration series of PC-295 by 
Western immunoblotting. As positive controls, we used material of human 
pheochromocy1oma for CgA, of rat pituitary for SGIII and of the human in vitro cell line 
lNCaP for androgen receptor expression. The procedure of protein extraction was used 
as previously described(Noordzij, 1996). Frozen tissues of the PC-295 xenografts were 
crushed in a liquid-nitrogen-chilled metal cylinder. The tissue homogenates were 
transferred into a lysis buffer (10mM TRIS (pH 7.4), 150 mM NaCI (Sigma), 1 % Triton 
X-100 (Merck, Germany), 1 % deoxycholate (Sigma), 0.1 SDS (Gibco), 5 mM EDTA 
(Merck) and protease inhibitors (1mM phenylmethylsulfonyl fluoride, 1mM aprotinin, 50 
mg/l leupeptin, 1 mM benzamidine and 1 mg/l pepstatin; all from Sigma). After 
centrifugation of the mixture at 100,000 rpm at 4°C for 10 minutes, the protein content 
of the supernatants was measured by the Bradford method (Bio-Rad protein assay, 
MOnchen, Germany). 
20 j.lg of each sample was transferred to an SDS polyacrylamide gel and gel 
electrophoresis was performed with prestained markers as size standards (Novex, San 
Diego, CAl. The gels were blotted to a 0.45j.lm cellulose nitrate membrane (Schleicher 
& Schuell, Germany). The immunoblot was blocked with PBS (pH 7.7) containing 0.1% 
Tween-20 (Sigma) and 5% dry milk for one hour. The CgA, androgen receptor or SGIII 
antibodies were added in their optimal concentration and incubated overnight on an 
orbital shaker at 4°C. After rinsing four times 15 minutes with PBS, incubation for one 
hour was performed with the secondary horseradishperoxidase-conjugated antibodies 
and goatumouse for mouse monoclonal, goaturabbit for rabbit polyclonal antibodies, 
respectively. Subsequently, a short incubation wilh a mixture of 10 mlluminol and 100 
j.ll oxidizing agent (BM chemiluminescense kit, Boehringer Mannheim GmbH, Germany) 
followed, after washing for four times 15 minutes with PBS. Excess reagent was 
removed and antibodies were visualized by exposure of the blots to an X-ray film. 
Reverse Transcriptase-polymerase chain reaction 
RNA was isolated by using the single step RNAzolTM B method (Campro, The 
Netherlands(Chomczynski, 1987). Frozen tissue (100mg) was homogenized in 1 mlof 
RNAzolTM . Chloroform (0.1 ml) was added and the mixture was vortexed for 15 seconds 
followed by 5 minutes incubation on ice. The homogenate was then centrifuged at 4 °C 
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at 12,000 g for 15 minutes. The upper water-phase containing the RNA was removed 
and mixed with an equal volume of isopropanol. This mixture was then kept at 4 'C for 
15 minutes and after that centrifuged at 4'C at 12,000 g for 15 minutes. The 
supernatant was removed and the RNA pellet was washed twice with 75 % ethanol by 
vortexing and centrifugation at 4'C at 12000 g. The pellet was then dried and 
resuspended in sterile H,O. The concentration was determined at OD 260 and solutions 
of 1 ~g/~1 were prepared for further use in Reverse Transcriptase-polymerase chain 
reaction (RT-PCR). The quality of the isolated RNA was checked by determining the 
260/280 ratio and by formaldehyde gel-electrophoresis to check the ribosomal (28 S 
and 18S) bands. 
RT-PCR was performed for CgA, SGIII, PAM, PC1 and 2 and 112-microglobulin 
(112MG) with a standard protocol. Reverse transcriptase reaction was performed with a 
mastermix containing 5 mM MgCI" PCR buffer, 10 mM dNTP's, RNAse inhibitor (10 
units), Reverse transcriptase (25 units), 2.5 mM random hexamer primers and 0.5 ~g 
RNA in a total volume of 1 0 ~I covered with 50 ~I of mineral oil. The mastermix was 
then processed at 42'C for 60 minutes followed by a 15 minutes incubation at 99'C and 
the reaction stopped at 4 'C for five minutes. The cDNA mix that was formed was then 
used totally with the mastermix of the polymerase chain reaction (PCR) protocol. In this 
protocol, the mastermix contained reaction buffer, Goldstar Red DNA polymerase 
(Eurogentec, Seraing, Belgium; 1 unit), 15 ~M sense and antisense primer in a total 
volume of 40 ~1. All samples were first denaturated at 94 'C for 10' and then 
amplification was performed for 35 cycles of l' 94'C, l' 60'C and l' 72'C and a final 
extension at 72'C for 10'. The PCR product was checked on an 1% agarose gel and, if 
necessary, followed by Southern blotting. 
RESULTS 
A decline in proliferative activity (Figure 1A), a rapid and persistent loss of 
androgen receptor expression (Figure 1C), as previously shown for the PC-82 
xenograft model(Ruizeveld de Winter, 1992), and an increase of apoptosis in the PC-
295 human prostate cancer xenograft is associated with a rapid tumor volume decrease 
(Figure 18) after androgen withdrawal. The percentage of BrdU incorporating cells after 
one hour IP administration decreased rapidly from a basal percentage of 10 in the 
controls to nearly zero at day four after castration. Accordingly, the MIB-1 expression 
decreased from an initial percentage of 20 in the controls to near zero at day four after 
castration. Within a period of two days, the expression of androgen receptor in about 90 
% of PC-295 cells disappeared. The percentage of apoptotic cells increased from the 
moment of castration to a maximum at day four, when about 20 % of the tumor cells 
were apoptotic. The prostate specific antigen serum levels paralleled the dramatic 
tumor volume decrease, and decreased rapidly after castration to zero after 7 days 
(Figure 1C). 
Androgen withdrawal also leads to an immediate increase in the proportion of NE 
cells. The number of NE cells, as marked by the expression of CgA, increased from an 
initial 1,000 cells per square mm to 60,000 NE cells per square mm at day seven after 
castration (Figure 1A). The course of CgA expression in time is given in Figure 2 in 
which the immunostainings of the different time points are shown. The typical granular 
staining for CgA increased clearly and positive cells were still observed 21 days post-
castration. The NE cell was the main tumor cell type found already from day 7 post-
castration on, as determined by immunohistochemistry for both CgA and Sglli. 
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Figure 1: Monitoring of 
proliferation, apoptosis, NE 
differentiation and tumor volume 
changes In the PC·295 model after 
androgen withdrawal. 
A) Resulls of the 
immunohistochemical staining for 
proliferation (BrdU, 03(Mice received 
BrdU IP one hour prior to sacrifice.); 
MIB-1, 0) and neuroendocrine 
differentiation (egA,.). Proliferation is 
shown in mean percentage positive 
cells scored per 1000 cells (n=3). 
whereas the NE differentiation is 
shown as the number of egA positive 
cells per mm3, One·way ANOVA 
showed that both BrdU and MIB-1 
decreased in time (K-W. p<0.05). At 
each time point mean values are given 
(n=3). 
8) Results from volume 
measurements (.&) after castration 
and the immunohistochemical staining 
for apoptosls by TUNEL (.) 
Apoptosis is shown as percentage of 
positive cells scored per 1000 cells. 
Tumor volume decrease was 
significantly different from controls (I· 
test, p < 0.05). At each time point 
mean values are given (n=3). 
C) Results from prostate specific 
antigen serum measurements 
(PSA,D) and immunohistochemical 
staining for the androgen receptor 
(AR, +; scored as pecentage/1000 
tumor cells) for the different time 
paints post-castration. 
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Figure 2: Immunohistochemical staining for CgA in the PC-295 model at different time pOints 
post-castratlon. 
A) Control tissue of a poorly differentiated PC-295 tumor with one NE cell; 8) PC-295 tumor 1 day after 
castration, with one NE cell (open type); C) PC-295 tumor 2 days after castration, with dispersed NE 
cells; D) PC-295 tumor 4 days after castration, with a cluster of NE cells; E) PC-295 tumor 7 days after 
castration, with a large number of NE cells F) PC-295 14 days after castration; G) PC-295 tumor 21 
days after castration; and H) H & E staining of the PC-295 tumor in the control situation 
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It was clear that the characteristic cribriform growth pattern of untreated PC-295 tumors 
disappeared around four days post-castration, finally resulting in a solid tumor largely 
composed of islets of CgA positive cells surrounded by murine stromal cells. Increased 
expression of the neuropeptides serotonin and bombesin was detected in part of the 
CgA positive cells at 7, 14 and 21 days post-castration (Data not shown). Increased 
expression of somatostatin receptors was seen 4 and 7 days post-castration, whereas 
expression of calcitonin or VIP was not detected at all. The PC-295 tumor cells showed 
increased expression of Bcl-2 from 4 days post-castration on. The BcI-2 expression was 
found in non-NE cells at day 14 and 21 post-castration in predominantly CgA and 8gll1 
immunostained tumor fields. 
Western blot analysis confirmed the immunohistochemical results, showing the 
castration-induced increase of CgA expression associated with a decreased expression 
of the androgen receptor (Figure 3). The specific CgA 68 kD signal and the amount of 
smaller 30 kD CgA derived peptide clearly increased after androgen withdrawal, 
whereas 112 kD AR expression was clearly lost two days after castration. An increased 
expression of 63/61 kD 8GIII (Figure 4) was observed from 7 days post-castration on 
The amounts of the processed forms of 8G III, as indicated by the 48, 28 and 20 kD 
fragments, decreased after androgen withdrawal. 
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FIGUUR 3: Expression of the androgen receptor (AR) and Chromogranin A (CgA) 
in the PC-295 model following androgen withdrawal analyzed by Western 
blotting. 
Both panels show the time points To, T.o.5, T.
" 
T.'.5, T.2, T.4 and T.7• In the upper 
panel the decreasing signal of androgen receptor expression is found at 110-112 kD. 
The CgA signal can be found between 66 and 75 kD in the lower panel, which are 
the lowest bands in the control Pheochromocytoma (pheo). Both panels also show 
the processed proteins or degradation products. 
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Immunohistochemical double labeling of PC-295 tumors clearly showed absence 
of any expression of MIB-1 in CgA positive cells. For BrdU labeling however, a different 
result was observed. Tumors of mice injected with BrdU one hour prior to sacrifice did 
not show BrdU labeled CgA positive NE cells. Continuously BrdU labeled tumors 
respectively showed 5% and 10% double labeled NE cells at day two and four post-
castration, while 40% and 70% of the whole cell population was BrdU 
positive, respectively. 
To T.o.5 T_1 T_1.5 T_2 T-4 T_7 T_21 PIT PrCa 
-.- ... 
63/61kD ~ 
48kD ~ • .;;;...+~"-
28kD 
20kD 
-
FIGURE 4: Expression of Secretogranin III in the PC-295 model following 
androgen withdrawal analyzed by Western blotting. 
Secretogranin III is expressed as 63/61 kD (upper arrow) double band in prostate 
carcinoma (PrCa), pituitary (Rat) and in the PC-295 models at all indicated time 
points. The processed forms of the protein are also visible at the lower bands of 48 
kD, 28 kD and 20 kD (compare the pituitary lane) 
egA 
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Figure 5: Results of RT·PCR for NE 
markers in the PC-295 model 
postcastration 
Expression patterns of egA, 8GIII, 
p2MG and PAM are shown for Ihe 
different time pOints in the tumors post-
castration. The lengths of the peR 
products are given. H69 is a small cell 
lung cancer cell line, and -RT and w 
are controls for reverse transcriptase 
and water, respectively. 
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RT-PCR with human specific CgA and SGIiI primers demonstrated a clear 
increase of the NE phenotype in PC-295 after four days of androgen withdrawal by 
using p2MG expression as internal human control (Figure 5). No significant variation in 
PAM expression was noted after castration, as indicated by two alternatively spliced 
mRNA variants. 
DISCUSSION 
In this report, we extend the previous observations done in the PC-295 human 
prostate cancer xenograft model and describe in more detail the characteristics of NE 
differentiation in prostate cancer under hormonal regulation. The growth and regression 
of the PC-295 human prostate cancer xenograft in the presently described castration 
experiment was comparable to the result of earlier studies performed with this 
model(van Weerden, 1996). The tumor doubling time was 13 days and the half-life time 
of tumors after castration was 4.3 days, which was within the same range as found in 
earlier experiments. After 21 days of androgen withdrawal only 10 % of the initial tumors 
(200 in stead of 2000 mm3) was left, so the PC-295 tumor model regressed rapidly after 
androgen wilhdrawal. Both Western blot analysis and immunohistochemistry showed a 
rapid decrease in androgen receptor expression in the PC-295 tumors(Noordzij, 1996), 
comparable to the behavior of the fully androgen dependent human PC-82 xenograft 
after castration(Ruizeveld de Winter, 1992). This was parallelled by a clear and rapid 
decrease of the prostate specific antigen serum levels, clearly demonstrating the 
androgen dependent character of the PC-295 model. 
The immunohistochemical results showed a rapid decrease of BrdU and MIB-1 
positive cells from 10% and 20% in the controls to about 0% in tumors at day 4 and 7, 
respectively. Both nuclear proliferation markers showed a 50% decrease two days post-
castration. The TUNEL staining for apoptosis showed a maximum of apoptotic cells at 
four days after castration. The NE phenotype was clearly and rapidly induced at 4 days 
after androgen withdrawal at which time point there were only a few proliferating cells 
left. 
Analysis for CgA by Western and RT-PCR confirmed the increased expression of 
the CgA protein and RNA in time from a basal expression level in the controls to a 
maximum at 7 and 14 days post-castration. There is considerable variation in the basal 
level of NE cells in the androgen supplemented situation, which could be explained by 
an inter-tumoral variation between different mice, which seems to be associated with 
environmental, e.g. host-derived factors, rather than that it is due to an intrinsic tissue 
heterogeneity. Expression levels of the NE phenotype in the different tumors were 
confirmed by comparing the immunohistochemical picture with the Western and RT-
PCR data at the different time points. In spite of inter-tumoral differences in CgA 
expression levels at the moment of castration, a clear increase in the mean value of NE 
differentiation was observed 4, 7 and 14 days post-castration. RT-PCR analysis showed 
that expression of CgA mRNA initially decreased following androgen wilhdrawal where 
after it increased again after day 4 when the tumor cells did not proliferate. The 
difference between immunohistochemistry and RT-PCR from day 0 to day 4 is most 
likely caused by inter-tumoral variation in basal egA expression levels. Another 
explanation is that the levels of CgA mRNA are higher in NE cells of the controls 
compared to NE cells directly after androgen withdrawal. 
The induction of NE differentiation after androgen withdrawal has now clearly 
been shown. To further characterize NE cells and the process of NE differentiation we 
are testing other and possible early markers of NE differentiation. In the PC-295 model, 
we detected increased expression of SGIIi at both protein level by Western blotting and 
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immunohistochemistry and at mRNA level as determined by RT-PCR analysis. This 
clearly indicates that the regulated secretory pathway (RSP) is active in these prostatic 
NE cells. Holthuis et al were able to clone the various components of the genetic route 
of the RSP in Xenopus laevis(Holthuis, 1995), and found several NE markers that are 
co-expressed with Sglll, like Ac45 and X7365 for the RSP. The expression of CgA is 
not a requisite for regulated secretion of bioactive neuropeptides, as CgA is just a 
general marker for NE cells and not functionally involved. It will be relevant to study 
RSP related proteins, like Sglll and PC1 which are currently being studied, to establish 
whether neuropeptides can be actively secreted by NE cells in the PC-295 model. 
No changes in the PC-295 model were found in PAM-mRNA expression levels 
as determined by RT-PCR. PAM was expressed as three splice variants which was 
similar to the expression pattern of PAM in lung cancer celilines(Vos, 1995). PAM is not 
necessarily expressed in NE cells, as it is a protein that activates neuropeptides by 
amidation after their secretion from NE cells. It is therefore not surprising that the 
expression of PAM did not increase in the PC-295 model after castration. 
Serotonin and bombesin, but not but VIP and calcitonin were expressed in the 
PC-295 model. Using somatostatin autoradiography by ['25 1_ TYR"]-SS-28, which binds 
with high affinity to the five known somatostatin-receptor subtypes, specific binding was 
demonstrated for ss-receptors type sst1 and sst2 in PC-295 tumor tissue (L. Hofland, 
Department of Internal Medicine, unpublished results). These results indicate that a 
number of growth modulating neuropeptides and some of their receptors can playa role 
in the PC-295 model. 
From the double stainings of CgA with BrdU and MIB-1, it was concluded that the 
greater part of the NE cells was in the Go-phase of the cell cycle which was in 
agreement with other studies on prostate cancer(Bonkhoff, 1994a; Bonkhoff, 1994b). 
From the double labeling studies with MIB-1 and CgA it was seen that the few 
proliferating cells at 7 days post-castration were surrounding the predominantly CgA 
positive islets of the PC-295 human prostate cancer tissue. Subsequently, comparing 
the Western blot results for CgA and androgen receptor clearly showed that the NE 
cells did not express the androgen receptor. NE cells thus seem to be an androgen 
independent, non-proliferating part of the prostatic epithelium. 
Bonkhoff et al predominantly found in benign prostatic glands that proliferation 
was restricted to the prostatic basal cell layer and that basal cells did not express the 
androgen receptor. In prostate cancer specimens, androgen receptor negative NE cells 
expressed cytokeratins 18 and 5, and these cells were found in the proximity of 
proliferating cells. In the PC-295 experimental tumor model, clustered NE cells are thus 
also found in the proximity of proliferating cells, indicating a possible interaction 
between NE cells or their products and neighbouring proliferating cells. The fact that 
basal, proliferating cells and CgA positive NE cells are the only cells surviving androgen 
deprivation suggests that the absence of androgen receptor expression plays a key role 
in their survival. Another factor for cellular survival is BcI-2 that protects cells from 
undergoing apoptosis. This is also shown in our model as Bcl-2 expression increases 
after androgen withdrawal. Post-castration, Bcl-2 is not expressed in NE cells but in a 
proportion of non-NE putative androgen independent cells in the PC-295 xenograft. In a 
recent publication(Xue, 1997), Xue et al showed a specific keratin expression pattern 
for most NE cells in prostate cancer patient material by using serotonin as NE marker 
combined with the luminal epithelial cell marker (Cytokeratin 18) and a typical basal cell 
marker (cytokeratin 5;RCK 103). A minority of the prostatic NE cells expressed only 
cytokeratins for basal cells or luminal cells. NE cells thus form a heterogeneous 
population. However, no expression of Bcl-2 in NE cells in patient material was found, 
suggesting that Bcl-2 expression is lost during NE differentiation of Bcl-2 positive basal 
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cells(Xue, 1997). In the in vivo model LuCaP, cell lineage markers prostate specific 
antigen, neuron-specific enolase (NSE) and Bcl-2, were used to mark the different 
epithelial cell types found in prostate cancer tissue(Liu, 1996). They proposed a model 
in which Bcl-2 positive proliferating epithelial cells differentiated into either a lineage of 
NSE expressing NE cells or a lineage of prostate specific antigen expressing exocrine 
secretory cells. In this latter population, the expression of NSE is heterogeneous. These 
amphicrine, i.e. both NSE and prostate specific antigen positive, cells, may be induced 
to express BcI-2, which might result in tumor cells surviving hormonal manipulation. 
These results partly support the stem cell model for benign prostatic hyperplasia 
proposed by Isaacs and Coffey(lsaacs, 1989). They propose a model of prostatic stem 
cells, which divide into a limited number of amplifying, basal cells followed by a limited 
number of cell divisions to finally form transit cells that differentiate into the different 
epithelial cell subpopulations. In prostate cancer, most probably the amplifying step in 
this model is not limiting, resulting in numerous types of exocrine and endocrine cells 
expressing different combinations of cytokeratins. 
In the PC-295 model, we found BrdU positive NE cells. As we did not find MIB-1 
expression in NE cells, the NE cells apparantly did not proliferate, rather than that a 
fraction of CgA positive cells entered S-phase shortly post-castration. Such cells are 
supposed of being arrested before mitosis. Another more plausible explanation is that 
the BrdU labeled cells were amplified post-castration and differentiated into NE cells in 
the time that followed between BrdU labeling and sacrifice at day 2 or 4 after castration. 
Considering Xue et al and the present results, there are possibly two routes of NE 
differentiation in androgen dependent epithelia: a regular route from proliferating cells 
via an intermediate cell type to NE cells and an alternative route of induced NE 
differentiation from exocrine luminal cells by androgen withdrawal. 
The CgA and Sglll stainings, the increased apoptosis and the non-proliferative 
status of most of the NE cells seen at the controls (To) and at 7 days post-castration in 
the currently described PC-295 xenograft, clearly show the process of neuroendocrine 
differentiation as being induced by androgen withdrawal. From the histological picture it 
is also clear that the changes in NE expression are not due to a selection of NE cells. 
The BrdU positive NE cells are probably the best indicators of the post-castration 
amplified cells that differentiate into a NE cell. The greater part of the NE cells found 
after 4 days of androgen withdrawal differentiated from Go-phase arrested luminal or 
intermediate cells. Clearly, the induction of the NE phenotype is a proliferation 
independent process in the PC-295 model. PC-295 tumors did not grow without 
androgens neither in female mice nor after long-term castration of PC-295 tumor 
bearing mice (data not Shown). This may be explained by the rapid decrease in 
proliferation and the rapid tumor regression of the PC-295 tissue following castration. 
Probably, the decreased tumor vascularity in PC-295, observed after prolonged 
androgen withdrawal, caused the death of surviving non-proliferating cells. All together, 
neither the induction of the NE phenotype, nor BcI-2 expression of non-NE cells post-
castration in PC-295 did not lead to androgen independent growth or maintenance of 
the tumor vascularity. 
As the prognostic value of CgA expression or occurrence of NE differentiation in 
prostate cancer is still under debate, further testing of Sglll and PAM as possible better 
NE-related prognostic markers for the progression of prostate cancer is still relevant. 
Possible changes in expression of components of the regulated secretory pathway or 
PAM might have effects on, for example, overproduction of bioactive growth stimulating 
neuropeptides. 
The PC-295 in vivo model is a potential model for further studies of the induction 
of NE differentiation by androgen withdrawal, the regulated secretory pathway in 
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particular. In addition, PC-310, another androgen dependent, NE differentiated prostate 
cancer model is currently under investigation and might provide us with additional 
knowledge on NE differentiation. Differentiation of NE cells from basal or luminal cells 
and the role of NE cells in progression of prostate cancer are important aspects to be 
studied as well. 8GIII, PAM, or other markers for NE differentiation are to be tested 
retrospectively for their prognostic value in the survival of patients undergoing radical 
prostatectomies. Human prostate cancer xenograft models with NE differentiation will 
be used to answer fundamental questions on prostate cancer. 
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Abstract 
BACKGROUND: Androgen independent growth leads to progressive prostate 
cancer after androgen ablation therapy. This may be caused by altered specificity of the 
androgen receptor (AR), by ligand independent stimulation of the AR, or by paracrine 
growth modulation by neuropeptides secreted by neuroendocrine cells. 
METHODS: We established and characterized the androgen independent FGC-
DCC from the androgen dependent LNCaP cell line. The androgen independent DU-
145, LNO, FGC-DCC and PC-3 and the androgen dependent LNCaP and PC-346C cell 
lines were used to study growth modulation of gastrin releasing peptide (GRP), 
calcitonin (CT), serotonin (5-HT) and vasoactive intestinal peptide (VIP) by 3H-thymidine 
incorporation. Specificity of the growth-modulating effects was tested with the anti-GRP 
monoclonal antibody 2A 11 and induction of cAMP by neuropeptides. 
RESULTS: Androgen independent growth stimulation by neuropeptides was 
shown in DU-145 and PC-346C. 2A11 inhibited GRP-induced 3H-thymidine 
incorporation in DU-145 and PC-346C and inhibited proliferation of the FGC-DCC and 
PC-3 cell lines. With some exceptions, cAMP induction paralleled growth stimulation. 
Dideoxyadenosine (DDA) inhibited the GRP-induced growth effect in OU-145 and PC-
346C, whereas oxadiazoloquinoxaline-1-one (OOQ) had no effect on 3H-thymidine 
incorporation. None of the neuropeptides stimulated growth of LNCaP, LNO, FGC-DCC 
and PC-3. 
CONCLUSIONS: GRP-induced growth of DU-145 and PC-346C was specific and 
cAMP mediated. Androgen independent growth of FGC-OCC cells was mainly due to an 
induction of BcI-2 expression and possibly through the activation of an autocrine and 
neuroendocrine-like pathway as has been shown for the PC-3 cell line as well. Growth 
induction of non-NE cells by neuropeptides could be a possible role for neuroendocrine 
cells in clinical prostate cancer. 
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Introduction 
Prostate cancer is rapidly becoming the main cause of death for elderly men. 
Initially, most cases of prostate cancer can be successfully treated by an approach of 
androgen suppression or androgen receptor blockade. However, a major problem in the 
treatment of metastasized prostate cancer is the development of androgen independent 
disease. This androgen independent growth can be caused by at least four different 
mechanisms. First, mutations in the androgen receptor could lead to unrepressable 
growth activation of prostatic cancer cells. Second, the androgen receptor may interact 
with growth hormones other than testosterone or di-hydrotestosterone, e.g. 
glucocorticoids like LHRH (Culig, 1997b). Third, androgen receptor activation could be 
induced by a ligand independent activation through different types of growth factors, like 
Insulin-like growth factor(Peehl, 1996a; Chan, 1998; Lamm, 1998) or biogenic amines 
(Zhu, 1997). A fourth mechanism is receptor specific paracrine or autocrine growth 
modulation of human prostatic cancer cells by neuropeptides secreted by 
neuroendocrine (NE) cells. 
NE cells are present in the normal and neoplastic prostate(Noordzij, 1995c). 
Neuropeptides are growth factors either eutopically or ectopically produced by these NE 
cells. Serotonin (5-HT)(Abrahamsson, 1987; Seuwen, 1990; Abdul, 1994), bombesin or 
gastrin releasing peptide (GRP)(Cuttitta, 1985; Bologna, 1989; Moody, 1993; Speirs, 
1993; Bold, 1994; Aprikian, 1997), vasoactive intestinal peptide (VIP)(Gkonos, 1996; 
Solano, 1996), calcitonin (CT)(lwasaki, 1983; di-Sant'Agnese, 1986; Shah, 1994; 
Ritchie, 1997), parathyroid hormone-related protein (PTHRP)(lwamura, 1994a; Cramer, 
1996; Peehl, 1997; Wu, 1998a), and somatostatin (SMS)(Brevini, 1993) are all 
examples of growth modulating neuropeptides in neoplasia of lung, intestine, pancreas, 
prostate and other epithelia(Tutton, 1987; Dalsgaard, 1989). Most of the known 
neuropeptides act via cAMP induction through stimulation of adenyl cyclase(Gkonos, 
1995; Gysbers, 1996; Ichikawa, 1997) and Ca2' mobilization(Bunn, 1990; Sethi, 1991; 
Han, 1997; Wasilenko, 1997) or via cGMP-coupled receptor proteins(Sinnet-Smith, 
1990). The different mechanistic actions of these neuropeptides can be studied by 
using specific blockers of adenyl cyclase or guanylyl cyclase(Reid, 1990; Wessels-
Reiker, 1993; Cellek, 1996; Gysbers, 1996). 
The role of NE cells and their secreted bioactive neuropeptides in the 
progression of human prostate cancer from an androgen dependent to an androgen 
independent state is still unclarified. Previously, we showed that androgen suppression 
in the NE differentiated human xenograft model PC-295 lead to a proliferation 
independent induction of NE differentiation(Jongsma, 1998). We also showed 
expression of different components of the regulated secretory pathway, indicating that 
NE cells in prostate cancer are capable to actively secrete neuropeptides and other 
growth factors. Observations in another NE differentiated model, PC-310, showed a 
similar induction of NE differentiation after androgen suppression (unpublished results). 
The question remains why this induction takes place and whether these NE cells have 
the potential to induce androgen independent cell growth. Other groups investigated NE 
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differentiation in the prostate(Abrahamsson, 1996; Noordzij, 1996; Krijnen, 1997; Qiu, 
1998) and growth modulating effects of different neuronal-associated peptides like 
neurotensin (NT)(Seethalakshmi, 1996; Seethalakshmi, 1997), nerve growth factor f), 
(NGF-f),)(Paul, 1996; Geldof, 1997; Angelsen, 1998) and neuropeptides like 
prolactin(Nevalainen, 1997), and adrenomedullin(Miller, 1996) on prostate cancer cell 
lines. Extensive studies on neuropeptides and growth factors have been done in small 
cell lung cancer (SCLC)(Bepler, 1988) cell lines, which are well known for their 
autocrine growth pattern. One of these investigations resulted in a potential therapy for 
SCLC, i.e. the use of the anti-GRP monoclonal antibody 2A 11 as possible intervention 
treatment for SCLC patients(Avis, 1991). 
A study with a steroid dependent non-SCLC cell line showed that these cells 
adapted to serum free and growth factor free medium by producing GRP in an autocrine 
way associated with the appearance of NE features like neurite outgrowth and 
expression of NE specific markers(Siegfried, 1994). Prostate cancer cell lines showing 
the NE phenotype have not been described so far. However, it was shown that the 
androgen dependent LNCaP cell line adapted to androgen depletion by androgen 
independent cell proliferation(Pousette, 1997), expression of the anti-apoptotic protein 
BcI-2(Raffo, 1995; Dorai, 1997; Saeed, 1997), and strong neurite outgrowth. One group 
reported induced expression of both Bcl-2 and neuron specific enolase (NSE) after 
androgen suppression of the LNCaP cell line(Shen, 1996). 
In this study, we investigated the growth modulating properties of GRP, CT, VIP, 
and 5-HT on six human prostate cancer cell lines comprising both androgen dependent 
and independent cell lines, including an androgen independent variant of the LNCaP 
cell line that we established ourselves, with the aim to assess whether both types of 
prostatic cells can be stimulated to proliferate under influence of different neuropeptides 
in an androgen deprived situation. This effect of neuropeptides was assessed by 'H-
thymidine incorporation for proliferation and a radioimmunoassay (RIA) for cAMP 
induction. Specific antibodies and direct blockers of signaling transduction pathways 
were used to investigate the mechanism of growth activation by GRP in these prostatic 
cancer cell lines. Furthermore, we characterized the changes in expression of NE 
markers, chromogranin A (CgA), secretogranin III (Sglll), neuron specific enolase 
(NSE), expression of androgen receptor, PSA, and the anti-apoptotic marker Bcl-2 
during the establishment of the androgen independent variant of the androgen 
dependent LNCaP cell line. Using the two variants of LNCaP, we showed that androgen 
deprivation induced changes in gene expression and the ability to proliferate under 
influence of neuropeptides and androgens in an androgen deprived situation. 
MATERIAL AND METHODS 
Culture of cell lines 
The androgen dependent prostatic cancer cell line LNCaP (kindly provided by Dr. 
Julius Horoszewicz) is basically the same cell line that is made available through 
ATCC(Horoszewicz, 1983). The androgen independent PC-3(Kaighn, 1979) and DU-
145(Stone, 1978) were obtained from the American Type Tissue Collection (Rockville, 
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MD). These three cell lines were maintained in RPMI 1640 (Gibco BRL, Life 
Technologies, Scotland) supplemented with 7.5% fetal calf serum (FCS). All culture 
media were supplemented with penicillin 100U/ml, streptomycin 100 Ilg/ml, and 
glutamine 0.1 mg/ml. The androgen independent LNO celiline(van Steenbrugge, 1991) 
was grown in RPMI 1640 supplemented with androgen depleted, i.e. 5% dextran 
charcoal stripped FCS (DCC). 
The androgen dependent PC-346C cell line(Romijn, 1996), was established 
recently at our laboratory from a human prostate cancer xenograft model in nude 
mice(van Weerden, 1996), and was found to be androgen dependent. These cells were 
grown in Dulbeco's Modified Eagle's Medium (DMEM)/F12 (Gibco) medium 
supplemented with various growth factors, 2% FCS and 10·10M of the synthetic 
androgen R1881 as described before(Romijn, 1996). This culture medium was 
designated as Swedish Culture Medium (SCM). The mouse fibroblast cell line Swiss 
3T3(Todaro, 1963) was maintained in RPMI1640 with 7.5% FCS. The human breast 
cancer cell line ZR-75.1 was maintained in DMEM supplemented with 10% FCS and 10' 
9M Estradiol (E2). 
Establishment of FGC-DCC from LNCaP 
A seventy percent confluent culture of LNCaP (passage 37) was deprived of 
androgens and subsequently cultured in RPMI 1640 supplemented with 5% DCC. 
From this point onward the cultured cells were named FGC-DCC. At each subsequent 
passage, confluent flasks were frozen at -80°C for protein or mRNA extraction. The first 
passages grew relatively slow with a clear neurite outgrowth pattern known from 
neuronal cells. After about 10 passages the FGC-DCC cells started to grow with a 
growth rate exceeding that of the parental LNCaP cell line. 
Proliferation assays with 3H·thymidine incorporation 
We evaluated the growth modulating properties of the neuropeptides GRP, VIP, 
CT (Sigma) and 5·HT (RBI, Natick, MD, USA) by incubation of the different cell lines in 
flat bottomed 96 well plates (Co-star) with different concentrations of the neuropeptides. 
The cell lines LNCaP and PC·346C were plated at 5000 cells/well, LNO, FGC-DCC, 
PC-3 and DU-145 were plated at 2500 cells/well and the control Swiss 3T3 was plated 
at 3000 cells/well. All experiments, except for PC-346C, were performed in standard 
RPMI 1640 supplemented with 5% DCC. PC-346C experiments were performed in 
DMEM/F12 supplemented with insulin, selenite, transferrin, bovine serum albumin, 
epidermal growth factor, and 2% DCC (SCM-A). Testing of neuropeptide activity with 
these cell lines was performed under the condition of androgen depletion in DCC. This 
resulted in variable basal levels of 3H-thymidine incorporation as some cell lines grew 
slowly without androgens (LNCaP, LNO and PC-346C) and others grew relatively fast 
(FGC-DCC, DU-145 and PC-3). The PC·3 and DU-145 cell lines grew even faster in 5% 
DCC than in 7.5% FCS. Determination of the appropriate conditions for all cell lines led 
to the following concept. Cells needed to adjust 48 hours to 5% DCC in 96 wells plates 
before starting the incubation with neuropeptides. After 48 hours of culture, 
neuropeptides were added to the wells to a final volume of 250 fil at concentrations 
ranging from 10.12 to 10.7 moles/liter. After 32 hrs 0.5 IlCi of 3H-thymidine (5 Ci mmol, 
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Amersham, Inc, UK) was added for 16 hrs. The plates were then frozen at -20°C until 
final measurement. Cells were harvested with a Skatron cell harvester on I?-plate filters 
(Wallac Oy, Finland) and were subsequently counted in a 1205 betaplate liquid 
scintillation counter (LKB, Wallac, Turku, Finland). Data were expressed as means of 8 
duplicates per neuropeptide concentration. 
Specificity of the growth modulating effects of GRP in Du-145, 3T3 and PC-346c 
was analyzed in the 3H-thymidine incorporation assay with the anti-GRP MoAb 
2A11(Cuttitta, 1985) (kindly provided by Dr. F. Cuttitta, NCI, Rockville, MD). The MoAb 
2A 11 was added at 1-10 Ilg/ml prior to incubation of these cell lines with GRP. Inhibition 
of signaling transduction pathways activated by GRP was investigated in the 3H_ 
thymidine incorporation assay by adding the specific adenyl cyclase blocker, 
dideoxyadenosine (DDA) or guanylyl cyclase blocker, 1 H-[1 ,2,4joxadiazolo[4,3-
ajquinoxaline (ODO) at inhibiting concentrations just before exogenous GRP was added 
to the cells. 
Proliferative activity of the androgen dependent LNCaP, PC-346C and the 
androgen independence of FGC-DCC was tested through addition of R1881 at 
concentrations ranging from 10.13 to 10.8 M. 
Radioimmunoassay (RIA) for c-AMP induction by neuropeptides 
LNCaP-FGC, PC-346c, and ZR-75.1 cells were plated on 24 well plates at 
2.5x105 cells/well. Swiss 3T3 was plated at 2.0x105 cells/well and PC-3 and DU-145 
were plated at 1.5x1 05 cells/well. After 3 days of incubation cells were washed with PBS 
and subsequently incubated with 0.1 mM Isobutylmethylxanthine for 30 minutes (IBMX, 
Sigma) in their experimental media. The cells were then incubated with different 
neuropeptides, GRP, VIP, CT and 5-HT for 10 minutes to induce intracellular c-AMP 
levels. Culture medium was removed and the cells were lysed with cold 0.1 N HC!. The 
24 well plates or the contents of each well were stored at -80°C until final measurement 
with a RIA for 1251-succinyl-c-AMP (scintillation proximity assay, Amersham). 
Western Blot analysis 
We investigated the expression patterns of the NE markers CgA, Sglll and NSE 
as well as Bcl-2, and androgen receptor (AR) in the established FGC-DCC cell line by 
Western blotting. For expression of CgA and SGIII human pheochromocytoma was 
used as positive control and the LNCaP cell line for AR expression. The procedure of 
protein extraction was as previously described(Noordzij, 1996). 
20 Ilg of each protein sample was transferred to an SDS (Gibco) polyacrylamide 
gel and gel electrophoresis was performed with prestained markers as size standards 
(Novex, San Diego, CAl. The gels were blotted to a 0.451lm cellulose nitrate membrane 
(Schleicher & Schuell, Germany). The immunoblot was blocked with PBS (pH 7.7) 
containing 0.1% Tween-20 (Sigma) and 5% dry milk for one hour. The CgA, androgen 
receptor, NSE, Bcl-2 and SGIII antibodies were added in their optimal concentration. 
The blot was incubated overnight on an orbital shaker at 4°C. After rinsing the blot four 
times 15 minutes with PBS, incubation for one hour was performed with the secondary 
HRP-conjugated to GoataMouse and GoataRabbit antibodies, for mouse monoclonal 
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and rabbit polyclonal primary antibodies, respectively. Subsequently, a short incubation 
with a mixture of 10 mlluminol and 100 jll oxidizing agent (BM chemiluminescense kit, 
Boehringer Mannheim GmbH, Germany) followed, after washing for four times 15 
minutes with PBS. Excess reagent was removed and antibodies were visualized by 
exposure of the blots to an X-ray film. 
Reverse transcriptase polymerase chain reaction (RT-peR) analysis 
RNA was isolated by using the single step RNAzolTM B method (Campro, The 
Netherlands(Chomczynski, 1987). Cell suspension was added to 1 ml of RNAzol"', 
whereafter chloroform (0.1 m[) was added and the mixture was vortexed for 15 sec. 
followed by 5 minutes incubation on ice. The homogenate was then centrifuged at 4 'C 
at 12,000 g for 15 minutes. The upper,RNA containing, water-phase was removed and 
mixed with an equal volume of isopropanol. This mixture was then kept at 4 'C for 15 
minutes whereafter it was centrifuged at 4'C at 12,000 g for 15 minutes. The 
supernatant was removed and the RNA pellet was washed twice with 75 % ethanol by 
vortexing and centrifugation at 4'C at 12000 g. The pellet was then dried and 
resuspended in sterile H20. Concentration was determined at OD 260 and solutions of 
1 ~g/~1 were prepared for further use in Reverse Transcriptase Polymerase Chain 
Reaction (RT-PCR). 
RT-PCR was performed with human specific primers for CgA, SGIII, androgen 
receptor, BcI-2 and 1?2Microgiobulin (1?2MG) -for mRNA quality control. RT reaction was 
performed with a mastermix containing 5 mM MgCI" PCR buffer, 10 mM dNTP's, 
RNAse inhibitor (10 units), RT (25 units), 2.5 mM random hexamer primers and 0.5 ~g 
RNA in a total volume of 1 0 ~I covered with 50 ~I of mineral oil. The mastermix was 
then processed at 42'C for 60 minutes followed by a 15 minutes incubation at 99'C and 
the reaction stopped at 4'C for five minutes. The resulting cDNA mix was used in total 
with the mastermix of the PCR protocol. This mastermix contained reaction buffer, 
supertaq DNA polymerase (HT Biotechnology Ltd., UK), 15 ~M of both sense and 
antisense primers in a total volume of 40 ~1. All samples were first denaturated at 94'C 
for 10' and then amplification was performed for 35 cycles of l' 94 'C, l' 60'C and l' 
72'C and a final extension at 72'C for 10'. The PCR product was checked on an 1 % 
agarose gel. 
RESULTS 
Table I lists the data of the 'H-thymidine incorporation assays and the cAMP 
measurements following exposure of the cell lines to various neuroppetides. The growth 
modulating effects of the four neuropeptides, GRP, CT, 5-HT and VIP varied among the 
prostatic cancer cell lines. [n control cell lines, incubation with the neuropeptides resulted 
in increased 'H-thymidine incorporation in response to GRP, CT and 5-HT (Swiss 3T3) 
or induced increased intracellular cAMP level in response to VIP (ZR-75-1). The 
androgen dependent PC-346C cells responded significantly to all four neuropeptides as 
is shown in figure 1. Growth stimulation varied from 30% by 5-HT at high concentrations 
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Table 1: Growth modulating effects of neuropeptides on human prostate cancer cell lines under 
androgen deprived culture conditions 
Cell line FCS Assay ORP CT 5·HT VIP R1881 
FOC AD H·T + 35%(10' ) -40% -0% -30% ++ 200% 
cAMP . · NA . 
FGC·DCC AID H·T +5% -15% -10% - 50% -40% 
cAMP NA NA NA NA NA 
PC·346C AD H·T +60% +80% + 30%(10' ) + 100% +100% 
cAMP . · . 2·3 x . 
DU145 AID H·T +45% +60% +15% -0% NA 
cAMP 2·3 x 3x . . 
PC·3 AID H·T -6% -10% -7% -0% NA 
cAMP 1.5 x · 1.7 x NA 
SWiss 3T3 AID H·T +25% +30% +30% +20% NA 
cAMP 2x 1.3 x 1.5 x . 
ZR·75·1 AID H·T NA NA NA NA NA 
cAMP 7.5·9 x 
Table 1 :Growth modulating effects of the neuropeptides on human prostate cancer cell 
lines LNCaP. FGC-DCC. PC-346C. DU-145. PC-3 and control cell lines Swiss 
3T3 and ZR-75-1 under androgen deprived culture conditions. Tritium thymidine 
incorporation ("H-T) values indicated are means (n=8) of percentage growth 
stimulation or inhibition compared to the control situation over the whole range 
of neuropeptide concentrations that were tested. If the effect is seen only at one 
concentration. this concentration is indicated in moles between brackets. The 
values of cAMP induction by the four neuropeptides are the mean induction 
ratios of two separate experiments (n=2). If marked with -. no significant 
changes in cAMP were induced by that specific neuropeptide. NA = not 
analyzed. AD= androgen dependent. and AID= androgen independent. 
to 100% by VIP. Significant induction of cAMP could be measured after incubation of 
PC-346C with VIP. but not in response to GRP. CT or 5-HT. In the LNCaP cell line. no or 
little growth stimulation was observed with any of the neuropeptides. whereas VIP and CT 
even inhibited 3H-thymidine incorporation. No significant induction of intracellular cAMP 
could be measured. Similarly. no significant growth stimulation of the androgen 
independent cell line FGC-DCC was observed after incubation with the neuropeptides 
GRP. CT. VIP and5-HT and VIP decreased 3H-thymidine incorporation by 50%. The 
synthetic androgen. R1881. served as a positive control for proliferation of the androgen 
dependent cell lines. The dose-response relationship of R1881 in the LNCaP parental cell 
line and the androgen independent FGC-DCC are shown in figure 2. In contrast to LNCaP 
showing a biphasic growth pattem in response to R1881. FGC-DCC did not show any 
increase of 3H-thymidine incorporation in response to R1881. 
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Figure 1: The growth modulating effects of neuropeptides on PC-346C 
The tritium thymidine incorporation as percentage of control levels are given for PC-346C 
cells after exposure to CT (0), VIP ('I), GRP (6) and 5-HT (). Values shown are means 
of 8 duplicates and standard deviations are shown as error bars at each neuropeptide 
concentration. Significant stimulation was observed with VIP, CT and GRP (Student T-
test, p> 0.01). 
The androgen independent DU-145 cells showed a significant increase 'in 3H_ 
thymidine incorporation in response to CT, GRP and to a lesser extent 5-HT. This was 
accompanied by significant increases in intracellular cAMP levels for CT and GRP. 
None of the neuropeptides tested did stimulate 3H-thymidine incorporation in the PC-3 
cell line, but the neuropeptides GRP and 5-HT significantly induced intracellular cAMP 
levels. 
The growth modulating effects of GRP in DU-145, PC-346C and Swiss 3T3 are shown 
in figure 3a-c. The specificity of the stimulatory effect of GRP with these cell lines is 
shown by parallel incubations with the anti-GRP MoAb 2A 11. Clearly, MoAb 2A 11 
blocked GRP-induced increase of 3H-thymidine incorporation in all three cell lines in a 
concentration dependent manner by intercepting the exogenously added GRP before it 
can reach GRP receptors on the cell surface. In absence of exogenously added GRP, 
3H-thymidine incorporation in PC-3 cells decreased by 50% after incubation with MoAb 
2A 11 when the cells were grown under standard culture conditions (data not shown). 
For DU-145 and PC-346C, the GRP-induced 3H-thymidine incorporation was further 
studied after incubation with the adenyl and guanylyl cyclase blockers, DDA and ODO. 
DOA significantly blocked increased 3H-thymidine incorporation at 10ftM and 0.1 f'M, 
whereas 000 at 2ftM and 20 nM had no effect on the before mentioned growth effects 
of GRP in PC-346C and DU-145. 
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Figure 2: The effect of androgen suppression on the androgen dependent LNCaP celiline 
A) The dose·response relationship of R1881 in LNCaP and FGC·DCC under 
androgen suppression. Tritium thymidine incorporation as percentage of control 
levels shows clearly the biphasic growth pattern of LNCaP ('\7), whereas FGC· 
DCC ( ) shows no growth in response to R1881 and even a decrease in 
proliferation at higher concentrations 
B) The changes in morphology of FGC·DCC after androgen suppression of the 
LNCaP parental. Clearly, neurite outgrowth is visible in the FGC·DCC celis 
which is absent in the LNCaP before androgen depletion (magnification 310 X). 
Characterization of the FGC·DCC celiline, showed induction of BcI·2 expression 
from passage 3 on and an increased expression of 8GIII and N8E after hormonal 
depletion at both protein level (Western blot, figure 4) and mRNA level (data not 
shown). Clearly, the 26 kD Bcl·2 protein is expressed in FGC·DCC and not in the 
parental LNCaP. The expression of the 61/63 kD double band of 8gll1 and expression 
of the 28 kD processed form can be clearly seen in FGC·DCC, whereas these are 
almost absent in LNCaP. The 44 kD N8E protein is expressed in both LNCaP and 
FGC·DCC. Androgen receptor was expressed from the second passage of FGC·DCC 
on, whereas P8A levels in FGC·DCC cullure medium dropped to zero after hormone 
wilhdrawal (data not shown). 
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Figure 3: Effects of MoAB 2A 11, DDA and ODO on the specificity of the GRP induced 
growth in DU-145, Swiss 3T3 and PC-346C 
The GRP induced increase (.) in tritium thymidine incorporation in DU-145 (A), 
Swiss 3T3 (B) and PC-346C (C) is inhibited partly by 1 fIg 2A11/ml (.) and 
completely by 10 fIg 2A11/ml (). DDA blocks the GRP action in DU-145 (A) and 
PC-346C (C) at 0.1 I'M (0) and in DU-145 (A) at 10 I'M (.), whereas 20 nM 
ODO (+) has no effect on the GRP induced growth effect in DU-145 (A) and PC-
346C (C). 
DISCUSSION 
We have demonstrated that growth of prostatic cancer cell tines under the 
condition of androgen depletion can be modulated by neuropeptides which are known 
to be produced by neuroendocrine cells. The action of these neuropeptides differed 
from one cell line to the other irrespective of their androgen dependent status. 
Furthermore, we described the establishment and properties of FGC-DCC, an androgen 
independent derivative of LNCaP,. 
Significant growth effects of VIP, GRP, CT and 5-HT were measured in the 
androgen dependent PC-346C cell line and in response to GRP, 5-HT and CT in the 
androgen independent DU-145. The effect of 5-HT that we observed in DU-145 was 
comparable to the results of Hoosein et al(Abdul, 1994; Hoosein, 1996), who observed 
an increased proliferation in response to relatively high concentrations of 5-HT (0.1 I'M 
and higher), as we observed increased 3H-thymidine incorporation already at 0.01 and 
O.1flM 5-HT in DU-145. Thus, we observed a higher sensitivity of DU-145 cells for 5-HT. 
The growth stimulation of DU-145 by CT was not found by other investigators(Shah, 
1994; Ritchie, 1997). who tested the action of neuropeptides under different culture 
conditions, i.e. total serum depletion instead of 5% as used in the present study. This 
may be also an explanation for the differences in growth effects in response to 
neuropeptides observed by other investigators in PC-3 and LNCaP. We observed no 
significant growth effects of any of the tested neuropeptides in the LNCaP, LNO and 
FGC-DCC cell lines. This also applied to the PC-3 cell line, which in contrast to other 
studies, did not react to exogenously added GRP. Various studies have shown binding 
of 1251_ Tyr4-bombesin to prostatic cell lines and that PC-3 possessed far more binding 
sites for GRP than DU-145 or LNCaP(Reile, 1994; Aprikian, 1996). We only observed 
significant growth stimulation of PC-3 by exogenously added GRP under the culture 
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Figure 4: Characterization of FGC-DCC establishment by BcI-2, N8E and 8gll1 
expression 
A) Expression of 26 kD Bcl-2 protein in FGC-DCC (marked by different passage 
numbers) and LNCaP (low and high passage number) on western blot. L70a is a 
BcI-2 expressing subline of LNCaP and served as positive control. 
B) Expression of N8E as a 44 kD band on western blot in FGC-DCC (marked by 
different passage numbers) and LNCaP (low and high passage number). H-69 is 
a human small cell lung cancer (8CLC) cell line, which served as a positive 
control. 
C) Expression of 8g111 in FGC-DCC (marked by different passage numbers) and 
LNCaP (low and high passage number) on western blot. Human 
pheochromocytoma served as a positive control. 8g11 is clearly visible as a 63/61 
kD double band together with the 48 kD and 28 kD processed forms of 8glli. 
condition of medium with 1 and 2,5% DCC, but not with 5% DCC. However, the basal 
3H-thymidine incorporation rate of PC-3 cells was much lower with 1 % DCC than with 
5% DCC in the experimental medium, indicating changes in cell growth by serum 
depletion. Furthermore, the growth induction by GRP that Bologna et al observed in PC-
3(Bologna, 1989) was relatively at minor level when compared to the GRP-induced 
growth that we observed in DU-145. Their results with PC-3 in response to GRP seem 
to be similar to our observations, which showed that exogenously added GRP did not 
induce significant growth stimulation, Following the incubation with the anti-GRP 
antibody 2A 11 in PC-3 cells, further substantiated that PC-3 proliferation in standard 
culture medium is strongly dependent on GRP as 3H-thymidine incorporation dropped 
by 50%. Probably, GRP is endogenously produced at high concentrations by PC-3. This 
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endogenous GRP production is partly inhibited by culturing the PC-3 cells at lower DCC 
serum concentrations, which explains the additional growth stimulation by exogenously 
added GRP with 1 and 2.5% DCC in the experimental medium. 
In six occasions of increased 3H-thymidine incorporation levels (Table 1), 
neuropeptide exposure was associated with increased intracellular cAMP levels. By 
contrast, intracellular cAMP levels increased upon exogenously added GRP and 5-HT 
in PC-3 cells, without affecting cell proliferation. This observation is consistent with the 
possibility that PC-3 cells produce GRP and 5-HT, as stated above. As PC-3 cells do 
have receptors for both GRP and 5-HT, PC-3 cells can be stimulated to grow in an 
autocrine way by these neuropeptides. We can not offer an explanation for the fact that 
we did not observe intracellular cAMP induction in PC346C in response to GRP and 
CT, whereas these peptides did increase cAMP in DU-145, Swiss 3T3 and PC-3. 
Possibly, the cAMP containing medium used for culturing the PC-346C cell line 
abrogates measurement of cAMP changes following exposure to GRP and CT. To 
speculate about the observed cAMP induction by VIP in the PC-346C cells, we think 
that the cAMP induction in PC-346C cells after exposure to VIP is stronger than that 
after exposure to GRP and CT. The major part of our data on intracellular cAMP 
measurements seem to match with those of Gkonos et al(Gkonos, 1995). However, it 
was striking to see that their induced levels of intracellular cAMP were about ten-fold 
higher then ours, e.g. salmon CT induced a three-fold increase of cAMP in DU-145 
whereas Gkonos et al observed a thirty-fold induced increase of cAMP by human CT in 
DU-145. 
The increased 3H-thymidine incorporation observed in GRP-exposed DU-145, 
PC-346C and control cells of Swiss 3T3 could specifically be blocked by the anti-GRP 
MoAb 2A 11 (at 10ftg/ml and 1 ftg/ml) when added prior to administration of the 
neuropeptide GRP. As discussed above, the anti-GRP MoAb 2A 11 also appeared to 
compete with endogenously produced GRP in PC-3 cells. Thus, for prostatic carcinoma 
the MoAb 2A 11 has shown to be a potent inhibitor of GRP-induced proliferation and of 
GRP producing cell lines, as was shown before for SCLC cell Iines(Cuttitta, 1985; 
Moody, 1993; Speirs, 1993; Halmos, 1997). 
Adenyl cyclase inhibitor DDA blocked the GRP-induced increase of 3H-thymidine 
incorporation in DU-145 completely or by 50% at 10 11M and 0.1 11M DDA, respectively. 
On the other hand, guanylyl cyclase inhibitor ODQ did not affect the GRP-induced 
growth modulation in DU-145. Thus, GRP specifically induces intracellular cAMP in DU-
145 as measured by RIA for cAMP. The same results with DDA were obtained for GRP 
exposed PC-346C cells, whereas ODQ partly blocked the GRP-induced growth 
stimulation. The results of DDA and ODQ in DU-145 and PC-346C have to be 
interpreted with caution as in contrast to MoAb 2A 11, these cyclase inhibitors do not 
interfere directly, but which might at high concentrations(Reid, 1990; Wessels-Reiker, 
1993; Gonzalez, 1997)have an indirect effect on cell cycle progression through the 
MAPK signaling pathway. In conclusion, GRP is a potent NE growth factor in prostate 
cancer cell lines that acts specifically under androgen suppression via induction of the 
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second messenger cAMP in both androgen independent (DU-145, PC-3) and androgen 
dependent (PC-346C) cells. 
The LNCaP and FGC-DCC cell lines showed a clear difference in their androgen 
dependent status as LNCaP showed its normal biphasic growth pattern with an 
optimum growth at 10·'0 M R1881 as published before(van Steenbrugge, 1991), 
whereas FGC-DCC could not be stimulated by androgens at all, indicating that FGC-
DCC is growing androgen independently. As expected, the synthetic steroid did not 
influence intracellular cAMP levels in the parental LNCaP. No major changes were 
observed between LNCaP and FGC-DCC with respect to their response to the four 
neuropeptides. VIP induced a 50% decrease in 3H-thymidine incorporation at 10 to 100 
nM. However, the anti-GRP MoAb 2A 11 decreased the basal 3H-thymidine 
incorporation of FGC-DCC cells by 40% at 10 flg/ml whereas the LNCaP cells did not 
respond to MoAb 2A 11. Like the PC-3 cells, FGC-DCC cells after androgen 
suppression possibly have adjusted to an autocrine growth pattern, by producing growth 
factors like GRP endogenously. 
As expected, AR expression did not disappear totally at protein or at mRNA level 
in FGC-DCC but it was low in comparison to the parental LNCaP. PSA levels 
decreased rapidly to zero after androgen suppression and continued to be low in FGC-
DCC after subculturing. The neuronal appearance of the FGC-DCC cells after androgen 
suppression was prominent, as was also seen by others shortly after androgen 
withdrawal(Raffo, 1995; Shen, 1996; Saeed, 1997). The expression of the anti-apoptotic 
protein BcI-2 was induced gradually during passage 2 and were at high level of 
expression from passage 3 on for at least 18 passages. Likewise, others found an 
increase in Bcl-2 expression(Raffo, 1995; Shen, 1996) or a decrease in BcI-2 
expression because of initiation of the apoptotic program(Saeed, 1997). Our results 
clearly show an induction of BcI-2 expression during LNcaP prostatic cancer cells 
progression from an androgen dependent to an androgen independent state. The 
expression pattern for the NE markers SGIII and NSE were different to that of BcI-2 as 
there was already a basal but low expression of both markers in the parental LNCaP. 
No expression of the NE marker CgA was observed in LNCaP and FGC-DCC at protein 
level or at mRNA level. To our knowledge, no further reports are available about NE 
differentiation in prostatic cell lines except for that of Shen et al (Shen, 1996). They 
found an induction of NSE expression at protein level after 10 and 20 days of androgen 
suppression of the LNCaP cell line. In our hands, however NSE was already expressed 
in the parental LNCaP cells when cultured under standard conditions, whereas 
expression increased slightly after subsequent passaging. In the in vivo model LuCaP, 
three cell lineage markers PSA, neuron-specific enolase (NSE) and Bcl-2, were used to 
mark different epithelial cell types found in prostate cancer tissue(Liu, 1996). They 
proposed a model in which BcI-2 expressing proliferating epithelial cells could 
differentiate into either a lineage of NSE expressing NE cells or a lineage of PSA 
expressing exocrine secretory cells. In this latter popUlation, the expression of NSE is 
heterogeneous. These amphicrine, i.e. both NSE and PSA positive, cells, can be 
induced to express Bcl-2, which might result in tumor cells escaping hormonal 
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suppression. In the presently studied androgen dependent LNCaP cell line both PSA 
and NSE, but not Bcl-2, are expressed,. Clearly, Bcl-2 expression is induced in FGC-
DCC and PSA expression is down-regulated. We conclude that FGC-DCC is not a NE-
differentiated cell line although the cells show a characteristic neuronal morphology. We 
found no significant increase in the expression of NE markers, as CgA was not 
expressed at all and the other markers were present in both the parental LNCaP and 
the FGC-DCC cell lines. Expression of the androgen receptor in FGC-DCC cells further 
supports this, as androgen receptor expressing NE cells have not been demonstrated in 
prostate cancer sofar(Krijnen, 1993). Instead the concept of Liu et a/(Liu, 1996) is 
applicable here, namely that the FGC-DCC subline of LNCaP is an example of a 
neoplastic, androgen independent, NSE, Sglll, Bcl-2 and AR expressing, but PSA 
negative prostatic epithelial cell that could possibly metastasize. This cell type could be 
committed to cell division and not to differentiation, which might be the reason why NE 
markers as well as the androgen receptor are expressed. 
We have shown in this study the induction of androgen independent growih both 
by adding growih modulating neuropeptides to prostatic cancer cell lines and by 
androgen suppression of an androgen dependent cell line, LNCaP leading to an 
androgen independently growing cell line, FGC-DCC. The growih modulating effect of 
GRP on DU-145 and PC-346C was specifically induced as shown with MoAb 2A 11 and 
the adenyl and guanylyl cyclase inhibitors. The growth of the metastatic PC-3 cell line is 
inhibited by MoAb 2A11 and strongly dependent on serum concentration which 
indicates an autocrine growth pattern for GRP. The FGC-DCC cells were also inhibited 
by MoAb 2A11, which is indicative of an androgen suppression-induced activation of an 
autocrine pathway in these cells. In vitro, we have shown that induction of. Bcl-2 
expression is one way to bypass androgen withdrawal which possibly leads to 
progression of prostate cancer. In vivo, there are some studies that support the idea of 
a role for NE differentiation in the progression of prostate cancer(Krijnen, 1997; Jiborn, 
1998). Induction of NE differentiation is a result of androgen withdrawal as we showed 
in two in vivo human prostate cancer xenograft models(Jongsma, 1998). Krijnen et 
al(Krijnen, 1997) showed in hormonally treated patients that clinical progression of 
prostate cancer correlated well with increased expression of NE, i.e. CgA positive, cells. 
By measuring the effects of neuropeptides in vitro, we provide evidence for androgen 
independent growih of non-NE cells induced by growih factors that are known to be 
produced by NE cells. In vivo, the expression of markers from the regulated secretory 
pathway are being studied, comprising the regulated secretion of bioactive 
neuropeptides from prostatic NE cells. Studying the progression of a NE differentiated 
in vivo model, assessing growih modulatory effects of neuropeptides in vivo and 
studying the process of induction of NE differentiation in vivo and in vitro after androgen 
withdrawal contributes to assess the role for NE differentiation in clinical prostate 
cancer. 
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ABSTRACT 
Neuroendocrine (NE) cells are androgen independent cells and secrete growth-
modulating neuropeptides via a regulated secretory pathway (RSP). We studied NE 
differentiation following androgen withdrawal in the androgen dependent prostate 
cancer xenograft PC-310. Expression patterns of Chromogranin A (CgA), 
Secretogranin III (Sglll) and prohormone convertase-1 (PC1) were analyzed to mark 
the kinetics of NE differentiation both in vivo and in vitro. PC-310 tumor-bearing nude 
mice were sacrificed at 0, 2, 5, 7, 14 and 21 days post-castration. PC-310C cultures 
initiated from collagenase-treated tumor tissue could be maintained up to four 
passages, and androgen deprivation experiments were performed similarly. PC-310 
tumor volumes decreased by 50% in 10 days post-castration. Proliferative activity and 
prostate specific antigen (PSA) serum levels decreased to zero post-castration. In vivo, 
androgen receptor (AR) expression decreased initially but returned to control level from 
5 days post-castration on. PSA levels in PC-310C culture media first decreased but 
increased after 5 days. CgA, Sglll and 7B2 expression increased in vivo from 5 days 
post-castration on. Subsequently, PC1 and peptidyl a-amidating monooxygenase, as 
well as the vascular endothelial growth factor were expressed from 7 days post-
castration on and finally growth factors like gastrin releasing peptide and serotonin were 
expressed in a small part of the NE cells 21 days post-castration. 
Like in the PC-310 xenograft, NE differentiation was induced and AR expression 
relapsed after prolonged androgen suppression in PC-31 ~C. For PC-31 DC cells this 
relapse was associated with secretion of PSA. PC-310C is the first culture of human 
prostatic cancer cells having the NE phenotype. The PC-310 model system is a 
potential androgen dependent model for studying the role of NE cells in the progression 
of clinical prostate cancer. Androgen deprivation of NE differentiated prostate cancer 
may induce the formation of NE and AR+ tumor residues which are capable of actively 
producing growth factors via a RSP, possibly leading to hormone refractory disease. 
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INTRODUCTION 
Neuroendocrine (NE) differentiated cells form an androgen independent 
subpopulation of the prostatic glandular cells (Abrahamsson, 1996). NE cells are 
considered to be non-proliferating cells which do not express the androgen receptor 
(Krijnen, 1993) and therefore are assumed to be unaffected by androgen deprivation. 
NE cells have been localized in nearly all clinical prostatic adenocarcinomas in different 
frequencies (Abrahamsson, 1986; di-Sant'Agnese, 1992b; Aprikian, 1993; Bonkhoff, 
1995; di-Sant'Agnese, 1995; Noordzij, 1995a; Noordzij, 1995c). 
Prostatic NE cells may regulate homeostasis and secretion of prostatic fluid, 
either actively or passively. NE cells can be identified by immunohistochemistry (IHC) 
with specific antibodies against secreted products for example serotonin (5-HT) (Xue, 
1997) and gastrin-releasing protein (GRP) or secretion-associated proteins, like 
Chromogranin A (CgA) (O'Connor, 1986; Abrahamsson, 1989; Schmid, 1994; Hendy, 
1995), which is the commonly used marker for neuroendocrine differentiation. NE cells 
show a heterogeneous cytokeratin expression pattern as there are basal, luminal and 
intermediate NE cell types (Bonkhoff, 1994b; Bonkhoff, 1994a; Xue, 1997) and are 
often found near Bcl-2 positive prostate cancer cells (Colombel, 1992; Cohen, 1994). 
Xue et al showed no co-expression of 5-HT with the anti-apoptotic oncogene Bcl-2 
(Xue, 1997). Likewise, we previously showed that CgA positive cells did not co-express 
BcI-2 (Jongsma, 1998) and that there was a proliferation independent induction of NE 
differentiation after androgen withdrawal. This induction did not allow progression of 
tumor growth of non-NE tumor cells after prolonged androgen suppression. Other 
studies revealed that androgen deprivation in clinical prostate cancer induced NE 
differentiation (Jiborn, 1998) or showed correlation of NE differentiation with progressive 
behavior (Krijnen, 1997). 
Most of the studies on the prognostic value of CgA for NE differentiation did not 
show a correlation between CgA expressing NE cells and poor prognosis or 
progression of prostate cancer (Abrahamsson, 1986; di-Sant'Agnese, 1992b; Aprikian, 
1993; di-Sant'Agnese, 1995; Noordzij, 1995a; Noordzij, 1995c). There are more 
markers of the NE phenotype next to CgA as NE differentiated cells have an activated 
regulated secretory pathway (RSP) (Holthuis, 1996b) next to the lysosomal and an 
exocrine constitutive pathway. Along the RSP pathway secretion and processing of 
bioactive neuropeptides and growth hormones, like insulin and glucagon in the 
pancreas (Smeekens, 1992; Tucker, 1996), are regulated. The RSP consists of a 
sequence of processes linked from transcription/translation of various factors to final 
secretion of neuropeptides at the plasma membrane from secretory granules (Holthuis, 
1995). Different markers can be identified, such as granular markers Secretogranin III 
(Sglll) and Secretogranin V (7B2) (Martens, 1989; Sigafoos, 1993; Braks, 1996), 
carboxy peptidase E and the processing enzymes prohormone convertase 1 and 2 
(PC1 and 2). The enzyme peptidylglycine a-amidating monooxygenase (PAM) (Vos, 
1995; Vos, 1996) is expressed in or in the near vicinity of NE cells. Evaluation of these 
markers of the RSP is ongoing in X. Laevis, human lung and prostate cancer (Huttner, 
1995; Eib, 1996). It may be relevant to evaluate the prognostic value of the markers of 
the RSP and the PAM marker in clinical specimens with long term follow up data or 
evaluate the expression in prostate cancer models. 
The role of NE cells in the progression to androgen independent growth is still 
unclear and there are not many representative prostate cancer models with NE 
differentiation. Several groups have recently been developing prostate tumor models 
both in vitro cell lines (Romijn, 1996) and in vivo xenografts (Liu, 1996; Nagabhushan, 
1996; van Weerden, 1996). The presently available prostate cancer cell lines lack the 
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potency to differentiate into NE cells. NE differentiation was studied in the panel of in 
vivo human prostate cancer xenograft models developed at our Institution. Some did 
not express the NE phenotype at all, whereas some lost their NE phenotype after a few 
passages in nude mice (Noordzij, 1996). It appeared that in the androgen dependent 
PC-295 and PC-310 models part of the cells constitutively has the NE phenotype. 
These two models are very suitable for studying NE differentiation in prostate cancer 
and the role that NE cells may play in the progression of prostate cancer. In both the 
PC-295 and PC-310 models, androgen deprivation induces increased numbers of NE 
cells. The kinetics of NE differentiation have been intensively studied in the PC-295 
model (Jongsma, 1998). In this completely androgen dependent model, the tumor 
rapidly regressed and like the non-NE cells also the NE cells eventually died. 
The PC-310 xenograft does not regress completely after androgen withdrawal. 
Therefore, we considered this tumor model more suitable for studying the process of 
NE differentiation of androgen dependent cells to NE cells and the consecutive 
maturation of these NE cells in the long-term. We first characterized the kinetics of NE 
differentiation after androgen depletion in the PC-310 model by using CgA, MIB-1, AR 
and PSA as cellular markers and analyzed the expression of Sglll, PC-1, PAM and 7B2 
as the different markers of the RSP, and the expression of different growth factors like 
sefotonin, gastrin releasing peptide, vasoactive intestinal peptide and VEGF after 
androgen suppression. Among the limited number of available in vitro cell lines of 
human prostate cancer, none showed the NE phenotype (Noordzij, 1996). Attempts 
were made to set up in vitro cultures of the PC-310 xenograft and the effect of androgen 
deprivation was evaluated whether the in vitro PC-310 culture had the potency of NE 
differentiation and behaved similarly to the xenograft in vivo in an androgen depleted 
environment. 
MATERIALS AND METHODS 
PC-310 xenograft model 
The nude mouse human prostate cancer xenograft model PC-310 was 
established from a primary prostatic tumor after radical prostatectomy of a previously 
untreated patient (van Weerden, 1996). The tumors usually grow with a doubling time of 
about 16 days and a lag phase of 2-3 months. The model represents a strictly androgen 
dependent and histologically moderately differentiated tumor, organized in solid sheets 
and microacini. In short, PC-310 tumors were implanted subcutanously at both 
shoulders of intact NMRI male nude mice (Harlan, Horst, The Netherlands). Optimal 
growth conditions were reached by supplementation of PC-310 transplanted mice with 
testosterone implants, as previously described (van Steenbrugge, 1984). 
Subcutanously growing tumors developed within 2-3 months and were grown up to a 
maximum volume of 2000 mm"- Tumor volume changes were followed weekly by two 
perpendicular diameter measurements (01 and 02) after which the volume was 
calculated from the formula: V=(I1/6)(01 x 02)312. 
Castration experiment with the PC-310 human prostate cancer xenograft model 
Castration experiments were performed with 24 testosterone-supplemented PC-
310 bearing male NMRI mice (Harlan, Horst, The Netherlands) at the Erasmus Center 
for Animal Research (Project nr. 102.98.02). Androgen withdrawal was performed by 
castrating the mice under hypnorm anesthesia (Janssen Pharmaceuticals, Oxford, UK) 
and by removing the silastic testosterone implant. Mice were sacrificed at 0, 2, 5, 7, 14 
and 21 days after castration, four mice per time point. 
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After blood samples were taken for determining serum prostate specific antigen 
levels, mice were sacrificed, Tumor volumes were measured and tumor nodules were 
removed, The tumors were cut into small pieces which were either fixed in 4% buffered 
formalin and paraffin embedded for immunohistochemical analysis or snap frozen in 
liquid nitrogen and stored at - 80°C for biochemical analysis, The paraffin embedded 
material was processed routinely for hematoxylin and eosin staining, 
In vitro initiation of primary culture from PC-310 xenograft tissue 
Initiation of primary cultures from xenograft material was performed according to 
Limon et al (Limon, 1990). Tumors were mechanically disaggregated after washing the 
tumor tissue in RPMI1640 + PIS, and necrotic tissue and blood clots were removed, 
The tissue was minced into 1- to 2-mm3 pieces which were put into RPMI1640 + PIS, 
After sedimentation for 10-15 minutes the supernatant was separated from the 
pellet. The supernatant was centrifuged at 175g for 10 minutes and the resulting pellet 
was resuspended in 3 ml medium and transferred into a culture flask, 10 ml medium 
containing collagenase A (final concentration 200 U/ml) was added to the pellet 
obtained after sedimentation and this suspension was incubated at 37°C for 2-3 hours. 
The cell suspension was transferred into centrifuge tubes, RPMI1640 + PIS was added 
and the cells were centrifuged at 175g for 10 minutes, 
The resulting pellet was resuspended in 10 ml Swedish culture medium, i.e. in 
Dulbeco's modified Eagles medium (DMEM F12) supplemented with various growth 
factors, 2% FCS, 1O"0M R1881 and PIS as described before (Romijn, 1996), After 
sedimentation for 10-15 minutes, the ensuing supernatant was centrifuged, 
resuspended in medium and transferred into culture flasks, Subsequent supernatant 
cultures were established by resuspending the sedimented pellet and repeated 
sedimentation for another 10-15 minutes, The different supernatant fractions were 
incubated in different culture flasks, The PC-310 xenograft was initially grown as a 
mixed culture of mouse fibroblasts and PC-310C human epithelial cells, After passaging 
of the cultures and subsequent treatment with Amphotheracin B, which could effectively 
kill mouse fibroblasts, pure cultures of PC-310C cells were obtained. 
Androgen deprivation of PC-310C cultures 
Series of confluent flasks with PC-310C were rinsed with PBS and subsequently 
cultured in medium with dextran charcoal (DCC) treated FCS for 0,2,5,7, 14 and 21 
days, At each time-point, culture medium was sampled and cells were harvested and 
frozen at -80°C for RNA and protein extraction, Likewise, small petri dishes were plated 
with PC-310C cells (n=2) and cells were grown in DCC containing medium, At the 
different time-points, the level of proliferation was assessed as the percentage cells with 
blue mitotic figures and the level of apoptosis was assessed as the percentage cells 
containing blue and pink apoptotic bodies by quantitative immunofluorescence 
microscopy of Hoechst 33342 and propidium iodine (PI) staining of the PC-310C 
cultures, 
The PC-310C cells were also grown on glass slides under various conditions and 
were used for immunohistochemical staining for NE-associated proteins, 
Immunohistochemistry 
To identify the fraction of cells expressing the NE phenotype, paraffin embedded 
tissue sections of the PC-310 xenografts were stained with antibodies against CgA 
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(monoclonal clone LK2H10; ICN Pharmaceuticals, Aurora Ohio or polyclonal rabbit anti 
human CgA, DAKO), Sglll (rabbit polyclonal antibody; provided by the Department of 
Animal physiology, University of Nijmegen) (Holthuis, 1996a) and PC1 and PC2 (Alexis 
Biochemicals, 10P's, Breda, The Netherlands). For identification of the proliferative 
capacity, tissue sections were stained with the antibody against the proliferation 
associated Ki-67 antigen (MIB-1, Immunotech, Marseille, France). In addition, apoptotic 
cells were identified by counting the apoptotic bodies in the hematoxylin and eosin 
staining of the tissues. Other antibodies used were directed against the androgen 
receptor (clone F39.4, kindly provided by Dr. A.O. Brinkmann, Department of 
Endocrinology and Reproduction, Erasmus University); the cytoplasmic Bcl-2 antigen 
(clone 124, Dako, Glostrup, DK), the growth factor VEGF (rabbit polyclonal, DAKO) and 
against the neuropeptides bombesin (rabbit polyclonal GRP, DAKO; and anti-GRP 
MoAb 2A11; kindly provided by Dr F. Cuttitta, NCI, Bethesda, USA), serotonin (5-HT; 
rabbit polyclonal antibody), vasoactive intestinal polypeptide (VIP, rabbit polyclonal) and 
Calcitonin (rabbit polyclonal). 
Paraffin embedded xenograft tissues were cut at 4 ~m sections for single 
immunostaining and 2 ~m for double immunostaining. The sections were mounted on 3-
amino-propyl-triethoxysilane coated glass slides and incubated overnight at 60"C. The 
slides were deparaffinized and endogenous peroxidase activity was blocked with 3.3% 
hydrogen peroxide (H202) in methanol for 10 minutes. The following steps were also 
performed for the PC-310C glass slides after a 10-minute fixation in 4% formaldehyde. 
Antigen retrieval was then performed in 10 mmollL citrate buffer (pH 6.0) in a 
microwave at 700 watt for an initial 10 minutes and a subsequent 5 minutes(Shi, 1991). 
The slides were allowed to cool down to room temperature and then put into the 
?equenza immunostaining system (Shandon, Uncorn, UK) and rinsed with phosphate 
buffered saline (PBS). All slides were pre-incubated with normal goat serum (DAKO, 
Glostrup, DK) diluted 1:10 in PBS, which yields for all compounds used hereafter, for 15 
minutes. The primary antibody was incubated at the appropriate concentration for 2 
hours at room temperature or overnight at 4°C. The secondary antibody was incubated 
for 30 minutes, being either horseradish-peroxidase conjugated goatamouse or 
goatarabbit (1 :50), or biotinylated goatamouse and goatarabbit (1 :400) for monoclonal 
and polyclonal antibodies, respectively. In case of biotinylated goatamouse and 
goatarabbit, a horseradish-peroxidase streptavidin biotin complex diluted 1: 1 :200 in 
PBS, prepared at least 30 minutes prior to use, was incubated for a subsequent 30 
minutes. Between the subsequent steps, the slides were rinsed four times with PBS. 
The bound horseradish-peroxidase was visualized in 10 minutes with diaminobenzidine 
(DAB, Fluka, Neu-Ulm, Germany) in PBS containing 0.075% H202 as substrate. Slides 
were rinsed extensively in tap water and finally counterstained in Mayer's Hematoxylin, 
dehydrated through a series of alcohol and embedded in malinol. 
To assess the properties of the NE cells, double staining of CgA respectively with 
MIB-1, androgen receptor and Bcl2 was performed on the PC-310 xenograft tumors. 
The double staining procedure consisted of two consecutive stainings with two primary 
antibodies. The first being always a horseradish-peroxidase-related stable 
diaminobenzidine complex, whereas the second staining was performed with an 
alkaline phosphatase conjugated goatamouse secondary antibody. In between both 
stainings, the slides were rinsed with PBS for one hour and again boiled in a microwave 
in 10 mmollL citrate buffer (pH 6.0) for 10 minutes. As negative control, PBS replaced 
the primary antibody in all stainings. Radical prostatectomies, containing normal 
prostatic tissue were used as positive control for CgA, Sglll, PC1, PC2, androgen 
receptor, GRP, 5-HT, VEGF, Bcl2 and MIB-1 expression. 
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For most markers, the number of positive cells was determined by quantitative 
counts of all cells in tumor squares at 310x magnification from which the number of 
positive cells per square mm was calculated. In total, positive cells were scored as 
percentage of the total cell number, in ;, 10 squares. For androgen receptor, VEGF, 
GRP, 5-HT, PC1, and PC2 the level of immunostaining was assessed semi-
quantitatively. 
Western blot analysis 
We further confirmed the expression patterns of CgA, Sglll, Bcl-2, 7B2 and 
androgen receptor in our castration series of the PC-310 tumor by Western blotting. As 
positive controls, we used material of human pheochromocytoma for CgA, of rat 
pituitary for Sglll and of the human in vitro cell line LNCaP for androgen receptor 
expression. The procedure of protein extraction was as previously described (Noordzij, 
1996). Frozen tissues of the PC-310 xenografts were crushed in a liquid-nitrogen-chilled 
metal cylinder. The tissue homogenates or PC-310C cell culture pellets were 
transferred into a lysis buffer (10mM TRIS (pH 7.4), 150 mM NaCI (Sigma), 1 % Triton 
X-100 (Merck, Germany), 1 % deoxycholate (Sigma), 0.1 SOS (Gibco), 5 mM EOTA 
(Merck) and protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM aprotinin, 50 
mg/L leupeptin, 1 mM benzamidine and 1 mg/L pepstatin; all from Sigma). After 
centrifugation of the mixture at 100,000 rpm at 4°C for 10 minutes, the protein content 
of the supernatants was measured by the Bradford method (Bio-Rad protein assay, 
MOnchen, Germany). 
20 fl9 of each sample was transferred to a SOS polyacrylamide gel and gel 
electrophoresis was performed with pre-stained markers as size standards (Novex, San 
Diego, CAl. The gels were blotted to a 0.45flm cellulose nitrate membrane (Schleicher 
& Schuell, Germany). The immunoblot was blocked with PBS (pH 7.7) containing 0.1 % 
Tween-20 (Sigma) and 5% dry milk for one hour. The CgA, 7B2 (Mon 102/144, kindly 
provided by Prof. Dr WM van der Ven, Leuven, Belgium), Bcl-2, androgen receptor or 
Sglll antibodies were added in their optimal concentration and incubated overnight on 
an orbital shaker at 4°C. After rinsing four times 15 minutes with PBS, incubation for 
one hour was performed with the secondary horseradish-peroxidase-conjugated 
antibodies and goatumouse for mouse monoclonal, goaturabbit for rabbit polyclonal 
antibodies, respectively. Subsequently, a short incubation with a mixture of 10 ml 
luminol and 100 ftl oxidizing agent (BM chemiluminescense kit, Boehringer Mannheim 
GmbH, Germany) followed, after washing for four times 15 minutes with PBS. Excess 
reagent was removed and antibodies were visualized by exposure of the blots to an x-
ray film. 
Reverse Transcrlptase-polymerase chain reaction 
RNA was isolated by using the single step RNAzolTM B method (Campro, The 
Netherlands (Chomczynski, 19871. Frozen tissue (100mg) or cell culture pellets were 
homogenized in 1 ml of RNAzol" . Chloroform (0.1 ml) was added and the mixture was 
vortexed for 15 seconds followed by 5 minutes incubation on ice. The homogenate was 
then centrifuged at 4°C at 12,000 g for 15 minutes. The upper water-phase containing 
the RNA was removed and mixed with an equal volume of iso-propanol. This mixture 
was then kept at 4 °C for 15 minutes and after that centrifuged at 4°C at 12,000 g for 15 
minutes. The supernatant was removed and the RNA pellet was washed twice with 75 
% ethanol by vortexing and centrifugation at 4°C at 12000 g. The pellet was then dried 
and resuspended in sterile H20. The concentration was determined at 00 260 and 
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solutions of 1 ~g/~1 were prepared for further use in Reverse Transcriptase-polymerase 
chain reaction (RT-PCR) or Northern blot analysis. The quality of the isolated RNA was 
checked by determining the 260/280 ratio and by formaldehyde gel-electrophoresis to 
check the ribosomal (28 Sand 18S) bands. 
RT-PCR was performed for CgA, Sglll, PAM, PC1 and 2 and B2-microglobulin 
(B2MG) with a standard protocol. Reverse transcriptase reaction was performed with a 
mastermix containing 5 mM MgCI2, PCR buffer, 10 mM dNTP's, RNAse inhibitor (10 
units), Reverse transcriptase (25 units), 2.5 mM random hexamer primers and 0.5 ~g 
RNA in a total volume of 10 ~I covered with 50 ~I of mineral oil. The mastermix was 
then processed at 42°C for 60 minutes followed by 15 minutes incubation at 99°C and 
the reaction was stopped at 4°C for five minutes. The cDNA mix that was formed was 
then used totally with the mastermix of the polymerase chain reaction (PCR) protocol. In 
this protocol, the mastermix contained reaction buffer, Supertaq polymerase (HT 
Biotechnology Ltd., Cambridge, UK; 1 unit), 15 ~M sense and antisense primer in a 
total volume of 40 ~1. All samples were first denatured at 94°C for 10' and then 
amplification was performed for 35 cycles of l' 94°C, l' 60°C and l' 72°C and a final 
extension at 72°C for 10'. The PCR product was checked on a 1 % agarose gel and, if 
necessary, followed by Southern blotting. The internal control of human B2MG clearly 
showed the equal amounts of mRNA that were used for each time-point. 
Northern blot analysis 
Northern blot analysis was performed by running a formaldehyde gel in MOPS 
buffer containing 20 ~g of each sample including the controls. The RNA content of the 
gel was consequently blotted overnight onto a hybond-N+ filter in 10 x Standard saline 
citrate (10xSSC; 1.5 M sodium chloride and 0.15 M sodium citrate). The filter is checked 
for RNA and ribosomal bands are marked. After rinsing the filter in 2xSSC, the blot is 
cross-linked in a GS gene Iinker™ UV chamber (Bio-RAD, MUnchen, Germany) and 
ready for (pre)hybridization with different probes against CgA, Sglll, PAM and B2-
microglobulin as control. 
RESULTS 
Androgen withdrawal in the PC-310 xenograft showed a decrease in volume 
directly after castration. The PC-310 tumor doubling time was 16 days before castration. 
After castration, the PC-310 tumors had regressed with 50% within 9 days. Between 14 
and 21 days post-castration tumor volume was maintained at about 30-40 % of the 
initial tumors. (Figure 1 a). The decline in tumor volume was associated by a rapid 
decrease of proliferating, MIB-1 expressing, cells from 20 % in the controls to zero at 7 
days post-castration (Figure 1a). Apoptotic counts increased after 2,5, and 7 days post-
castration, and returned to control levels after 14 and 21 days (data not shown). The 
serum PSA level dropped rapidly post-castration and was maintained around zero after 
14 days (figure 1b). The expression of the 110-112 kD androgen receptor protein 
decreased directly after castration but a markedly increased expression was observed 
on Western blot after 5 to 7 days post-castration (figure 2a). 
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Figure 1: Castralion experiment of PC-310 xenograft. Effect on tumor volume, M18-
1 score, the number NE cells and PSA value (ng/ml) 
A) The effects of androgen withdrawal on tumor volume (e), M18-1 expression (6) and 
the number of NE cells marked by CgA (0) at different time points post-castration (n=3). 
8) PSA (.) serum levels in the nude mice PC-310 model at different points in time post-
castration (n=3). 
Expression of the NE marker CgA increased rapidly after castration up to an 
approximately 40-fold increase after 14 days of androgen withdrawal (figure 1a). From 
the histological picture it is clear that changes in NE differentiation are not due to a 
selection of NE cells as a 40-fold increase in the number of NE cells is seen, when 
there is only a 60-70 % volume decrease at 14 and 21 days post-castration. On 
Western blot, the increased expression of CgA at 78 and 68 kD could clearly be 
visualized as could also the increased processing of the protein into 49, 31 and 18 kD 
proteins after 14 and 21 days of androgen withdrawal (figure 2b). Likewise, increased 
mRNA levels for CgA were found in Northern blot analysis (figure 3). RNA of the same 
series of tissues was reverse transcribed and the resulting cDNA was used in 
subsequent PCR reactions analyzing the expression of CgA and other markers of NE 
differentiation. Expression of markers of the regulated secretory pathway (RSP) were 
found to be increased after androgen deprivation of PC-310 in vivo. Induction of Sglll 
and 782 were found to be comparable to the increased CgA expression at 5 or 7 days 
after androgen withdrawal (figure 4). Temporal induction of mRNA expression of PC1 
and PC2 was found at day 5 and 7, respectively. PAM-mRNA expression was 
temporarily induced at day 7 post-castration, when the expression of the largest of the 
three PAM splice variants(Vos, 1995) was mainly increased. Increased expression of 
the RSP markers was confirmed by immunohistochemistry (IHC) and Western blotting 
(table 1). From this table, it is clear that the expression of Sglll and 782 is already 
apparent at day 5 and 7 post-castration, whereas the processing enzymes PC1, PC2 
and PAM are expressed later in the NE cells at day 7 and becomes more apparent at 
day 14 and 21 post-castration. The anti-apoptotic protein 8c1-2 was expressed at low 
levels in the androgen supplemented mice, but decreased at both mRNA and protein 
level after androgen withdrawal (result not shown). Furthermore, expression of the 
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endothelial growth factor. VEGF. was clearly increased at 14 and 21 days post-
castration. Interestingly. also GRP and 5-HT expression could clearly be detected as a 
relatively late event of NE differentiation from 14 days post-castration on. Expression of 
vasoactive intestinal peptide or calcitonin was not found during the 21 day period 
studied. From IHC double labeling studies. we found that about 50 % of the epithelial 
tumor cells expressed the androgen receptor (CgA'. AR+). and the other 50 % were NE 
cells (CgN. AR'). 
2A 
AR: 
110 kd 
28 
egA: 
68 kd 
49 kd 
30 kd 
18 kd 
Day 0 day 2 day 5 day 7 day 14 day 21 LNCaP 
day 0 day 2 day 5 day 7day 14 day 21 Pheo 
Figure 2: Expression of the androgen receptor (AR) and Chromogranin A (CgA) 
following castration in the PC-310 xenograft model. Both panels show the time points 
To. T.2• T.5. T-7• T_14 and T.21 after androgen withdrawal. In the upper panel (2A) the 
signal of AR expression is found at 110-112 kD which first rapidly decreased and is 
subsequently reexpressed in the PC-310 model. The increased CgA signal can be 
found between 68 and 78 kD in the lower panel (2B). which is the highest band in the 
control pheochromocytoma (Pheo). After 7 days clear processing of the protein is 
shown by smaller fragments at ± 49 kD and at ± 30 kD. 
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Figure 3: Expression of NE marker CgA on Northern blot in the PC-310 model 
system after androgen withdrawal. CgA mRNA expression at 2,3 kB clearly increased 
post-castration in the PC-310 xenograft model (3A) and in the in vitro cell line. 
Table 1: Expression of NE markers, neuropeptides and growth factors in PC-310 in 
vivo after androgen suppression as determined by immunohistochemistry and Western 
blot analysis (7B2) 
Time CgA 8gll1 7B2 PC1 PAM GRP VEGF 5·HT (days) (8g3) 
Control + ± ± 
· · 
. 
· · 
2 + ± ± 
· · · · 
5 ++ + + 
· · 
. 
· · 
7 +++ ++ ++ ± + ± + · 
14 ++++ +++ +++ ++ ++ + ++ ± 
21 +++++ ++++ +++ ++++ +++ + ++++ ++ 
CgA, 8glll, PC1, PAM, GRP, VEGF, 5·HT were all determined by IHC, whereas 7B2 
was determined from Western blot. Expression was scored as following: -, no 
expression, ±, sporadic expression, +, focal expression, ++, few cells positive per 
optical field, +++, clustered cells positive per optical field, ++++, more clusters of 
positive cells per optical field, +++++, 50% of tumor positive. The expression of 7B2 
was determined from weak expression (±) to high expression (+++). 
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Table 2: Effecls of androgen withdrawal on PC-310C in vitro. Proliferation, 
apoptosis and culture P8A levels after androgen withdrawal 
Time (days) Apoptosis (%) (total) Mitotic cells (%) 
Control 2.1 ± 0.5 2.8 ± 1.3 
2 5.7±1.3 2.3 ±0.9 
5 7.8 ±1.5 0.9 ± 0.9 
7 10.0 ± 2.7 2.1 ± 1.6 
14 6.3 ± 2.3 1.2 ± 0.6 
21 5.9 ± 1.6 0.4 ± 0.6 
o 2 5 7 14 21 controls 
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Figure 4: NE differentiation and regulated secretory pathway in PC-310. RT-PCR 
was performed for expression of 8G3, PC1, 782, CgA, PAM and ~2MG in PC-310 
xenograft after castration. H69 was used to check PC1, 782 and PAM analysis and 
Ph eo for 8G3 and CgA. The products of the primer sets are indicated as the length in 
nucleotides of the mRNA that is specifically amplified. 
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Figure 5: Expression of CgA, SG3, PAM and B2MG in PC-310C. The products of 
the primer sets are indicated as the length in nucleotides of the mRNA that is 
specifically amplified. Pheochromocytoma was used as a control for CgA and Sg3 
expression and H69 was used for PAM expression. 
Androgen depletion of PC-310C cultures led to increased numbers of apoptotic 
cells and a decreased level of proliferation as determined by Hoechst 33342 and PI 
staining (table 2). The total amount of apoptotic cells was counted as the increased 
number of Hoechst 33342 or Hoechst 33342/ PI staining nuclei containing fragmented 
DNA and/or apoptotic bodies, whereas the number of blue, Hoechst 33342 stained, 
mitotic figures decreased in time after androgen suppression. PSA levels of the culture 
medium initially decreased but without refreshing the culture medium PSA levels 
increased in time. Some proliferating cells were still present after 21 days of androgen 
withdrawal and PSA levels in the medium were high. Androgen receptor expression 
initially decreased to a limited extent after androgen withdrawal but after five days of 
androgen depletion an increased level of the 110-112 kD androgen receptor was found. 
Similarly to the in vivo grown PC-310 tumor, in PC-310C cultures the expression of the 
NE markers CgA and Sglll increased after 14 days of androgen withdrawal at both 
mRNA level (figure 3b, 5) and protein level (figure 6b). The mRNA levels of PC1 and 
PC2 did not increase and a slight increase in the levels of PAM-mRNA was found 
(figure 5). 
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Figure 6: NE differentiation in the in vitro PC-310C culture after androgen 
withdrawal. 
A: Overview of the PC-310C after 5 passages in culture which grows in monolayer 
colonies. 
B: Comparison of egA expression in PC-3IOC cultures growing with or without androgens on 
glass slides. 14 days post-castration a clear increase in NE differentiation is shown. 
Magnification 31 OX. 
DISCUSSION 
This study of the PC-310 prostatic carcinoma xenograft model aims at a 
comparison of the kinetics of inducible neuroendocrine differentiation on androgen 
depletion in an androgen dependent model system both in vivo and in vitro. The 
androgen dependent human PC-310 xenograft model was established from a primary 
untreated tumor and behaves as an androgen dependent clinical tumor. The growth and 
regression profiles of the PC-310 xenograft in the presently described castration 
experiments was comparable to studies earlier performed (van Weerden, 1996). 
Hormonal suppression of the model induced an initial increase of apoptosis, decreased 
proliferation and down regulation of the androgen receptor. This was paralleled by a 
rapid and prominent decrease of prostate specific antigen (PSA) serum levels, 
demonstrating the androgen dependent character of the PC-310 model, as was 
previously demonstrated for the PC-295 model (Jongsma, 1998). As a consequence, 
the PC-310 tumors regressed, and after 21 days of androgen withdrawal only 30-40 % 
of the initial tumor volume was left. The rapid loss of androgen receptor expression in 
the PC-310 tumors was comparable to that observed previously in the androgen 
dependent human PC-82 xenograft after castration (Ruizeveld de Winter, 1992). In 
contrast to the PC-82 however, after 5 days of androgen depletion the expression level 
of the androgen receptor returned to above normal. Constitutive high androgen receptor 
expression has been found in Trans Urethral Resection specimens of clinical hormone 
refractory tumors (van der Kwast, 1991), but lower expression of the androgen receptor 
was noted during regression of hormonal treated prostate cancer (Gil-Diez de Medina, 
77 
1998). In the same study, increased levels of the androgen receptor were observed in 
hormone refractory specimens as well as increased expression of the basal epithelial 
marker, cytokeratin 5 and the epidermal growth factor (EGF) receptor. Androgen 
receptor positive prostatic cancer cell lines, like the LNCaP also continue to express the 
androgen receptor after hormone depletion (Esquenet, 1997; Koivisto, 1998). 
NE differentiation was clearly induced at 5 days after androgen withdrawal as 
shown by expression of CgA. At that time point only a few proliferating non-NE cells 
were left. Analysis for CgA at both RNA and protein level demonstrated the increased 
expression of the CgA in time from a low basal expression level in the controls to a 
maximum at 21 days post-castration. Despite inter-tumoral differences in basal CgA 
expression levels at the moment of castration, increased CgA expression was observed 
at 5, 7, 14 and 21 days post-castration at the IHC level, which was confirmed by 
Western blot analysis, RT-PCR and Northern blot analysis as shown by the induction of 
the 2.3 kb mRNA transcript of CgA after androgen withdrawal. 8y comparing the 
Western blots for CgA and androgen receptor post-castration, it was extrapolated that 
from day 7 post-castration on there were both NE cells present as well as cells 
expressing the androgen receptor. However, IHC double staining for AR and CgA 
confirmed that CgA and androgen receptor did not co localize. Thus post-castration, the 
NE cells represent the androgen independent, non-proliferating part of the prostatic 
tumor. 
From the stainings for CgA and MI8-1, it was seen that the proliferation at 7 days 
post-castration was near zero, whereas there were still increased numbers of NE 
differentiated tumor cells. It can be concluded that the greater part of the NE cells was 
in the Go-phase of the cell cycle which is in agreement with our previous study of the 
PC-295 model (Jongsma, 1998) as well as with other studies on NE differentiation and 
proliferation in prostate cancer (80nkhoff, 1994a; 80nkhoff, 1994b). In clinical prostate 
cancer specimens, 80nkhoff et al (80nkhoff, 1994b) found that androgen receptor 
negative NE cells expressed cytokeratins 18 and 5, and that these cells were found in 
the proximity of proliferating cells. In the PC-310 experimental tumor model, during a 
period of 21 days post-castration NE cells were found scattered over the tumors and 
were definitively not associated with proliferative activity of the surrounding non-NE 
cells. 
The kinetics of NE differentiation, after androgen withdrawal was clearly 
demonstrated by the time related induction of other secretogranins and processing 
enzymes belonging to the regulated secretory pathway (R8P) (Holthuis, 1995) next to 
the observed induction of CgA. RT-PCR analysis of the R8P markers clearly showed 
the time dependent induction of 782, 8glll, PC1, PC2, and PAM in the PC-310 NE cells. 
The kinetics of NE differentiation and the maturation of secretory granules in prostatic 
NE cells was also shown by IHC in the PC-310 model. Increased expression at protein 
level of 8gll1 by IHC and 782 by Western blotting was detected from 5 to 7 days post-
castration on, whereas induction of PC1, PC2 and PAM was shown later, i.e. at day 14 
and 21 post-castration during apparent maturation. These results indicate that the NE 
cells in the PC-310 model possess an active R8P and also demonstrate the time 
dependent maturation in the secretory granules as shown by the increased expression 
of the prohormone convertase, PC1 and the increased processing of CgA coinciding at 
14 days post-castration (Figure 2b). Clearly, the 78 and 68 kD CgA protein (Noordzij, 
1996), is processed by PC1 to form products and processed proteins ranging from - 49 
kD to - 31 kD and - 18 kD as was shown before by others (8arbosa, 1991; Metz-
80utigue, 1993; Eskeland, 1996). 
PAM is most likely expressed in NE cells, as the protein activates neuropeptides 
by amidation mainly in the secretory granules of the R8P, but expression in non-NE 
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cells has also been described (Saldise, 1996). The increase of PAM in the PC-310 
model after castration coincides with the time-related induction of expression of RSP 
associated proteins. It has yet to be proven whether PAM is expressed in NE cells or in 
the neighboring non-NE cells, but preliminary IHC data indicate increased PAM 
expression with a granular 'NE like' staining pattern 14 days post-castration (data not 
shown). 
VEGF, GRP and 5-HT, but not VIP and calcitonin were only expressed post-
castration in the PC-310 model. The expression of VEGF co-localized in the NE cells 
and the expression was induced shortly in time after the expression of CgA and Sgili. 
Expression of GRP and 5-HT was only found in a small part of the NE cells relatively 
late, at 14 and 21 days post-castration. This indicates that possibly other neuropeptides 
and growth factors for endothelial cells can be induced post-castration in the PC-310 
model. Apparently, the PC-310 tumors respond to castration by induced VEGF, GRP or 
5-HT expression that may induce proliferation of endothelial cells or non-NE cells. 
Induction of VEGF may be a consequence of NE differentiation, but alternatively VEGF 
expression can be induced by hypoxia (Semenza, 1998), which is a common condition 
observed in prostatic tumors (Zhong, 1998). Possibly, increased hypoxic stress after 
androgen withdrawal induced VEGF expression in the NE differentiated cells. 
, Previously, we suggested that the condition of NE differentiation and the absence 
of androgen receptor expression plays a key role in the survival of prostate cancer cells, 
whereas Bcl-2 protects the remaining androgen independent cells from undergoing 
apoptosis (Jongsma, 1998). Here we show another unexpected behavior of androgen 
dependent cells, being the drop in androgen receptor expression shortly after androgen 
withdrawal followed by a relapse of expression after 5 days post-castration. Part of the 
initially androgen dependent PC-310 cells differentiated into NE cells following 
androgen withdrawal, whereas the remaining carcinoma cells are behaving as 
androgen sensitive tumor cells surviving in an androgen deprived situation. In 
contradiction to what has been reported about the LuCap 23 model (Liu, 1996) and to 
our previous observations in the PC-295 model, here we showed an alternative route of 
overcoming cell death after androgen deprivation by both a strong induction of NE 
differentiation and a transient down-regulation of the androgen receptor, without 
inducing BcI-2 expression. 
The establishment of in vitro cultures from PC-310 epithelial cells in a specialized 
culture medium has enabled us to study the in vitro effect of androgen deprivation on 
the kinetics of NE differentiation in PC-310C and compare it with the behavior of PC-
310 in vivo. To our knowledge PC-310C is the first human cell culture of a primary 
untreated prostatic adenocarcinoma containing cells with the NE phenotype and which 
can be induced to differentiate into NE, i.e. CgA and Sglll positive cells after androgen 
depletion. The in vitro model PC-310C resembles the in vivo model for most parameters 
like the decrease in proliferation, the induction of apoptosis, the regulation of AR 
expression and the less stronger but significant induction of CgA mRNA expression. 
The main difference with the in vivo situation is the observation that after an initial 
decrease of PSA in vitro, the PSA levels increased again to control level. An 
explanation for this finding is that PSA can not be degraded in the absence of stromal 
cells or is not removed by the blood stream in vitro. Otherwise, PSA secretion is 
induced by androgen deprivation, or PSA leaks into the culture medium from dying 
cells. Alternatively, androgen independent activation of the androgen receptor by growth 
factors added to the culture medium, e.g. by insulin, EGF or hydrocortisone might be 
involved. 
The difference in the stainings for CgA, Sglll, PC 1 and PC 2, the non-
proliferative status of most of the NE cells as observed in the controls (To) and at 7 days 
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post-castration and the temporal increase in apoptosis in the PC-310 model system, 
clearly show the proliferation independent process of neuroendocrine differentiation and 
maturation of NE cells as being induced by androgen withdrawal. 
Expression of CgA is not a requisite for regulated secretion of bioactive 
neuropeptides in the PC-310 model, but co-expression in the PC-310 model system 
with R8P related proteins, like 8glll, 7B2 and the time related induction of PC1 and 
PAM expression indicates that the NE cells have the potency to actively secrete growth 
factors like neuropeptides from secretory granules (Holthuis, 1995; Holthuis, 1996a). 
This statement is fortified by the relatively late induction of GRP and 5-HT expression 
during granular maturation. Likewise, the induced expression of VEGF may lead to the 
growth of new blood vessels, which may playa decisive role in progression of prostate 
cancer to hormone independence. Furthermore, we consider the possibility of androgen 
independent activation of the androgen receptor, for instance by neuropeptides like 
GRP, IGF-1 (Chan, 1998) or cytokines like IL-6 which can not be excluded (Hobisch, 
1998) as the androgen receptor is still expressed on 50 % of the PC-310 cells in the 
androgen depleted situation. 
As the role of NE differentiation in progression of prostate cancer is still unclear 
(Krijnen, 1997; Jiborn, 1998), testing of other markers than CgA such as 8glll, 7B2, 
PC1 and PAM as putative NE-related prognostic markers for the progression of clinical 
prostate cancer is still relevant. Possibly, changes in expression of components of the 
regulated secretory pathway like PC1 or PAM might have effects on, for example, 
overproduction of bioactive growth stimulating neuropeptides in prostate cancer after 
androgen suppression and thus lead to hormone refractory disease. 
The PC-310 model system is a unique model for further studies on induction of 
NE differentiation both in vivo and in vitro by androgen withdrawal, the role of the 
regulated secretory pathway in the progression of prostate cancer in particular. In 
addition, androgen independent growth or prostate cancer progression is currently 
under investigation in a long-term androgen suppression experiment of the PC-310 in 
vivo model. Induction of NE differentiation, maturation of NE cells and temporal down 
regulation of androgen receptor protein expression in prostate cancer might be the 
same as the clinical behavior of a major part of hormone refractory prostate cancer 
patients who relapse after initial 1-2 years of remission of the disease. The only cells in 
the PC-310 tumor left after 21 days are androgen independent, CgA expressing NE 
cells and androgen receptor expressing androgen sensitive cells, which do not 
proliferate nor go into apoptosis. Further studies on the PC-310 model system will yield 
information as to whether NE cells playa role in the maintenance of tumor residues by 
initiating growth induction of androgen receptor positive non-NE cells e.g. by different 
growth factors. 
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ABSTRACT 
Neuroendocrine (NE) cells are androgen independent cells and secrete growth-
modulating peptide hormones via a regulated secretory pathway (RSP). We studied NE 
differentiation following long-term androgen withdrawal in the androgen dependent 
human prostate cancer xenograft PC-310. Tumor-bearing nude mice were sacrificed at 
0,2,5,7, 14,21,47, 84 and 154 days post-castration. Half-life of the PC-310 tumor 
was 10 days, with a stabledormant residual tumor volume of 30-40% after 21 days and 
longer periods of androgen deprivation. Proliferative activity and prostate specific 
antigen (PSA) serum levels decreased to zero post-castration, whereas cell cycle arrest 
was manifested by increased p27~P1 expression. A temporary down regulation of 
androgen receptor (AR) expression was observed after androgen deprivation. The 
granine family expression of CgA, Sglll and 7B2 increased in vivo from 5 days post-
castration on. Subsequently, prohormone convertase 1 (PC1) and peptidyl a-amidating 
monooxygenase, as well as the vascular endothelial growth factor were expressed from 
7 days post-castration on. Finally, growth factors like gastrin releasing peptide and 
serotonin were expressed in a small part of the NE cells 21 days post-castration, but 
strong expression was induced late during androgen deprivation, i.e. 84 and 154 days 
po~t-castration, respectively. Androgen deprivation of the NE differentiated PC-310 
model induced the formation of NE, AR- and non-NE, AR' tumor residues. The NE 
residues actively produced growth factors via a RSP, among others VEGF inducing 
angiogenesis, which may lead to hormone refractory disease. The dormant non-NE, 
AR' tumor residues were shown to remain androgen sensitive even after longterm 
androgen deprivation. In the PC-310 xenograft, a time dependent NE differentiation and 
subsequent maturation was induced after androgen depletion. In conclusion, the 
androgen dependent PC-310 model constitutes an excellent model for studying the role 
of NE cells in the progression of clinical prostate cancer. 
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INTRODUCTION 
Neuroendocrine (NE) differentiated cells form an androgen independent 
subpopulation of the prostatic glandular cells (Abrahamsson, 1996) and are considered 
to be non-proliferating cells which do neither express the androgen receptor (AR) 
(Krijnen, 1993) nor the anti-apoptotic oncogene BcI-2 (Xue, 1997). Prostatic NE cells 
may regulate homeostasis and secretion of prostatic fluid, by interaction with non-NE 
prostatic glandular cells. Variable numbers of NE cells occur in nearly all clinical 
prostatic adenocarcinomas (Abrahamsson, 1986; di-Sant'Agnese, 1992b; Aprikian, 
1993; Bonkhoff, 1995; di-Sant'Agnese, 1995; Noordzij. 1995a; Noordzij. 1995c). NE 
cells are often found near Bcl-2 positive prostate cancer cells (Colombel, 1992; Cohen, 
1994). Many studies on the prognostic value of chromogranin A (CgA), the general 
marker for NE differentiation, have been performed. Although suggested otherwise, no 
clear correlation between CgA expressing NE cells and poor prognosis or progression 
of prostate cancer has been shown (Abrahamsson, 1986; di-Sant'Agnese, 1992b; 
Aprikian, 1993; di-Sant'Agnese, 1995; Noordzij. 1995a; Noordzij. 1995c). However, a 
recent study did show a correlation between NE differentiation with response to 
endocrine therapy of prostate cancers (Krijnen, 1997). Other studies revealed that 
androgen deprivation of clinical prostate cancer induced either NE differentiation or 
tumor residues (Van de Voorde, 1994; Chen, 1997; Guate, 1997; Jiborn, 1998; Pruneri, 
1998). Other investigators identified non-NE related changes concerning AR status and 
tumor staging (de Vere White, 1997; Reuter, 1997; Culig, 1998). 
NE cells can be identified by immunohistochemistry with specific antibodies 
against secreted products including serotonin (5-HT) (Xue, 1997) and gastrin-releasing 
peptide (GRP) or secretion-associated proteins, like CgA (O'Connor, 1986; 
Abrahamsson, 1989; Schmid, 1994; Hendy, 1995). Based on its possible role in 
progressive behavior of different types of cancer, e.g. small cell lung cancer and 
gastrinoma (Alexander, 1988; Chu, 1996; Kelley, 1997), also in prostate cancer 
research more attention is payed to GRP in recent years (Aprikian, 1998). 
NE cells have an activated regulated secretory pathway (RSP) (Holthuis, 1996b) 
besides the lysosomal and the constitutive pathway. The RSP consists of a sequence of 
processes linked from transcription/translation of various factors to final secretion of 
peptide hormones (Smeekens, 1992; Tucker, 1996) at the plasma membrane from 
secretory granules (Holthuis, 1995). Different RSP markers can be identified, such as 
the granular markers Secretogranin III (Sglll) and Secretogranin V (7B2) (Martens, 
1989; Sigafoos, 1993; Braks, 1996), carboxy peptidase E and the processing enzymes 
pro hormone convertase 1 and 2 (PC1 and 2). The enzyme peptidylglycine a-amidating 
monooxygenase (PAM) (Vos, 1995; Vos, 1996) is expressed in or in the near vicinity of 
NE cells. 
Recently, several groups have developed both in vitro (Romijn, 1996) and in vivo 
prostatic cancer models (Liu, 1996; Nagabhushan, 1996; van Weerden, 1996). NE 
differentiation was studied in the panel of in vivo human prostate cancer xenograft 
models developed at our institution (Noordzij. 1996). The androgen dependent PC-295 
and PC-310 models constitutively express the NE phenotype. In both tumor models, 
androgen deprivation induced NE differentiation. The kinetics of short-term NE 
differentiation have been studied in both the PC-295 (Jongsma, 1998) and the PC-310 
model (Jongsma, 2000b). Data from both model systems clearly showed a proliferation 
independent induction of NE differentiation after androgen deprivation. In the completely 
androgen dependent PC-295 model, the tumor rapidly regressed and like the non-NE 
cells, the NE cells eventually disappeared. In contrast, the PC-310 xenograft did not 
totally regress after androgen withdrawal. Therefore, the latter model was considered 
.9-
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particularly suitable for studying the process of NE differentiation and the consecutive 
granular maturation of NE cells after long-term androgen deprivation and the role of NE 
cells in tumor progression. For this purpose we analyzed the time dependent 
expression patterns of GgA, different markers of the RSP, and different growth factors 
like 5-HT, GRP, vasoactive intestinal peptide (VIP) and vascular endothelial growth 
factor (VEGF) after androgen suppression. The effect of long-term androgen deprivation 
on the non-NE tumor population was investigated with the markers MIB-1, p27kiP, and 
AR. Furthermore, we studied tumor histology and effects on tumor vascular density 
during long-term androgen deprivation. Also, the ability of the dormant tumor residues 
to respond to testosterone re-supplementation was investigated to assess the androgen 
sensitivity of the PG-310 tumor residues. 
RESULTS 
Androgen deprivation of the PG-310 xenograft model showed a 50% decrease in 
tumor volume within 9 days which confirmed previous stUdies with this model 
(Jongsma, 2000b). Between 14 and 21 days post-castration the decrease in tumor 
volume stagnated at 30-40 % of the initial tumor volumes and remained constant 
throughout the rest of the experimental period (figure 1). The decline in tumor volume 
was associated with a rapid decrease of proliferating, MIB-1 expressing, cells from 20 
% in the controls to zero at 7 days post-castration (figure 1). p27k;P expression 
increased from day 2 on to maximum positivity of 85 % of the tumor cell population 
1A: tumor volume, NE differentiation 18: androgen dependence 
and cell cycle 
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Figure 1: Androgen deprivation of PG-310 xenograft model. Effect on tumor volume, 
proportion of MIB-1 and p27kiP expressing cells and the number NE cells per mm3. 
A) The effects of androgen withdrawal on tumor volume (e), MIB-1 expression (), 
p27"P expression ( ) and the number of NE cells marked by GgA (0) a t different time 
points post-castration (n=3). in the PG-310 model. 
B) Tumor volume in androgen deprived (e), androgen re-supplemented (O)PG-310 
tumors after castration at different time points post-castration (n=3). 
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Figure 2: Expression of the androgen receptor (AR) and Chromogranin A (CgA) 
following castration in the PC-310 xenograft model. The left panel show the time points 
To, T.2, T.5, T.7, T.'4 after androgen withdrawal for expression of the androgen receptor 
(2A). In the right panel (28) CgA expression is shown at day To, T.2, T.7, T.21 , and T.154. 
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(figure1). Apoptotic counts were increased at day 2, 5, and 7 post-castration, but 
returned to below control levels after 14 days (data not shown). The serum P8A level 
dropped rapidly post-castration and remained just above zero from 14 days post-
castration on, whereas the NE serum marker CgA increased from day 7 during the post-
castration period (table I). Expression of the 110-112 kD AR decreased directly after 
castration but increased from 7 days post-castration onwards as was observed by both 
WAstern blot and immunohistochemistry (figure 2a). 
egA: 
68 kd 
49 kd 
30 kd 
18 kd 
o 2 5 7 14 21 47 84 154 Pheo 
Figure 3: Expression of NE marker CgA on Western blot in the PC-310 model 
system after androgen withdrawal. The increased CgA signal can be found between 68 
and 78 kD in the lower panel, which is the highest band in the control 
pheochromocytoma (Ph eo ). After 7 days clear processing of the protein is shown by 
smaller fragments at 49 kD, 30 kD and 18kD. 
The proportion of CgA positive tumor cells increased rapidly up to approximately 
40-fold at 14 days after androgen deprivation (figure 1). Immunohistochemistry showed 
that islands of NE differentiated cells developed after longer time intervals of androgen 
deprivation (figure 2b). These islands were surrounded by areas of non-NE tumor cells. 
Double labeling studies showed that about 50 % of the epithelial tumor cells expressed 
the AR (CgA-, AR+), and the other 50 % were NE cells lacking the AR (CgA+, AR'). On 
Western blot, expression of egA (Mw 78 and 68 kD) was associated with increased 
processing of the protein into 49, 31 and 18 kD proteins from 14 days post-castration on 
(figure 3). Increased mRNA levels for egA were found in Northern blot analysis (data 
not shown). Reverse transcribed mRNA of the same series of tissues was used in 
subsequent peR reactions analyzing the time dependent expression of egA and other 
markers of NE differentiation. Expression of markers of the regulated secretory pathway 
(R8P) was found to be increased after androgen deprivation of PC-310 (figure 4). 
Expression patterns of 8gll1 and 7B2 were found to follow a similar pattern as observed 
for egA expression. Temporal induction of mRNA expression of PC1 and PC2 (data not 
shown) was found at day 5 and 7, respectively. Additionally, PC1 expression was again 
up regulated at day 84. PAM-mRNA expression was temporarily induced at day 7 and 
again at days 47 and 154 post-castration, with respect to the expression of the largest 
of the three PAM splice variants (Vos, 1995). The time dependent increase in the 
expression of the different R8P markers at mRNA level was confirmed by 
immunohistochemistry (table I). From this table, it is clear that the protein expression of 
8gl11 was already apparent at day 5 and 7 post-castration, whereas the processing 
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enzymes PC1 and PC2 were expressed at a later stage in the NE cells, i.e. at day 7 
with its highest expression at day 14 and 21 post-castration. Moderate levels of PAM 
expression were observed in non-NE cells during short-term castration, but after 47 and 
84 days of androgen deprivation strong PAM expression was observed in part of the NE 
cells. Double-labeling co-localized strong PAM expression in the secretory granules of 
CgA positive NE cells, whereas the moderate expression of the protein was observed in 
the non-NE cells. 
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Figure 4: NE differentiation and regulated secretory pathway in PC-310. RT-
PCR was performed for expression of 8glll, PC1, 782, CgA, PAM and B2MG in 
PC-310 xenograft after castration. H69 was used as positive control for PC1, 782 
and PAM analysis and Pheo for 8gll1 and CgA. The RT-PCR products are 
indicated as the length in basepairs (bp). 
Table I: Expression of NE markers, neuropeptides and growth factors in the PC-310 xenograft after long-tenm androgen 
deprivation as determined by immunohistochemistry and mouse plasma levels, 
Time PSA (pi) CgA (pi) CgA Sglll PC1 PAM GRP 5-HT VEGF CD31 (days) (ng/ml) (ng/ml) (Sg3) , 
ContrOl 196,9 0 + ± 
- - - - - ± i 
2 11.3 0 + ± - - - - - ± 
5 7.7 0 
-
+ 
- - - - - ± 
7 5.4 12 +++ + ± + ± - + ± 
14 1 39 ++++ +++ ++ 
-
+ ± 
-
± 
21 0.9 82 +++++ ++++ -+ ++ ± + ++++ + 
47 0.3 3960 -~ -+ +++ -+ 
- -
++-
-
84 0.1 6391 
-
-++ 
-
-+ ++ +++ +~ +++ 
154 0.1 2838 +++++ ++++ ++ +++ 
-
-++ -++ ~ 
CgA, Sglll, PC1, PAM, GRP, 5-HT, VEGF and CD31 were all determined by IHC. Expression was scored as following: -, no 
expression, t, sporadic expression, +, focal expression, ++, few cells positive per optical field, +++, clustered cells positive per optical 
field, ++++, more clusters of positive cells per optical field, +++++, 50% of tumor positive. pl= plasma; PSA plasma levels are mean 
values (n=3). 
Up to 7 days postcastration, expression of the vascular endothelial 
growth factor (VEGF), was not found whereas it was clearly increased from 14 
days post-castration. VEGF was exclusively detected in the vast majority of 
NE cells at day 47 and later. Tumor vascularization, defined by CD31 
positivity, was visible at day 47 and became marked at day 84 and 154 (table 
I). Interestingly, expression of the NE growth factors, GRP and 5-HT could 
clearly be demonstrated as a relatively late event of NE differentiation from 14 
days post-castration on, with its highest expression found at day 84 and 154 
post-castration (table I). Vasoactive intestinal peptide or calcitonin was not 
detectable during the whole experimental period of 154 days. 
21 Days of androgen re-supplementation to long-term androgen 
deprived PC-310 tumor bearing mice resulted in rapidly increasing tumor 
volumes (figure 1 B) and plasma PSA levels returned to normal in these mice 
(table II). Increased proportions of MIB-1 expressing and strong nuclear AR 
expressing cells were observed after day 56, whereas the proportion of cells 
expressing p27k,P (data not shown), CgA and other NE markers slightly 
decreased at both protein and mRNA levels (table II and figure 5). 
Table II: Effects of testosterone (T) re-supplementation on PC-310 tumor 
residues. MIB-1, CgA, and AR expression and PSA plasma levels are given 
as mean values ± S D (n=3) 
Time (days) MIB-1 cells (%) NE cells (cellslm ) 1(%) PSA plasma levels (ng/ml) 
Control 12.7 ± 2.1 0.8 ± 0.9 89.0 ± 2.3 234 ± 63 
35 0.2 ± 0.2 64.0 ± 14.0 37.2 ± 5.0 0.3 ± 0.2 
63 0.9 ± 0.9 57.3 ± 22.0 35.0 ± 7.4 <0.1 
35+21 T 10.8 ± 3.2 17.8 ± 6.8 50.7 ± 4.5 247 ± 85 
M 0 63 +T pheo H69 Figure 5: Effect of testosterone 
egA 481 bp 
8gll1 480 bp 
AR 685 bp 
PAM 650 
B2MG 294 bp 
fe-supplementation on NE 
differentiation in longterm androgen 
deprived PC-310 tumor tissue, 
Expression of CgA, 8glll, PC1, 
PAM, and AR in RT-PCR at 
different time points post-castration 
with or without supplementation of 
testosterone during three weeks. 
f!.2MG is used as a control for 
equal amounts of mRNA and the 
peR products are given in 
basepairs (bp) for each marker 
used. Pheochromacytoma (ph eo) 
and H69 (8CLC cell line) were 
used as controls. (M=100bp ladder) 
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DISCUSSION 
This study of the PC-310 prostatic carcinoma xenograft model focused 
on the behavior of the PC-310 model after long-term androgen deprivation 
with regard to time dependent NE differentiation, granular maturation and the 
subsequent sequential cellular changes in expression of NE cell products 
resulting in secretory signals. The growth and regression profiles of the PC-
310 xenograft in the presently described androgen deprivation experiments 
was comparable to those of previous studies (van Weerden, 1996; Jongsma, 
2000b). A temporal down regulation of the AR in non-NE cells was observed. 
This was paralleled by a rapid and prominent decrease of prostate specific 
antigen (PSA) plasma levels. Androgen deprivation of the PC-310 model 
induced temporally increased apoptosis, continuously decreased proliferation, 
and induced expression of the cell cycle inhibitor p27kiP • From 14 days post-
castration on 30-40 % of the initial PC-310 tumor volume was maintained as 
dormant tumors. The initial loss of AR expression in the PC-310 tumors 
postcastration was comparable to that observed previously in the androgen 
dependent human PC-82 xenograft (Ruizeveld de Winter, 1992). By contrast, 
after 5 days of androgen depletion the expression level of the AR in non-NE 
PC-310 tumor cells returned to control levels. 
The induction of NE differentiation from 5 days post-castration on is 
shown by a constitutively increased proportion of cells expressing CgA and 
the time related induction of other secretogranins and processing enzymes 
associated with the regulated secretory pathway (RSP) namely Sglll, PC1, 
PC2, PAM and 7B2 (Holthuis, 1995). The sequence of induction of three 
subsequently evolving maturation waves inside NE cells combined with the 
AR relapse in the PC-310 prostatic tumor residues after long-term androgen 
deprivation is unique. First, CgA and the other secretogranins, Sglll and 7B2 
are expressed to mark the NE status. Secondly, the processing enzymes PC1 
and PC2, associated with peptide hormone production, are expressed. And 
finally, all kind of growth factors or neurotransmitters, like GRP and 5-HT are 
expressed which may playa mitogenic role in the PC-310 tumor residues. 
The processing of CgA protein by PC1 to smaller proteins was shown before 
in other systems by others (Barbosa, 1991; Metz-Boutigue, 1993; Eskeland, 
1996). Additionally, the increased and substantially high CgA plasma levels 
found in PC-310 bearing mice from 14 days post-castration on (table 1) 
demonstrated that maturating NE cells in this prostatic cancer tissue actually 
secrete members of the granin family and possibly neuropeptides as well. 
Expression of the neuropeptides, GRP and 5-HT, was initially found in a few 
NE cells after 14 and 21 days post-castration, but became prominently 
expressed in the long-term androgen deprived tumors at 154 days post-
castration. Other neuropeptides and growth factors may be induced during 
long term androgen deprivation that potentially can stimulate non-NE, 
endothelial and murine stromal cells in the PC-310 model. It might be 
hypothesized that the time dependent induction of GRP and 5-HT expression 
in the maturating NE cells in the PC-310 tumor residues may cause induction 
of androgen independent growth of the AR positive non-NE cells. The 
importance of the presence of bombesin/GRP family in androgen independent 
prostate cancer has already been shown by others (Aprikian, 1998). 
PAM, a two-enzyme modality, is predominantly expressed in NE cells, 
as the protein activates neuropeptides by amidation during maturation of the 
secretory granules. However, expression in non-NE cells has also been 
described (Saldise, 1996). The moderate PAM expression in non-NE cells 
observed in the PC-310 model shortly after androgen deprivation coincided 
with the induction of secretogranins expressing NE cells. After long-term 
androgen deprivation we have now demonstrated the presence of numerous 
PAM positive NE cells at 47, 84 and 154 days post-castration. PAM 
expression was shown inside the secretory granules of NE cells by co-
localization with CgA. This NE cell specific expression is assumed to be 
associated with amidation of neuropeptides during the sequential maturation 
of NE cells after androgen deprivation in PC-310 tumor residues. Time 
dependent changes in expression profiles of the RSP markers, like PC1 or 
PAM may affect the overproduction of bioactive growth stimulating 
neuropeptides in prostate cancer during long term androgen deprivation and 
might induce the development of hormone refractory disease. The relation 
between maturation of NE cells with mitogenesis or innervation has already 
been shown for lung cancer (Cuttitta, 1993; Sorokin, 1997). 
VEGF co-localized in the NE cells and its expression was induced 
shortly after the manifestation of CgA and Sglll positive cells. Induction of 
VEGF expression may be the consequence of NE differentiation. The 
expression of VEGF may have contributed to an increased formation of CD31 
positive murine blood vessels in PC-310 tumor residues at day 84 and 154. 
This might play a role in progression of prostate cancer towards hormone 
independence, e.g. by inducing a second angiogenic switch (Hanahan, 
1996a). 
Double immunostaining confirmed that CgA and AR did not co-localize 
in the neither of the longterm androgen deprived PC-310 tumor residues. 
Thus, the NE cells in the prostatic tumor residues represent androgen 
independent cells, which are surrounded, by AR positive non-NE tumor cells. 
Part of the initially AR positive PC-310 cells differentiate into NE cells during 
androgen deprivation, whereas the remaining cells re-express the AR and 
persist in an androgen deprived situation. We studied the effect of androgen 
(testosterone) re-supplementation and observed increased proliferation of AR 
positive non-NE tumor cells in the presence of testosterone, resulting in 
rapidly increasing tumor volumes. The expression of p27 kiP decreased rapidly 
as testosterone induced progression of the cell cycle and high plasma PSA 
levels were restored. This clearly showed that the dormant PC-310 tumor 
residues were still androgen sensitive. A decrease in the percentage CgA 
expressing NE cells was expected as these cells do not express the AR and 
cannot be induced to proliferate by androgens. The rapidly proliferating AR 
positive non-NE cells overgrow the non-diViding NE cells. Sglll-mRNA 
expression tended to decrease more rapidly then that of CgA suggesting that 
maturation of the RSP in NE cells is inhibited by the re-supplementation of 
androgens. This experimental study clearly shows that the AR sensitive 
pathway is still intact in the PC-310 model after longterm androgen 
deprivation. 
The increasing role of the AR in the progression of prostate cancer as 
being adapted, hyperactivated, mutated or overexpressed has been shown by 
other groups (Culig, 1998; Gil-Diez de Medina, 1998). AR positive cells can 
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be grown in androgen deprived situation through activation of autocrine or 
paracrine routes (Culig, 1998; Jongsma, 2000a), activation of oncogenes, e.g. 
BcI-2 and ras, or inactivation of tumor suppressor genes (Jenster, 1999). High 
AR expression has also been found in transurethral resection (TUR) 
specimens of clinical hormone refractory prostatic tumors (van der Kwast, 
1991), but low expression of the AR was noted during regression of hormonal 
treated prostate cancer (Gil-Diez de Medina, 1998). The AR positive prostatic 
cancer cell line LNCaP also continue to express the AR after hormone 
depletion (Esquenet, 1997; Koivisto, 1998). Previously, we assumed that 
induction of NE differentiation and absence of the AR would playa key role in 
the survival of PC-295 prostate cancer cells, whereas induction of Bcl-2 
expression would protect the remaining cells from undergoing apoptosis 
(Jongsma, 1998). In contrast to our previous observations in the PC-295 
model and to what has been reported about the LuCap 23 model (Liu, 1996), 
the PC-310 model exhibits both a strong induction of NE differentiation and a 
transient down-regulation of the AR, but not an induction of Bcl-2 expression 
(data not shown). Both NE and AR upregulation after longterm androgen 
deprivation might be an alternative route to bypass androgen deprivation 
induced cell death, independent of an induced Bcl-2 pathway. 
Hormonal escape of prostate cancer can be the result of androgen 
independent activation of an AR sensitive pathway (Jenster, 1999). The 
possibility of androgen independent activation of the AR in PC-310, for 
instance by neuropeptides like GRP, or by IGF-1 (Chan, 1998) or cytokines, 
like IL-6, is an interesting option (Hobisch, 1998), particularly because the AR 
is well expressed in 50 % of the PC-310 cells in the long-term androgen 
deprived situation. Data of a pilot study of continuous administration for 21 
days of relatively high concentrations of GRP to PC-310 tumor bearing mice 
which were deprived of androgens for 35 days showed minor tumor volume 
increases and GRP had no effect on the level of NE differentiation or AR 
expression. In 2 out of 3 mice small but significantly increased amounts of 
PSA (±4 ng/ml) were measured in the mouse plasma at day 56 (Data not 
shown). We have shown in vitro that androgen independent growth of 
androgen deprived prostate cancer cells can be specifically induced by GRP 
(Jongsma, 2000a). Although, we did not observe androgen independent 
growth induced by neuropeptides in the PC-310 xenograft model during the 
154 days of androgen deprivation, we cannot exclude that progression to 
androgen independence will occur after a longer period of androgen 
deprivation. A possible explanation might be that the AR positive non-NE PC-
310 tumor cells have not been able to adapt the AR sensitive pathway. 
Adaptation of the AR sensitive pathway has been shown by Zhu et al through 
MAP kinase dependent activation of hormone receptor dependent gene 
transcription (Zhu, 1997). 
The precise role of NE differentiation in progression of prostate cancer 
is still difficult to assess. Different clinical stUdies have shown an induction of 
NE differentiation after neo-adjuvant hormonal treatment of patients 
undergoing a radical prostatectomy or transurethral resection of the prostate 
(Van de Voorde, 1994; Guate, 1997; Jiborn, 1998; Pruneri, 1998). These 
studies either showed a relation with high Gleason scores or suggested that 
there is a possible relation of NE cells with androgen independent prostate 
cancer. However, these studies did not prove that CgA positive NE cells can 
be of prognostic significance. One other study supported the view that NE 
differentiation in prostatic adenocarcinomas is a prognostic factor for 
progressive disease under subsequent hormone therapy (Krijnen, 1997). 
Plasma CgA levels in hormone refractory patients were also found to be 
significantly elevated (Kadmon, 1991; Cussenot, 1996b), as we observed in 
our PC-310 xenograft model too after long-term androgen deprivation. Their 
findings suggests that a hormonally pretreated tumor with induced NE 
differentiation may eventually lead to hormone refractory prostate cancer. As 
CgA cannot provide enough prognostic value in the progression of prostate 
cancer, testing of other markers as putative NE-related prognostic markers, 
such as Sglll, 782, PC1 and PAM for the progression of clinical prostate 
cancer seems relevant. 
The observed induction of NE differentiation, the sequential maturation 
of NE cells and temporary down regulation of AR protein expression in 
experimental prostate cancer might well represent the initial clinical behavior 
of hormonally treated prostate cancer patients (Van de Voorde, 1994; Guate, 
1997; Pruneri, 1998). Longterm hormone deprivation of PC-310 during the 
whole experimental period did not lead to hormone refractory cancer. Instead 
of this, dormant tumor residues were induced in which the maturating NE cells 
express different markers for NE differentiation evolving after longer periods 
of androgen deprivation, including growth modulatory neuropeptides like GRP 
and 5-HT. The truly dormant part of the PC-310 tumor residues consisted of 
the androgen sensitive AR positive residual tumor cells. 
The androgen dependent human PC-310 xenograft model may be very 
useful as a model for further studies on induction of NE differentiation after 
androgen deprivation, the possible role of the maturating RSP in progression 
of prostate cancer in particular. The present results showed that the NE cells 
in the androgen deprived PC-310 model possess an active peptide hormone 
producing RSP and demonstrate sequential NE maturation patterns resulting 
in different secretory signals. Further long-term androgen deprivation stUdies 
or growth modulatory studies in the PC-310 model will yield information as to 
whether the NE cells playa role in the 'dormant' tumor residues by initiating 
growth induction of AR positive non-NE cells by different growth factors that 
were released through the RSP. Otherwise, the role of the AR in formation of 
androgen independent prostate cancer is of particular interest. Further 
detailed studies on these different aspects of the PC-310 xenograft model 
may lead to a better understanding of prostate cancer behavior during 
hormonal treatment and the mechanism underlying prostate cancer 
progression. 
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MATERIALS AND METHODS 
PC-310 xenograft model 
The nude mouse human prostate cancer xenograft model PC-310 was 
established from a primary prostatic tumor after radical prostatectomy of a 
previously untreated patient (van Weerden, 1996). The tumors grow with a 
doubling time of about 16 days and a lag phase of 2-3 months. The model 
represents a strictly androgen dependent and histologically moderately 
differentiated relatively slow growing tumor, organized in solid sheets and 
microacini. Briefly, PC-310 tumors were implanted subcutanously at both 
shoulders of intact NMRI male nude mice (Harlan, Horst, The Netherlands). 
Optimal grow1h conditions were reached by supplementation of PC-310 
transplanted mice with testosterone implants, as previously described (van 
8teenbrugge, 1984). 8ubcutanously growing tumors developed wilhin 2-3 
months and were grown up to a maximum volume of 2000 mm'. Tumor 
volume changes were followed weekly by perpendicular diameter 
measurements (D1 and D21 after which the volume was calculated from the 
formula: V=(II/6)(D1 x D2)3/ . 
Hormonal manipulation of PC-310 tumor bearing mice 
Androgen deprivation experiments were performed with testosterone-
supplemented PC-310 bearing male mice (Harlan, Horst, The Netherlands) at 
the Erasmus Center for Animal Research. Androgen deprivation was 
performed by castrating the mice under hypnorm anesthesia (Janssen 
Pharmaceuticals, Oxford, UK) and by removing the silastic testosterone 
implant. Three mice were sacrificed at 0,2,5,7,14,21,47,84 and 154 days 
after castration. 
After blood samples were taken for determining serum prostate specific 
antigen levels, mice were sacrificed. Tumor volumes were measured and 
tumor nodules were removed. The tumors were cut into small pieces which 
were either fixed in 4% buffered formalin and paraffin embedded for 
immunohistochemical analysis or snap frozen in liquid nitrogen and stored at -
80°C for biochemical analysis. The paraffin embedded material was 
processed routinely for hematoxylin and eosin staining. 
9 Tumor bearing mice were castrated in a separate experiment and 2 
control mice were used. Three castrated mice were sacificed after day 35 and 
63 each. Three castrated mice were resupplemented after 35 days with a 
testosterone containing silastic implant and sacrificed at day 56. Tumor 
volumes were measured, serum samples were taken just before sacrifice and 
tumor tissue was sampled for either formalin fixation or storage at -80°C for 
biochemical analysis. 
Immunohistochemistry 
To identify the fraction of cells expressing the NE phenotype, paraffin 
embedded tissue sections of the PC-310 xenografts were stained with 
antibodies against CgA (polyclonal rabbit anti human CgA, DAKO), 8gll1 
(rabbit polyclonal antibody; provided by the Department of Animal physiology, 
University of Nijmegen) (Holthuis, 1996a) and PC1 and PC2 (Alexis 
Biochemicals, 10P's, Breda, The Netherlands). For identification of the 
proliferative capacity, tissue sections were stained with an antibody against 
the proliferation associated Ki-67 antigen (MIB-1, Immunotech, Marseille, 
France) and the p27K1P antigen. In addition, apoptotic cells were identified by 
counting the apoptotic bodies in hematoxylin and eosin staining of each 
tissue. Other antibodies used were directed against the AR (clone F39.4, 
kindly provided by Dr. A.O. Brinkmann, Department of Endocrinology and 
Reproduction, Erasmus University); the BcI-2 antigen (clone 124, Dako, 
Glostrup, OK), VEGF (rabbit polyclonal, DAKO) and against the 
neuropeptides bombesin (rabbit polyclonal GRP, DAKO; and anti-GRP MoAb 
2A11; kindly provided by Dr F. Cuttitta, NCI, Bethesda, USA), serotonin (5-
HT; rabbit polyclonal antibody, DAKO), vasoactive intestinal polypeptide (VIP, 
rabbit polyclonal, DAKO) and Calcitonin (rabbit polyclonal, DAKO). 
4 ~m sections for single immunostaining and 2 ~m for double 
immunostaining were incubated overnight at 60°C. The slides were 
deparaffinized and endogenous peroxidase activity was blocked with 3.3% 
hydrogen peroxide (H20 2) in methanol for 10 minutes. Antigen retrieval was 
then performed in 10 mmol/L citrate buffer (pH 6.0) in a microwave at 700 
watt for an initial 10 minutes and a subsequent 5 minutes(Shi, 1991). The 
slides were allowed to cool down to room temperature and then put into the 
sequenza immunostaining system (Shandon, Uncorn, UK) and rinsed with 
phosphate buffered saline (PBS). All slides were pre-incubated with normal 
goat serum (DAKO, Glostrup, OK) for 15 minutes diluted 1:10 in PBS. The 
primary antibodies were incubated overnight at 4°C. The secondary antibody 
was incubated for 30 minutes, being either horseradish-peroxidase 
conjugated goatamouse or goatarabbit (1 :50), or biotinylated goatamouse 
and goatarabbit (1 :400) for monoclonal and polyclonal antibodies, 
respectively. In case of biotinylated goatamouse and goatarabbit, a 
horseradish-peroxidase streptavidin1 :400 in PBS was incubated for a 
subsequent 30 minutes. Between the subsequent steps, the slides were 
rinsed four times with PBS. The bound horseradish-peroxidase was visualized 
in 10 minutes with diaminobenzidine (DAB, Fluka, Neu-Ulm, Germany) in PBS 
containing 0.075% H202 as substrate. Slides were rinsed extensively in tap 
water and finally counterstained in Mayer's Hematoxylin, dehydrated through 
a series of alcohol and embedded in malinol. 
To assess the properties of the NE cells, double staining of CgA 
respectively with MIB-1 and AR was performed. The double staining 
procedure consisted of two consecutive stainings with two primary antibodies. 
The first being always a horseradish-peroxidase-related stable 
diaminobenzidine complex, whereas the second staining was performed with 
an alkaline phosphatase conjugated goatarabbit secondary antibody which 
was subsequently stained with a Fast blue staining protocol. In between both 
stainings, the slides were rinsed with PBS for one hour and again boiled in a 
microwave in 10 mmol/L citrate buffer (pH 6.0) for 10 minutes. As negative 
control, PBS replaced the primary antibody in all stainings. Radical 
prostatectomies, containing normal as well as cancerous prostatic tissue were 
used as positive control for CgA, Sglll, PC1, PC2, AR, GRP, 5-HT, VEGF, 
Bcl-2 and MIB-1 expression. 
For MIB-1, CgA, Sglll and p27k1p , the number of positive cells was 
determined by quantitative counts of all cells in tumor squares at 300x 
magnification from which the number of positive cells per square mm was 
calculated. In total, positive cells were scored as percentage of the total cell 
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number, in <: 10 squares. For AR, VEGF, CD31, GRP, 5-HT, PC1, and PC2 
the level of immunostaining was assessed semi-quantitatively. 
Western blot analysis 
We further confirmed the expression patterns of CgA, Sglll, Bcl-2, 7B2 
and AR by Western blotting. As positive controls, material of human 
pheochromocy1oma was used for CgA, of rat pituitary for Sglll and of the 
human in vitro cell line LNCaP for AR expression. The procedure of protein 
extraction was done as previously described (~oordzij, 1996). Briefly, frozen 
tissues of the PC-310 xenografts were crushed in a liquid-nitrogen-chilled 
metal cylinder. The tissue homogenates were transferred into a lysis buffer 
(IOmM TRIS (pH 7.4), 150 mM NaCI (Sigma), 1 % Triton X-IOO (Merck, 
Germany), 1 % deoxycholate (Sigma), 0.1 SDS (Gibco), 5 mM EDTA (Merck) 
and protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM aprotinin, 
50 mg/L leupeptin, 1 mM benzamidine and 1 mg/L pepstatin; all from Sigma). 
After centrifugation of the mixture at 100,000 rpm at 4°C for 10 minutes, the 
protein content of the supernatants was measured by the Bradford method 
(Bio-Rad protein assay, MOnchen, Germany). 
20 fl9 of each sample was transferred to a SDS polyacrylamide gel and 
gel electrophoresis was performed with pre-stained markers as size standards 
(Novex, San Diego, CAl. The gels were blotted to a 0.45flm cellulose nitrate 
membrane (Schleicher & Schuell, Germany). The immunoblot was blocked 
with PBS (pH 7.7) containing 0.1% Tween-20 (Sigma) and 5% dry milk for 
one hour. The CgA, 7B2 (Mon 102/144, kindly provided by Prof. Dr WM van 
der Ven, Leuven, Belgium), BcI-2, androgen receptor or Sglll antibodies were 
added in their optimal concentration and incubated overnight on an orbital 
shaker at 4°C. After rinsing four times 15 minutes with PBS, incubation for 
one hour was performed with the secondary horseradish-peroxidase-
conjugated antibodies and goatamouse for mouse monoclonal, goatarabbit 
for rabbit polyclonal antibodies, respectively. Subsequently, a short incubation 
with a mixture of 10 ml luminol and 100 ftl oxidizing agent (BM 
chemiluminescense kit, Boehringer Mannheim GmbH, Germany) followed, 
after washing for four times 15 minutes with PBS. Excess reagent was 
removed and antibodies were visualized by exposure of the blots to an X-ray 
film. 
Reverse Transcriptase-polymerase chain reaction 
RNA was isolated by using the single step RNAzolTM B method 
(Campro, The Netherlands (Chomczynski, 1987). Frozen tissue (IOOmg) or 
cell culture pellets were homogenized in 1 ml of RNAzoITM. Chloroform (O.lml) 
was added and the mixture was vortexed for 15 seconds followed by 5 
minutes incubation on ice. The homogenate was centrifuged at 4°C at 12,000 
g for 15 minutes. The upper water-phase containing the RNA was removed 
and mixed with an equal volume of iso-propanol. This mixture was then kept 
at 4 °C for 15 minutes and after that centrifuged at 4°C at 12,000 g for 15 
minutes. The supernatant was removed and the RNA pellet was washed twice 
with 75 % ethanol by vortexing and centrifugation at 4°C at 12000 g. The 
pellet was then dried and resuspended in sterile H20. The concentration was 
determined at OD 260 and solutions of 1 ~g/~1 were prepared for further use in 
Reverse Transcriptase-polymerase chain reaction (RT-PCR) or Northern blot 
analysis. The quality of the isolated RNA was checked by determining the 
260/280 ratio and by formaldehyde gel-electrophoresis to check the ribosomal 
(28 Sand 18S) bands. 
RT-PCR was performed for CgA, Sglll, PAM, PC1 and 2 and 1>2-
microglobulin (1)2MG) with a standard protocol. Reverse transcriptase 
reaction was performed with a mastermix containing 5 mM MgCI" PCR buffer, 
10 mM dNTP's, RNAse inhibitor (10 units), Reverse transcriptase (25 units), 
2.5 mM random hexamer primers and 0.5 ~g RNA in a total volume of 1 0 ~I 
covered with 50 ~I of mineral oil. The mastermix was then processed at 42°C 
for 60 minutes followed by 15 minutes incubation at 99°C and the reaction 
was stopped at 4°C for five minutes. The cDNA mix that was formed was then 
used totally with the mastermix of the polymerase chain reaction (PCR) 
protocol. In this protocol, the mastermix contained reaction buffer, Supertaq 
polymerase (HT Biotechnology Ltd., Cambridge, UK; 1 unit), 15 ~M sense and 
antisense primer in a total volume of 40 ~1. All samples were first denatured at 
94°C for 10' and then amplification was performed for 35 cycles of l' 94°C, l' 
60°C and l' 72°C and a final extension at 72°C for 10'. The PCR product was 
checked on a 1 % agarose gel and, if necessary, followed by Southern 
blotting. The internal control of human 1>2MG clearly showed the equal 
amounts of mRNA that were used for each time-point. 
Northern blot analysis 
Northern blot analysis was performed by running a formaldehyde gel in 
MOPS buffer containing 20 ~g of each sample including the controls. The 
RNA content of the gel was subsequently blotted overnight onto a hybond-N+ 
filter in 10 x Standard saline citrate (10xSSC; 1.5 M sodium chloride and 0.15 
M sodium citrate). The filter was checked for RNA and ribosomal bands are 
marked. After rinsing the filter in 2xSSC, the blot is cross-linked in a GS gene 
IinkerTM UV chamber (Bio-RAD, MOnchen, Germany) and ready for 
(pre)hybridization with different probes against CgA, Sglll, PAM and B2-
microglobulin as control. 
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Abstract 
Most prostatic carcinomas show neuroendocrine differentiation. 
Several studies have tried to correlate neuroendocrine expression with 
disease status but the reported findings have been contradictory. Some 
prostatic neuroendocrine products, such as proadrenomedullin N-terminal 20 
peptide (PAMP), are amidated. Peptidylglycine u-amidating monooxygenase 
(PAM) is the only Carboxy-terminally peptide amidating enzyme known to 
date. We studied the expression of PAMP and PAM in the normal prostate, 
and in prostatic tumors (clinical specimens and human xenograft models), 
with or without prior androgen-deprivation therapy. We found a wide 
distribution of PAMP and PAM expressing neuroendocrine cells in the normal 
and malignant situation, although both markers were not always co-expressed 
by the same cells. There was no significant correlation of either marker to 
tumor grade, clinical progression or disease prognosis in the clinical 
specimens. However, higher PAMP or PAM expression was found after 
androgen-blockade therapy. In the PC-310 and PC-295 androgen-dependent 
xenograft models PAMP or PAM neuroendocrine differentiation was induced 
after androgen withdrawal. The higher induction of both markers in the PC-
310 might explain the long-term survival of this model after androgen 
deprivation. Our work shows an induction of the expression of neuroendocrine 
markers in prostate cancer after endocrine therapy. 
Introduction 
Prostate cancer is the most commonly diagnosed cancer in elderly 
men 1 and is becoming the leading malignant cause of death for men in this 
age group. 
Together with the basal and secretory cells, the normal prostatic 
epithelium has a well developed neuroendocrine (NE) cell population2. In 
prostatic carcinoma (PC), the most common pattern of NE differentiation 
corresponds to scattered isolated NE cells or clusters of NE cells focally 
distributed among the neoplastic cells3. The reported incidence of NE cells in 
PC has increased as the detection methods have improved'·5. The 
widespread distribution of NE cells in prostatic tumors has promoted many 
studies about the relationship of NE differentiation to prognosis in PC 
(reviewed by di Sant' Agnese PA6), but contradictory findings have been 
reported. Prostate cancer is androgen-dependent in early stages but usuall¥ 
relapses to an androgen-insensitive state after androgen-withdrawal therapy 
which implies more aggressive tumors and a poor prognosis for the patient. 
Since prostatic NE cells lack androgen receptor this population has been 
suggested to be androgen-independent8.9 and therefore, assumed to be 
involved in the development of refractory tumors. 
The function of the NE population in the normal and malignant prostate 
is not known. Together with generic NE markers such as chromogranin A 
(CgA), chromogranin 8 or neuron-specific enolase ,o.11 , NE cells produce 
biogenic amines and neuropeptides (reviewed by di Sant' Agnese PA'). The 
effects of some of these NE products on prostatic cells have been 
demonstrated in vitro in some instances. Thus, serotonin and 
bombesin/gastrin-releasing peptide (GRP) act as growth stimulating 
factors '2.'3, while somatostatin is a growth inhibitor14. The production and 
probable secretion of these kind of substances suggests that NE cells may 
playa role in the regulation of growth, differentiation and local homeostasis of 
the normal and neoplastic prostate. 
Proadrenomedullin N-terminal 20 peptide (PAMP) is a 20 amino-acids 
peptide originated from the post-translational processing of pre-
proadrenomedullin 15. Recently, we have detected PAMP in NE cells of the 
human normal prostate 16. NE expression in other tissues, such as the rat 
gastric mucosa, is also associated with the production of PAMp17• However, 
this peptide has first been described in the vascular wall, and in endocrine 
organs in normal and pathological situations'8.'9. PAMP is a pluripotent 
peptide: it was initially identified as vasodilator15, but it can additionally act as 
neural transmission inhibitor'°, endocrine secretion inhibitor" or as cell growth 
suppressor'2. Some of these roles could contribute to the regulation of 
prostatic homeostasis or functioning. 
At least 3 peptides produced by the prostatic NE cells (PAMP, GRP, 
and calcitonin) are Carboxy-terminally amidated peptides in vivo 18.23. The C-
terminal a-amidation is a two-step post-translational modification process 
necessary for many peptides to be completely bioactive23. It is sequentially 
performed by the peptidylglycine a-hydroxylating monooxygenase (PHM), and 
the peptidyl-a-hydroxyglycine a-amidating lyase (PAL)2'. 80th enzymes are 
included in a precursor, the peptidylglycine a-amidating mono oxygenase 
(PAM). PAM has been detected mainly in endocrine tissues25.2". At present, 
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different PAM mRNAs have been detected in rat prostate2? and in human 
prostatic xenografts grown into nude mice28,29, 
We presently performed a study on PAMP and PAM expression in 
prostatic human NE cells by means of their detection in a variety of 
specimens obtained from a broad spectrum of histopathological subgroups. 
Our aim was to get more insight into the possible role of NE subpopulations in 
the normal and the neoplastic prostate by studying the dynamics of the NE 
cell population in relation to tumor malignancy and after androgen deprivation 
treatment. 
Materials and Methods 
Patients 
Two control prostates were obtained from autopsies of healthy young 
individuals (17 and 23 years old) killed in traffic accidents. Neoplastic tissues 
were obtained through radical prostatectomies (RPs) during 10 years in the 
University Hospital Rotterdam, or through trans-urethral resections of the 
prostate (TURPs) mainly performed in the University Hospital Rotterdam, and 
Reinier de Graaff Hospital, Delft, The Netherlands. RPs were performed on 61 
patients with non-metastasized, clinically localized or locally advanced 
prostate cancer. The patients were followed regularly for a mean period of 82 
months (range 13-178). Clinical progression, defined as cytologically or 
histologically proven local recurrence or the appearance of distant metastasis, 
occurred in 27 of the 61 patients. Tumor specific death, defined as death due 
to direct tumor effects or metastasis or death due to tumor therapy, occurred 
in 11 of the 27 patients showing disease progression, TURPs were obtained 
from 29 patients with extensive tumors. Fourteen of them were pre-treated 
with androgen-blockade therapy, i.e. by anti-androgens, flutamide, androcur 
or with orchiectomy (P-TURPs). The rest (n=15) were untreated before 
undergoing surgery (U-TURPs). All tissue procurement protocols were 
approved by the relevant institutional committees. 
Prostates were fixed in 10% buffered formalin, dehydrated in alcohols, 
and embedded in paraffin for in situ detection. Slides of each case stained 
with hematoxilin and eosin (H&E) were used for determining the grade of the 
tumors according to Gleason's system (Gleason sum score, GSS). 
Human prostate tumor xeno~raft models 
PC-295 and PC-310 models3 were established respectively from a 
pelvic lymph node metastasis and from a primary prostatic carcinoma at the 
Department of Experimental Urology, Erasmus University, Rotterdam. These 
models are androgen-dependent and exhibit NE differentation which was 
demonstrated to be significantly increased after androgen ablation28,29,31. 
Briefly, small pieces of tumor were heterotransplanted in NMRI athymic nude 
mice by subcutaneous implantation. The male or female mice (obtained from 
the Harlan Company) were androgen-supplemented through Silastic implants 
containing testosterone (Sigma, St. Louis, MO). The tumors were grown up to 
a maximal volume of 2000 mm3 . For castration experiments androgen 
withdrawal was achieved by removing the Silastic implants and by castrating 
the male mice under hypnorm anesthesia (Janssen Pharmaceuticals, Oxford, 
UK). The mice were sacrificed at short-term intervals after androgen ablation: 
days 0, Yo, 1, 1 Yo, 2, 4, 7, 14, and 21 for PC-295 and days 0, 2, 5, 7, 14 and 
21 for PC-310. A long-term castration experiment was also performed for PC-
310, with mice sacrificed at 0, 21, 47, 84, 90 and 154 days after androgen 
withdrawal. Prostatic tumors were then either fixed in 4% buffered formalin 
and paraffin embedded for immunohistochemical analysis or snap-frozen in 
liquid nitrogen and stored at -80'C for Western blotting analrsis. 
In this study were also included other models3o.3 , both androgen-
dependent or independent, established at the Department of Experimental 
Urology, Erasmus University, Rotterdam: PC-82, PC-133, PC-135, PC-324, 
PC-329, PC-339, PC-346, PC-3461, and PC-374. All the tumors were grown in 
mice as described above. Although these tumors do not exhibit NE 
differentiation after androgen withdrawal31 , a small-scale castration 
experiment was designed: some of the mice bearing the mentioned tumors 
were sacrificed at 14 days after androgen withdrawal. Tissues were 
processed for immunohistochemical analysis. 
Antibodies and peptides 
Immunoreactivity for PAMP was demonstrated using a previously 
characterized polyclonal antiserum33 raised to the C-terminal peptide 
PAMPYY,3.,oAMIDE. It was applied at 1 :3000 on the histological sections and at 
1 :1500 for Western blotting. 
To detect PHM/PAM, two monoclonal antisera (clone G8 and clone 
E10, produced by Dr. Anthony M. Treston, NCI, NIH, USA&) were used. They 
were raised against bovine PHM region (bPAM,88.310; GenBank Accession 
number M18683) which shows a high homology with the human PAM288-31o 
sequence. Both antibodies were applied at 1 :2000 on sections of clinical 
material and at 1: 1 000 on sections of xenograft-derived tissues. 
A monoclonal antiserum raised against human CgA (Boehringer 
Mannheim, Germany) was applied to sections at a concentration of 2 Ilg/ml tb 
confirm whether or not PAMP and PAM expressing cells had the NE 
phenotype. Peptides PAMPYY13.'OAMIDE and bPAM288.31o, used for obtaining the 
specific antisera, were used for the absorption controls. 
Immunohistochemistry 
Sections 4 11m thick were obtained from the paraffin-embedded tissues 
and placed on StarFrost@ slides. Some reverse-face sections were mounted 
to assess co-localization of molecules. Sections were deparaffinized through 
xylene and 100% ethanol, and endogenous peroxidase activity was blocked 
with 3% H,O, solution in methanol for 30 min. After rinsing with tap water and 
distilled water, a microwave pre-treatment was applied for antigen retrieval. 
Slides were placed in a 0.01 M citric acid (Merck, Darmstadt, Germany) buffer 
(pH 6) and heated at 700 W for 12 min and other subsequent 5 min after 
adding distilled water. The slides were allowed to cool down to room 
temperature (RT), rinsed with PBS and placed into the Sequenza 
Immunostaining System (Shandon, Uncorn, UK). Thereafter, sections were 
incubated with normal goat serum (NGS; Dako, Denmark) diluted 1:10 in PBS 
for 20 min and incubated overnight at 4'C with the specific primary antiserum 
at the optimal concentration. After rinsing with PBS, sections were incubated 
at RT for 30 min with horseradish-peroxidase-conjugated goat anti-rabbit or 
& Anthony M. Trcstoll present address: Entremed, Inc., Rockville, J\1D, USA) 
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anti-mouse (according to the primary antiserum applied) immunoglobulins 
(both from Dako) diluted 1 :50 in PBS containing 3% NGS. The slides were 
rinsed four times with PBS before developing. Peroxidase activity was 
detected with 3-3'-diaminobenzidine tetrahydrochloride dihydrate (DAB; Fluka, 
Neu-Ulm, Germany)- H20 2 and after rinsing in tap water, slides were 
counterstained with Mayer's hematoxylin, dehydrated and embedded in 
malinol. 
Absorption controls were performed to test the specificity of the 
antisera. Solutions containing the specific antiserum pre-incubated overnight 
at 4°C with 10 nmol/ml of its respective peptide were applied onto the slides 
instead of the primary antiserum. 
Immunocytochemical double-staining 
A previously described double-staining protocol was applied34. In 
summary, sections were deparaffinized, rehydrated and endogenous 
peroxidase was inhibited, afterward they were microwave preheated as 
described above. Slides were incubated for 20 min with NGS (1 :20) at RT, 
and at 4°C overnight with the specific antisera mixture (containing one 
monoclonal and one polyclonal antiserum). Then, slides were treated with 
horseradish-peroxidase-conjugated goat anti-rabbit immunoglobulins and with 
unlabelled goat anti-mouse immunoglobulins (Dako), diluted 1:50 and 1:100 
respectively, for 30 min. Tissues were incubated with monoclonal alkaline 
phosphatase-anti-alkaline phosphatase (APAAP, mouse, monoclonal; Dako) 
at 1 :50 for 30 min. Goat anti-mouse antiserum was applied again, followed by 
APAAP, for 10 min each. The alkaline phosphatase was developed using 
naphthol AS-TR and new fuchsin as substrate. Peroxidase activity was 
detected with DAB and nickel enhancement. Slides were embedded in PBS-
glycerol. 
Quantification of immunostaining 
For the clinical specimens (RPs and TURPs) tissue sections adjacent 
to the immunostained slides were stained with H&E and the neoplastic zones 
were identified and marked. The markings were copied on the slides 
immunolabeled for PAM or PAMP. The evaluation of NE cells positive for 
PAMP or PAM was done semi-quantitatively. Ten fields of tumor tissue were 
randomly selected at 160x and cells showing granular cytoplasmatic 
immunostaining were counted. The quantitative data were transformed to a 
semi-quantitative final score considering the number and distribution of the 
positive cells (Table I). Therefore, every tumor was assigned two semi-
quantitative scores, one for PAMP and another for PAM. 
In the case of the xenograft models a quantitative evaluation of the 
PAMP expression was performed. Ten fields of neoplastic epithelium were 
randomly selected and scored at 400x by counting the number of positive 
cells. The final value aSSigned to each tumor was the arithmetic mean of all 
the values obtained. 
Statistical analysis of the data 
Statistical computer package SPSS was used to perform the statistical 
analysis. The PAMP or PAM score of each patient was correlated to the 
respective GSS. PAMP scores were correlated with PAM scores. Scores from 
experimental models were correlated with the post-castration time. The 
correlation was studied in every case calculating the non-parametric 
Spearman correlation coefficient (r). Scores from patients who underwent RP 
were also related to clinical progression and survival time (Kaplan-Meier 
method). The frequencies of PAMP or PAM induction for the untreated and 
pre-treated TURPs were compared by the Fisher's exact test. 
Protein extraction and Western blotting 
PC-310 prostatic tissues stored at -80'C were crushed in a metal 
cylinder cooled down at -80'C. The tissue homogenates were transferred into 
a lysis buffer containing 10 mM TRIS (pH 7.4), 150 mM NaCI (Merck), 1% 
Triton X100 (Merck), 1% deoxycholate (Sigma), 0.1% sodium dodecyl 
sulphate ~SDS; Fluka), 5 mM EDTA (Merck), and protease inhibitors 
(Complete M, Boehringer Mannheim). After centrifugation of the mixture at 
100.000 rpm at 4'C for 10 min, supernatants were recovered and the protein 
content was measured spectrophotometrically by the Bradford method (Bio-
Rad protein assay, MOnchen, Germany). 
For the Western blotting detection of PAMP, 35 fIg of each protein 
sample was mixed with sample buffer, heated to 95'C for 3 min, and 
transferred to 10-20% tricine SDS-PAGE gels (Novex, San Diego, CAl. 
Prestained markers were used as size standards (Novex). 5 ng of synthetic 
PAMP were loaded in separate wells as positive controls. Proteins were 
electrophoretically separated at 100 V for 2 hr under reducing conditions (5% 
p-mercaptoethanol). The gels were blotted to polyvinyldifluoride membranes 
(Immobilon PVDF; Millipore, Bedford, MA) at 30 V for 2 hr. The immunoblot 
Was blocked overnight at 4'C with PBS (pH 7.7) containing 5% dry milk. The 
anti-PAMP antiserum diluted in PBS/milk Was added subsequently, and the 
membranes were incubated for 1 hr on an orbital shaker at RT. After rinsing 
the membranes four times for 15 min each with PBS containing 0.1% Tween-
20 (Fluka Chemika, Switzerland) an incubation for 1 hr Was performed at RT 
with the horseradish-peroxidase-conjugated anti-rabbit secondary antibody 
(Amersham, Life Science, England) diluted 1 :5000 in PBS/milk. Membranes 
were rinsed again with PBSlTween as explained above, and finally incubated 
for 1 min with Western blotting luminol reagent (Santa Cruz Biotechnology 
Inc., Santa Cruz, CAl. Excess reagent was removed and blots were exposed 
to high performance chemiluminiscence film (Hyperfilm™ ECL™, Amersham). 
Results 
Immunodetection and quantification of PAMP in the clinical 
specimens 
PAMP immunostaining was exclusively detected in NE cells, both in the 
normal and the neoplastic prostates (Figures 1A-D). The intensity of the 
labeling, granular and cytoplasmatic, was usually strong, although some cells 
did stain more intensively than others. As previously observed in normal 
prostate 16, double immunostaining demonstrated that PAMP positive cells 
were a subpopulation of the CgA positive cells in the neoplastic specimens. 
PAMP immunoreactive cells in the neoplastic glands were distributed 
scattered either as isolated or clustered cells (Figures 1 B-D), whereas in the 
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normal glands they were mainly isolated (Figure 1A). The specificity of the 
staining was confirmed by the absorption controls (Figure 1 F). 
49 out of 61 (80%) RPs, 12 out of 15 (80%) U-TURPs and 11 out of 14 
(79%) P-TURPs exhibited NE PAMP expression. PAMP scores in relation to 
the respective GSS are shown in Tables II and III. There was no correlation 
between the PAMP score and the GSS for the RPs (r=-0.012, p=0.924) and 
for the U-TURPs (r=-0.078, p=0.782). However, the P-TURPs showed a 
positive correlation between the scores (r=0.489) although it proved to be 
statistically not significant (p=0.076). There was a very noticeable increase in 
the percentage of patients expressing high PAMP (score 3) from untreated 
(1/15=7%) to pre-treated (5/14=36%) TURPs (p=0.08). Concerning the 
patients who underwent radical prostatectomy, 78% (21/27) of those showing 
disease progression and 82% (9/11) of patients who died because of the 
tumor, exhibited PAMP-associated NE differentiation. On the other hand, 82 
% (28/34) of the patients without disease progression and 80% (40/50) of 
patients without tumor specific death showed also PAMP NE expression. 
Kaplan-Meier curves did not show a prognostic value of PAMP expression in 
relation to clinical progression and tumor specific survival (data not shown). 
Table I Semi-quantitative values for NE expression 
Semi-quantitative Expression level Evaluation criteria 
score 
0 Not detected No positive cells observed 
1 Low, irregular Positive cells in less than 5 fields 
2 Intermediate, regular Positive cells in at least 5 fields 
3 High More than 6 positive cells in at least 5 
fields or clusters of 10 or more 
positive cells in at least 1 field 
Table II Relationship between PAMP score and GSS in the RPs 
TUMORPAMP GLEASON SUM SCORE TOTAL 
SCORE 4 5 6 7 8 9 10 
0 0 1 1 4 3 3 0 12 
1 1 1 7 13 3 7 2 34 
2 1 0 0 3 0 0 0 4 
3 0 1 0 4 3 3 0 11 
TOTAL 2 3 8 24 9 13 2 61 
Table III Relationship between PAMP score and GSS in the TURPs 
TUMOR Pre-treated patients Untreated patients 
PAMP 
SCORE GSS TOTAL GSS TOTAL 
7 8 9 10 7 8 9 10 
0 1 2 0 0 3 0 0 2 1 3 
1 1 2 3 0 6 1 1 4 5 11 
2 0 0 0 0 0 0 0 0 0 0 
3 0 2 2 1 5 0 0 1 0 1 
TOTAL 2 6 5 1 14 1 1 7 6 15 
Figure 1: NE PAMP expression (A-E) and PAMP absorption control (F). PAMP 
cytoplasmatic and granular expression is well appreciated at the insert (C). The 
arrows paint some of the PAMP expressing clustered cells. Note the very high PAMP 
expression in the neoplastic epithelium of the PC-310 model (E). A: normal prostate; 
Band C: RPs from patients with GSS 7 and 8, respectively; D and F: TURP with 
assigned GSS 8 from a patient pre-treated with androgen blockade; E: tumor from 
the PC-310 model obtained at T.oo post-castration. Magnification: A-O and F, 125x; E, 
250x; insert, 500x. Counterstaining: Mayer's hematoxilin. 
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Immunodetection and quantification of PAMP in the xenograft 
models 
PAMP expressing cells showed a remarkable increase in the PC-310 
model with the post-castration time (Table IV). The first PAMP positive cells 
were observed at 48 hours after androgen ablation in randomly selected 
fields. At 7 days after castration (T.,), the expression started to increase 
mainly in the peripheral area of the tumor. However, the PAMP positive cells 
became numerous also in the tumor central zone with the androgen-
deprivation time (Figure 1 E). The maximal PAMP expression was reached 
after a period of 90 days of androgen withdrawal. There was a positive and 
strong significant correlation (r=0.976, p<O.001) between the post-castration 
time and the number of PAMP expressing cells. 
In the short-term castration experiment done with the PC-295 model, 
the PAMP-associated NE differentiation was much lower than in the PC-310 
model. The first PAMP cells were detected at T." and the maximum of PAMP 
positive cells (mean value 0.9 ± SEM) was observed at T.14. A positive and 
significant correlation (r=0.822, p=0.007) was found between the number of 
PAMP expressing cells and the time during which androgens were withdrawn. 
Table IV. Time course of the presence of PAMP positive cells in the 
androgen·deprivation experiment for the PC-310 prostate xenograft model 
POST-CASTRATION PAMP CELLS SEM 
DAYS (mean value) 
0 0.0 0.0 
2 0.2 0.1 
5 0.6 0.3 
7 5.8 1.2 
14 12.5 2.9 
21 10.3 2.6 
47 24.4 3.8 
84 19.7 2.7 
90 35.0 5.8 
154 42.7 5.9 
Both PC-310 and PC-295 models, showed a high increase of CgA 
expressing cells after androgen deprivation. CgA positive cells were found at 
low levels at To but became numerous in areas from the peripheral zone to 
the central zone of the tumors after longer periods of androgen deprivation, as 
shown previously'8.'9. All PAMP positive cells in these xenograft models were 
CgA expressing cells, but not conversely, which confirmed the PAMP cells as 
a subpopulation of the total prostatic NE cells. It is worth noting that in both 
models CgA cells showed a trend to be the main tumor cell type later during 
the post-castration period. This trend was also observed for the PC-310 
model PAMP population, but not for the PC-295. 
Most of the other xenograft models did not exhibit PAMP expression at 
all, neither at To nor at T.14. Some sporadic immunostained cells were 
observed at T.'4 in the androgen·dependent PC·82 (PAMP mean value=O.1) 
and PC-329 (PAMP mean value=0.3) models, and in the androgen-
independent PC·374 model (PAMP mean value=0.2). 
Immunodetection and quantification of PAM in the clinical 
specimens 
As described in the Material and Methods section, two monoclonal anti-
PHM antisera were used for immunolocalizing the PAM/PHM reactivity. In a 
pilot study, the distribution of the staining derived from the use of both 
antibodies was found to be similar. As the application of one of them (clone 
G8) resulted in a more sensitive detection, this antibody was used for the 
scoring of PAM expressing NE cells in the complete series of neoplastic 
specimens. 
As described for PAMP, PAM-associated NE expression was granular 
and cytoplasmatic in epithelial scattered cells of the normal and neoplastic 
prostates (Figures 2A, B, E and F). The scattered PAM immunolabeled cells 
were assessed as a subpopulation of the CgA expressing NE cells by serial 
reverse-face staining (Figures 2A and C). Double immunostaining and 
immunostaining on reverse-face sections performed to co-localize the 
amidating enzyme (PAM) and the amidated peptide (PAMP) revealed three 
types of NE cells both in the normal and in the tumor glands: First, positive 
cells for PAM but not for PAMP; second, positive cells for PAMP but not for 
PAM; and a third subpopulation of cells which were immunostained for both 
PAMP and PAM (Figures 2B and D). Most of the positive cells belonged to the 
third group exhibiting double immunoreactivity. PAM immunolabeling of NE 
cells was confirmed as specific by the appropriate absorption controls 
(Figures 2G and H). 
In the normal prostate, the PAM-stained NE cells were found 
distributed as single isolated cells scattered in the epilhelium of ducts and 
acini (Figures 2A and B), and were more abundant in the periurethral than in 
the peripheral glands. Furthermore, other prostatic structures such as the 
utriculus and the urethra exhibited many PAM expressing cells. In the tumors, 
PAM was observed in single or clustered NE cells (Figures 2E and F), as 
described above for PAMP expressing cells in the neoplastic tissues. 
Specific PAM immunoreactivity was also detected in non-NE epilhelial, 
endothelial, and muscle (smooth and striated) cells, as well as in neurons and 
nerves (Figures 3A-D). 
Table V Relationship between PAM NE score and GSS in the RPs 
TUMOR PAM GLEASoN SUM SCoRE ToTAL 
SCORE 4 5 6 7 8 9 10 
0 1 2 5 12 6 5 2 33 
1 1 1 3 9 2 6 0 22 
2 0 0 0 1 0 1 0 2 
3 0 0 0 2 1 1 0 4 
TOTAL 2 3 8 24 9 13 2 61 
With respect to the scoring of the immunostaining in the neoplastic 
specimens, 28 of 61 (46%) RPs, 4 of 15 (27%) U-TURPs and 5 of 14 (36%) 
P-TURPs exhibited NE-associated PAM expression (Tables V and VI). 
Spearman coefficients indicated no correlation between GSS and PAM score 
for the RPs (r=0.070, p>0.05). In the case of the TURPs it was observed a 
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Figure 2: NE PAM expression (A, 8, E and F), co-localization with egA (C) 
and PAMP (O), and absorption controls (G and H). Same type of arrows point 
to the same cells immunostained for PAM-egA (A and e) or PAM-PAMP (8 
and O). Arrowheads in F and H point to the same vessel. 
A-O: normal prostate; E and G: P-TURP, GSS 10; F and H: RP, GSS 9. 
Magnification: A-E and G, 140x; F and H, 125x . .counterstaining: Mayer's 
hematoxilin. 
Table VI Relationship between PAM NE score and GSS in the TURPs 
TUMOR PAM Pre-treated patients Untreated patients 
SCORE 
GSS TOTAL GSS TOTAL 
7 8 9 10 7 8 9 10 
0 2 4 3 0 9 1 1 3 6 11 
1 0 0 1 0 1 0 0 3 0 3 
2 0 0 0 0 0 0 0 0 0 0 
3 0 2 1 1 4 0 0 1 0 1 
TOTAL 2 6 5 1 14 1 1 7 6 15 
negative correlation between the scores from specimens of untreated patients 
(r=-0.302) and, conversely, a positive correlation for the scores from 
specimens of pre-treated patients (r=0.347), but none of them was statistically 
significant (p>0.05). 27% (4/14) of the P-TURPs and 7% (1/15) of the U-
TURPs exhibited high PAM expression (score 3). These percentages were 
not significantly different (p=0.169, n=29). In the patients who underwent RP, 
PAM-associated NE differentiation was detected in 44% (12/27) of patients 
with disease progression and 36% (4/11) with tumor specific death. 
Furthermore, PAM-associated NE immunolabeling was found in 47% (16/34) 
of the patients having no disease progression and 48% (24/50) of patients 
who did not die because of their tumor. Kaplan-Meier curves did not show a 
prognostic value of PAM expression in relation to the clinical progression or 
the tumor specific survival (data not shown). 
In general, PAM was less detectable than PAMP in every kind of 
tissue. To assess whether the relationship between PAM and PAMP 
expressions exists, the correlation between both scores was calculated. For 
the RPs, there was a positive and significant correlation (r=0.494, p<0.001). 
For the TURPs, the correlation was smaller and not significant: r=0.208 (U-
TURPs) and r=0.307 (P-TURPs). 
Immunodetectlon and quantification of PAM In the xenograft 
models 
The PC-310 xenograft tumors showed two kinds of PAM 
immunoreactivity (Figure 4A). A faint diffuse staining was found in the non-NE 
neoplastic epithelium, whereas a usually strong and granular labeling was 
localized in some epithelial cells later assessed as NE cells. Likewise, 
expression of PAM was found in the PC-295 model. During long-term 
androgen deprivation of the PC-310 model, we observed an increase in the 
number of PAM positive NE cells. The increase in PAM NE differentiation 
appeared later in time after androgen deprivation than PAMP differentiation. 
In PC-310 model PAM positive NE cells were observed for the first time at T.21 
but became numerous from T.84 onwards. Although an increase in the PAM 
NE cells was observed in time after androgen deprivation, we cannot present 
quantitative data because the parallel increased staining of non-NE PC-310 
tumor cells made the scoring of the PAM expressing NE cells unreliable. 
Strong PAM expression co-localized with PAMP and CgA expressing NE cells 
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Figure 3: Non-NE PAM expression, (A) Tumor epithelial cells showing a light 
but general cytoplasmatic labeling. (8) Stained endothelia irrigating a tumor 
zone. (C) Neurons in a prostatic ganglion. (D) Nerve. 
Magnification: A and 8, 500x; C and D, 250x. Cpunterstaining: Mayer's 
hematoxilin. 
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Figure 4: Immunoreactivity in the PC-310 model at T-90 . PAM (A and B) is 
expressed in NE and non-NE epithelial cells. Note that the more stained PAM 
cells in (B) are situated in coincident zones with the cells immunostained for 
CgA (C) and PAMP (D). Figures B-O correspond to the same epithelial node. 
Magnification: A, 500x; B-O, 125x. Counterstaining: Maye(s hematoxilin. 
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(Figures 48-0). In a short-term castration experiment the PC-295 
model showed a slight increase in PAM expressing NE cells. 
The other models showed different epithelial staining patterns. In the 
androgen-dependent PC-82, PC-329 and PC-346 models a pattern of low and 
diffuse expression was observed, while some parts of the endothelium were 
stained strongly. The androgen-independent PC-133, PC-135, PC-324, PC-
339, and PC-374 showed a stronger overall staining pattern, whereas the 
androgen-independent PC-346 subline, PC-3461, exhibited areas with strong 
epithelial staining surrounded by areas with low PAM expression. In these 
models the expression levels overall increased during 14 days of androgen 
deprivation, but these were assessed as non-NE, i.e. CgA negative, tumor 
cells. Exceptions were a high PAM expression in the peripheral zone of PC-
133 tumors, a strong PAM positivity in numerous PC-3461 tumor cells and an 
induction of NE-like PAM expressing cells in the PC-329 model during 
androgen deprivation. 
PAMP Western blotting 
The study was performed for the PC-310 model since it exhibited the 
highest number of PAMP positive cells as determined by 
immunohistochemistry. Total protein extracts from short-term (0, 2, 5, 7, 14 
and 21 post-castration days) and long-term (0, 21, 47, 84, and 154 post-
castration days) experiments were studied (Figure 5). The 3 kOa band, 
corresponding to fully processed PAMP, was not detectable in any of the 
xenograft extracts. However, other larger bands were observed from T_21 . 
Some of these bands have been previously described as PAMP precursor 
peptides (14 and 22 kOa). Other bands could not be interpreted so far. The 
intensity of the signal increased with the androgen deprivation time. Thus, the 
14 and 22 kOa bands became stronger from T-21 to T_84 , although were fainter 
at T-154. In the absorption controls no signal was detected (data not shown). 
PHM/PAM quantification by Western blotting technique was not 
feasible in the xenograft tumors due to the strong background derived from 
the mouse immunoglobulins present in the extracts, which were recognized 
by our detection system (data not shown). 
PAMP 0 2 5 7 14 21 o 21 47 84 154 
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Figure 5: PAMP Western blotting in the short-term (A) and long-term (8) PC-
310 post-castration experiments. Synthetic PAMP was loaded in a separate 
well (A). 
Discussion 
NE differentiation in prostatic carcinoma has been widely studied 
during recent years. Focal NE differentiation in most of the prostatic tumors 
has become evident as the sensivity of the techniques has been improved 
and the spectrum of tested NE markers has been enlarged'·5.3. The 
generalized presence of NE cells in PC and their characteristic of being 
androgen-independenta.9 has suggested that NE population may be involved 
in the progression of the disease and in the development of refractory tumors 
after endocrine therapy. Thus, several studies aimed at the possible 
implication of the prostatic NE population in the prognosis of prostate cancer 
considering pan-NE markers such as CgA, and other endocrine factors. So far 
conclusions have been contradictory, from an independent prognostic 
significance, to a null correlation6. The different results are likely due to the 
heterogeneity of the clinical material used in each study. 
We have studied a great variety of prostatic tissues for comparing the 
expression of two NE markers in different situations including: 1) normal 
prostate, 2) low and high grade PC obtained through RP from patients 
showing clinically localized or locally advanced disease, 3) high grade PC 
obtained through TURP from patients without prior treatment, 4) high grade 
PC obtained through TURP from patients pre-treated with androgen blockade 
and, 5) experimental models such as human prostate tumor xenograft models 
with different degrees of NE differentiation after androgen withdrawal. 
With immunohistochemical techniques two new markers were detected 
which were widely expressed in the NE population of human normal and 
malignant prostate: proadrenomedullin N-terminal 20 peptide (PAMP), and 
peptidylglycine a-amidating monooxygenase (PAM) enzyme. PAMP or PAM 
positive cells were distributed with similar patterns than other NE markers in 
the normal prostate'6.36. Thus, they were detected in ducts and acini, were 
more numerous in the periurethral than in the peripheral zone, and were also 
present in the prostatic urethra and utriculus. Since PAMP and PAM 
expressing NE cells were always subpopulations of the CgA expressing cells 
none of these markers can be considered more sensitive than CgA for 
localizing NE cells. PAMP is an amidated peptide and PAM is the only 
amidating enzyme known. It seems logic to think that the PAMP cells should 
express also PAM, although not conversely, since other prostatic 
neuropeptides like calcitonin and GRP also require amidation23, and these 
could be expressed in other cells than PAMP NE subpopulation. So far, a 
PAMP/PAM expressing subpopulation, and likely a PAMP-negative and PAM-
positive subpopulation could be expected. However, in every group of patients 
it was also detected third subpopulation, positive only for PAMP but not for 
PAM. This may account for the weak correlation between PAMP and PAM 
scores we found in the clinical specimens. The single PAMP subpopulation 
might reflect the accumulation of peptides in the cells after a period of active 
synthesis that will require the co-expression of PAM for their amidation. 
Alternatively, an unidentified amidating enzyme might be involved in the 
activation of PAMP in these cells, as suggested for other tissues37. 
Previous works have reported variable incidences of focal NE 
differentiation in PC'·5.35, what can be partially attributed to the different 
degree of expression detected by immunohistochemistry for each NE marker5. 
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In the clinical material we detected PAMP in approximately 80% of tumors 
obtained both by RP or TURP. The percentage of samples showing PAM-
associated NE differentiation was lower and more variable: 46% (RPs), 27% 
(U-TURPs) and 36% (P-TURPs). It is conceivable that PAMP, PAM and other 
regulatory sUbstances are produced by specific NE subpopulations which 
could exhibit different levels of metabolic or secretory activity and thus, which 
potentially will have diverse effect on neighboring non-NE tumor cells. 
Some investigators have found an increase of NE differentiation with 
decreasing tumor differentiation38• Others, have reported no correlation 
between NE differentiation and tumor grade39. In this work, we also 
investigated the relationship between the PAMP or PAM NE differentiation 
and the grade of the tumors. It is known that the histologic grade represented 
by the Gleason sum score is strongly correlated with the grade of 
dedifferentiation and the malignancy of the PC40 The TURPs specimens 
received high grade scores (GSS from 7 to 10), while RPs included GSS from 
4 to 10. In the RPs no correlation between the PAM or PAMP expression and 
the GSS was found. In the TURPs from pre-treated patients the correlation 
coefficients were positive (PAMP: r=0.489; PAM: r=0.347) while in the TURPs 
from untreated patients were negative (PAMP: r=-0.078; PAM: r=-0.302). 
Among these coefficients, only the one corresponding to PAMP/GSS in the P-
TURPs almost reached statistical significance (p=0.076). Therefore, when 
considering every clinical subgroup separately, PAMP or PAM NE 
differentiation does not seem to be directly associated with the tumor grade. 
However, the increase shown by the correlation coefficients calculated for the 
P-TURPs with respect to the U-TURPs suggests that, at least in high grade 
tumors, PAM and PAMP NE cells may acquire functional relevance in tumor 
dedifferentiation or regulation after endocrine therapy. Furthermore, at least 
PAMP differentiation is induced in the hormone refractory tumors after anti-
androgen therapy. We found high PAMP or PAM NE expression more 
frequently in the palliative TURPs (PAMP: 36%, PAM: 27%; n=14) than in the 
untreated TURPs (7% for both markers; n=15) being the PAMP incidences 
almost significantly different (p=0.08). Possibly, PAMP, PAM, or other 
substances produced and secreted by NE cells can act as alternative growth 
factor after androgen depletion. To elucidate whether or not these products 
are responsible for the emergence of hormone refractory tumors, the 
expression of their respective receptors by the neighboring neoplastic cells 
should be investigated whenever possible. 
Patients who underwent RP had a long follow-up (13-178 months) for 
clinical progression and tumor specific death. PAMP or PAM differentiation 
showed no prognostic value for disease progression or cancer related death 
for this group of RPs. This lack of prognostic value agrees with a previous 
work based on CgA expression performed on a similar group of patients3". 
However, some authors have reported that NE differentiation in PC is a 
prognostic factor for progressive disease, although this was concluded for a 
group of patients who had received endocrine therapy41. 
Beyond the extensive studies of PC-295 and PC-310 models, all 
remaining xenografts studied did not show any PAMP or PAM NE 
differentiation after androgen depletion. This result was expected since 
induction of NE cells by androgen deprivation has not been previously 
observed in these models3'. Androgen deprivation experiments with the 
androgen-der.endent PC-295 and PC-310 models have been extensively 
described's" ,31, Both models exhibit tumor regression after androgen 
deprivation but PC-310 tumors survive at least 5 months as dormant tumor 
residues, while PC-295 tumor epithelium regresses completely in a relatively 
short period of time's, This different behavior of the models explains why the 
long-term androgen-withdrawal experiment was carried out just in the PC-310, 
As reported by Jongsma et al.'s,,,, both models show a remarkable induction 
of NE differentiation with CgA positive cells becoming the main epithelial cell 
type after prolonged androgen withdrawal. In the present study, PAMP-
associated NE differentiation was found to be induced in the PC-310 and PC-
295 in different ways, The number of PAMP cells raised in PC-295 was very 
small, but it increased sharply parallel to the CgA positive cell population in 
the PC-310. High PAM NE differentiation was induced relatively late in the 
PC-310 model, whereas a limited induction of PAM positive NE cells was 
observed in the PC-295, It has been previously reported that PC-295 and PC-
310 tumors do express PAM mRNAs at every time-point of the androgen 
withdrawal experiment'S,,,. At sight of our observations, this mRNA could be 
mainly attributed to the non-NE PAM cells for PC-295, while in the PC-310, 
PAM mRNA probably corresponds to both NE and non-NE PAM expressing 
cells, The evidence of a distinct induction of NE subpopulations in PC-310 
and PC-295 models may be related to the different evolution of these tumors 
after hormone deprivation, PAMP or PAM NE subpopulations could be 
supplying factors alternative to the androgens making survival of the dormant 
PC-310 tumor residues possible, 
Western blotting analysis performed with PC-310 derived material 
detected some bands (Mw of 14 and 22 kDa) corresponding to PAMP 
precursors, Olher detected bands cannot be explained, but could correspond 
to binding-proteins associated PAMP, as suggested for its gene-related 
peptide, adrenomedullin42, The signal corresponding to PAMP precursors 
(specially the 14 kDa) increased as the post-castration time advanced, 
However, at T.
'54 their intensity apparently diminished, very likely due to the 
increase of the mouse stromal volume observed in the PC-310 model at this 
late time-point. The absence of a processed PAMP peptide in the PC-310 
extracts could be due to its rapid secretion or degradation, 
Assuming the androgen-insensitive nature of NE cells the regulation of 
PAMP and PAM expression should be considered androgen-independent. 
Nevertheless, the increase of PAMP and PAM expression in the PC-310 
model after androgen ablation, and the increased percentage of high PAMP 
and PAM scores found in the patients pre-treated by androgen-blockade 
therapy showed that androgen depletion results in PAMP, PAM and more 
generally, NE cell differentiation, Some authors43 have not found the typical 
hormone responsive elements required for activating gene transcription by 
steroid hormones in the human pre-proadrenomedullin gene, which is in 
concordance with our findings concerning PAMP, On the other hand, it might 
be possible that androgen exerts a transcription repressor effect on the pre-
proadrenomedullin gene, which could explain the increase of PAMP after 
androgen deprivation. 
NE cells produce a great variety of regulatory factors both in normal 
and neoplastic situations. Serotonin and GRP act as grow1h factors12,13,44, 
while somatostatin is a grow1h inhibitor", as tested in vitro. The production of 
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this regulatory sUbstances suggests that the presence and activity of NE cells 
may affect growth, differentiation and local homeostasis of the prostate. This 
is supported by the observation of a increased proliferative activity in exocrine 
cells surrounding NE tumor cells45• PAMP exerts a variety of effects on 
different cell types, acting as vasodilator substance 15, neural transmission 
inhibitor'°, or growth suppressor'2. Our observations suggest that PAMP may 
be responsible for the long-term survival of the androgen-dependent PC-310 
model as opposed to the rapid regression of the PC-295 tumors after 
androgen ablation. Furthermore, it is possible that PAMP induces vasodilatory 
effect on mouse stromal vessels. The detection of PAMP binding sites in the 
neoplastic cells, and the supplementation of the PC-295 or PC-310 tumor 
bearing mice with synthetic PAMP or with inactivating anti-PAMP 
immunoglobulins may be possible ways to study the precise effect of PAMP 
on prostatic carcinoma in the future. 
We found PAMP expression exclusively associated to the NE cell type. 
In contrast, PAM was also detected in non-NE cells such as endothelial, 
epithelial, or neuronal cells and nerves. This spread PAM detection is 
understandable since peptides requiring C-terminal amidation (like 
adrenomedullin46 or endothelin) have also been reported in some of these cell 
types. 
In summary, the study of PAMP and PAM expression in human 
prostate has demonstrated that they are two markers produced by specific 
subpopulations of NE cells widely distributed in normal and malignant tissue. 
Their expression is induced by androgen deprivation in some xenograft 
models and refractory tumors from patients, showing a similarity between the 
experimental and the clinical settings. In non-palliative patients receiving no 
prior hormonal treatment PAMP and PAM presence is not related to the tumor 
grade, clinical progression or survival time. In the patients previously treated, 
the trend to a positive correlation between PAMP or PAM NE differentiation 
with the tumor grade suggests a possible change in the functional relevance 
of these cells after androgen depletion. The possibility of a significant 
functional role for PAMP in prostatic tumor biology is supported by the fact 
that the androgen-dependent PC-310 tumors (showing an increasing PAMP 
NE differentiation) demonstrate long-term survival after androgen deprivation. 
To date, no particular functional role has been demonstrated for 
prostatic NE cells, neither in normal nor in neoplastic biology. Our study 
shows that specific NE subpopulations, such as those expressing PAMP or 
PAM, may be implicated in the progression of the disease after anti-androgen 
therapy. 
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CHAPTER 7 
GENERAL DISCUSSION 
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NE cells and the regulated secretory pathway 
Endocrine cells have an important function in organs like the pituitary 
and pancreas, producing all kinds of peptide hormones and neuropeptides. 
The endocrine cells form the islets of Langerhans in the pancreas in which the 
processing and regulated secretion of insulin or glucagon takes place via the 
regulated secretory pathway. In Xenopus laevis, the light to dark background 
adaptation (Holthuis, 1995) is triggered by production of pro-opiomelanocortin 
(POMC) by NE cells in the intermediate lobe of the pituitary. POMC is 
processed to smaller hormones, among others melanocyte stimulating 
hormone (MSH), which induces melanin production giving the dark skin 
pigment. The coordinated expression of different proteins from the regulated 
secretory pathway is necessary for a controlled production of peptide 
hormones by NE cells. A role for endocrine cells in differentiation of the 
hypothalamo-pituitary gonadal axis and in the embryonal or pubertal 
development of different epithelia, like the prostatic epithelium has been 
postulated (Pearse, 1969; Grube, 1986; Thoss, 1995; Sanchez-Montesi nos, 
1996; Kosut, 1997; Reinecke, 1997; Xue, 1998a). Sanchez-Montesinos et al. 
(Sanchez-Montesi nos, 1996) showed that the development of the sympatho-
adrenal system in the adrenal medulla consists of three different expression 
patterns. Firstly, expression of the early markers like CgA and CgB was 
observed, followed secondly by induced expression of NE markers of the 
regulated secretory pathway like Sglll, 7B2, PC1 and PC2 and thirdly the late 
appearing markers like Sgll, PC3 and neuropeptide Y were expressed. This 
very much resembles the sequential events of NE cell maturation that we 
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Figure 1: Schematic presentation of the process of NE cell maturation 
observed by studying the expression patterns of the different markers of the 
regulated secretory pathway in the PC-310 xenograft model during long-term 
androgen deprivation (Chapter 5). Figure 1 schematically shows that 
androgen deprivation of hormone dependent prostate cancer induces a 
process of NE differentiation, evolving in subsequent maturation steps. The 
first step of PC-310 NE cell differentiation is the induced expression of early 
differentiation markers, like CgA. Prolonged maturation leads to expression of 
the typical peptide hormone production markers, like Sglll, PC1 and PC2. 
Subsequently, further NE cell maturation in the PC-310 model leads to the 
production of neurotransmitters and growth factors, like 5-HT and GRP. This 
latter time dependent production of growth modulating peptides may be 
important for either maintaining tumor dormancy or in development of 
hormone refractory prostate cancer. 
NE cells and clinical prostate cancer 
Different patient studies of hormonal pretreatment by either chemical 
castration with an LH-RH analogue or by combination of endocrine 
monotherapies, like Hutamide and a cytostatic agent such as estramustine 
phosphate (EMP) before radical prostatectomies or trans-urethral resections 
of the prostate have shown the concomitant induction of NE differentiation 
(Van de Voorde, 1994; Guate, 1997; Jiborn, 1998; Pruneri, 1998). However, 
induction of NE differentiation in most of these studies has not yet been 
proven to be of prognostic significance in relation to prostate cancer 
progression. Rather, the strong induction of NE differentiation could be a 
bystander effect of androgen deprivation, without playing a role in tumor 
progression. This is confirmed by the results of the PAM and PAMP studies 
performed both in clinical specimens as well as in the PC-310 in vivo model 
after long-term androgen deprivation (Chapter 6). The only role that one may 
be certain about is that the induced NE cells are necessary for maintenance 
of PC-310 tumor residues (Chapter 5). Hormonally pre-treated patients with 
induced NE differentiated tumor do not necessarily have a shorter disease 
free survival time compared to patients without NE differentiation (Van de 
Voorde, 1994; Jiborn, 1998; Pruneri, 1997). On the contrary, prostatic tumors 
with higher CgA expression showed a significant correlation with bad 
prognosis (Krijnen, 1997). Still, the exact role of NE differentiation in 
progression of prostate cancer is difficult to assess. 
NE differentiation in human prostatic xenograft models 
Previously, NE differentiation in both the xenograft models and the initial 
patient material was studied on basis of CgA expression (Noordzij, 1996). The 
differentiation status of the available in vivo human prostate cancer xenograft 
models (described in Chapter 1) and of recently developed sublines of some of 
these models was re-evaluated. By using an improved and more sensitive 
staining technique for CgA expression we found more models with NE tumour 
cell differentiation than previously reported (Noordzij, 1996). The expression 
patterns of CgA and the marker for the regulated secretory pathway, Sglll 
(table I) as well as the AR status (data not shown) were studied. 
125 
126 
MODEL Androgen NE differentiated 
dependent CgAlSglll 
PC·B2 + ± 
PC·i33 
PC·135 
PC-295 + + 
PC·3i0 + + 
PC-324 + 
PC-329 + +/' 
PC-339 ± 
PC·346 + 
PC·346B ++ ±l+ 
PC·3461 
PC·34GBI + 
PC-374 + + 
Table I: Status of androgen dependence and expression of the NE markers, 
CgA and Sglll, in human prostate xenograft models. 
Seven of the thirteen presently available tumor models at our institution 
showed NE differentiation as defined by immunoreactivity against CgA as well 
as Sgili. These models are the androgen dependent models PC-B2, PC-295 
(Chapter 2), PC-310 (Chapters 4,5 and 6), PC-329, the BALB/c (B) subline of 
the PC-346 xenograft (PC-346B) and the androgen independent models, PC-
324 and PC-339. The CgA expression pattern in these models closely 
resembles the pattern of NE differentiation that was found in clinical prostatic 
tumors (Cohen, 1991; Aprikian, 1993; Krijnen, 1993; Noordzij, 1995a). In the 
other models, PC-133, PC135, PC-346, and its sublines PC-3461 and PC-
346BI no expression of CgA was found in the presence of androgens whereas 
a low but detectable level of NE differentiation was observed in tumors grown 
on androgen deprived mice. 
The androgen dependent models, PC-295, PC310, PC-B2, PC-346B 
and PC-329 can easily be hormonally manipulated and show a homogeneous 
response to hormone withdrawal. The NE differentiated PC-295 and PC-310 
are the two models mainly studied for induction of NE differentiation after 
androgen deprivation, because the induction is relatively fast and these models 
had previously been shown to continuously express CgA (Noordzij, 1996). In 
the PC-295 model, NE differentiation is induced immediately after androgen 
withdrawal. This model regresses rapidly due to strong induction of apoptosis 
and a sharp decrease in proliferation. After three weeks of androgen 
deprivation the tumors only contain small dispersed tumor fields consisting of 
either NE differentiated or Bcl-2 positive cells. The PC-310 model shows the 
same pattern of induction of NE differentiation and decreased proliferation after 
androgen deprivation, but in this model the level of apoptosis was not as high 
as observed in the PC-295 model. 
Morphologically, the PC-324 and PC-339 tumors are very poorly 
differentiated and the tumor cells stain with CgA and Sglll in a pattern known 
from small cell prostate cancer (SCPC). Using RT-PCR, high expression levels 
of CgA, Sglll and PC-1 mRNA were found whether PC-324 tumors were grown 
with or without androgens (unpublished results). Furthermore, over-expression 
of p53 and BcI-2 was found. Apparently, morphology and immunohistochemical 
features of PC-339 are consistent with a SCPC model. 
Other in vivo prostate cancer models have been reported, like the 
SCPC model UCRU-PR-2 (Haaften-Day, 1987; Jelbart, 1988; Jelbart, 1989), 
CWR22 and derived sublines (Pretlow, 1993; Wainstein, 1994; Nagabhushan, 
1996; Agus, 1999) as well as transgenic mice models, like CR2-T-Ag 
(Garabedian, 1998) and GyfT or I1h1fT (Perez-Stable, 1996; Perez-Stable, 
1997). To our knowlegde these models do not show NE differentation as 
determined by CgA expression. 
The PC-346 model (van Weerden, 1996) developed at our institution 
and the CWR22 (Pretiow, 1993; Wainstein, 1994) xenograft model are 
unique, as they both relapse after androgen deprivation and androgen 
independent sublines, PC-3461 and CWR22R, respectively, could be 
generated. PC-3461 does not express CgA, and to our knowledge CWR22R 
does not express the NE phenotype. This strongly argues against a direct role 
of NE differentiation in progression of prostate cancer as these two 
progressive prostate cancer models do not show the NE phenotype observed 
in the PC-310 model. 
In present prostate cancer research, the androgen dependent human 
PC-310 xenograft model still remains a unique model for further studies on 
induction of NE differentiation following androgen deprivation both in vivo as 
well as in vitro. Our studies on the PC-310 model showed a clear induction of 
the regulated secretory pathway during androgen deprivation. In particular, 
the expression patterns of different markers like Sglll, 782, PC1 and PC-2 
implicate that in androgen deprived prostate cancer, the complex process of 
regulated secretion of different hormone peptides can be induced. Regulated 
secretion of POMC through this NE pathway might induce systemic effects. 
ACTH dependent Cushing's syndrome, which is a rare occurring disease in 
hormonally treated clinical prostate cancer, might then be a consequence 
(Matzkin, 1987). It is useful to study the long-term effects of androgen 
depletion on hormone dependent prostate cancer. PC-310, PC-295, PC-346 
and PC-82 are relevant androgen dependent models to further study the 
induction of NE differentiation and the regulated secretory pathway. In 
conclusion, the hypothesized role of NE cells in the progression of prostate 
cancer from the androgen dependent state to an androgen independent or 
hormone refractory state has not been supported by our observations in the 
androgen dependent prostate cancer xenograft models. Nevertheless, on the 
basis of our data a role of NE cells in the progression to androgen 
independent growth cannot be excluded. 
Hormone dependence, apoptosis and the role of the androgen 
receptor 
Hormone deprivation in the PC-310 model system induced apoptosis, 
NE differentiation and decreased proliferation (Chapter 4 and 5). Furthermore, 
there is a transient down-regulation of AR expression in vivo, giving an strong 
nuclear expression in approximately 50 % of PC-310 tumor residues after 
long-term androgen deprivation. Long-term androgen deprivation of the PC-
310 model leads to the formation of tumor residues consisting of mixed cell 
types of both NE differentiated and AR positive cells. After androgen 
deprivation, AR expression is transiently down-regulated in all androgen 
dependent models. At longer time intervals, AR is partly re-expressed in most 
of these models except for PC-295 and PC-329, as AR expression in the PC-
295 model completely disappeared. In two of the androgen independent 
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models, PC-374 and PC-3461, AR expression levels increased after androgen 
deprivation. The androgen independent xenografts PC-133, PC-135, PC-324 
and PC-339 never express the AR in either presence or absence of 
androgens. 
In vitro, the PC-310 model showed the temporal decrease of the AR 
only in the short-term androgen deprived cultures. In PC-310C cultures AR 
expression could not be detected by Western blot after 56 days of androgen 
deprivation, although the cells did express the AR up to 28 days after 
androgen deprivation (data not shown). This loss in expression may be 
explained either by induced NE differentiation of the AR positive cells or by 
loss of the cells through detachment of the AR positive cells from the culture 
flasks. Detachment of cells could be caused by defective cell-cell adhesion or 
by induction of apoptosis. Induction of apoptosis in the AR positive PC-310C 
cells means that the balance between cell cyle arresting proteins (p16, p53, 
p27 and p21) and apoptosis related proteins (Scl-2, Sax, Caspase 3 and 9, 
etc) has favoured the cells to undergo apoptosis. 
Androgen re-supplementation to the long-term androgen deprived PC-
310 tumor residues in the in vivo xenograft model clearly demonstrated that 
the non-NE AR positive tumor cells still had the capacity to proliferate upon 
androgen stimulation. This was associated with decreased p27kiP1 expression 
and consequently with rapidly increasing tumor volumes and high PSA 
production (Chapter 5). 
Many investigations are performed to study the potential role of the AR 
in progression of prostate cancer where the AR is being adapted, hyperactive, 
mutated or overexpressed (Culig, 1998; Gil-Diez de Medina, 1998). 
Constitutive high AR expression has been found in trans-urethral resection 
specimens of clinical hormone refractory tumors (van der Kwast, 1991), and 
decreased expression of the AR was noted during regression of hormonally 
treated prostate cancer (Gil-Diez de Medina, 1998). These results are in line 
with the observed high expression levels of the AR after long-term androgen 
depletion of PC-310 and temporal decrease in AR expression during PC-310 
tumor regression following short-term androgen withdrawal. 
Development of hormone refractory prostate cancer has been related 
to several causes like mutations or amplifications of the AR gene or direct 
stimulatory effects on the AR of the anti-androgens used. Recent studies have 
shown agonistic effects of the non-steroidal anti-androgen bicalutamide 
(Casodex), which directly led to withdrawal of the anti-androgen (Scher, 1996; 
Kelly, 1997; Wirth, 1997; Iversen, 1999). Different mechanisms of adaptation 
of AR pathway during androgen independent activation are under 
investigation. Mutations of the AR, AR gene amplifications or induction of anti-
apoptotic escape pathways (Scl-2, p53) may account for androgen 
independence of prostate cancer (Culig, 1998; Jenster, 1999). In particular, 
adaptation of the AR sensitive pathway has recently gained a lot of interest, 
e.g. involvement of the MAPK pathway (Hobisch, 1998; Jenster, 1999). 
Activation of PSA expression via androgen responsive elements (ARE's) in 
the PSA promotor region may be activated independent of androgens. One 
explanation offered in the literature is that secretory products of NE cells, e.g. 
GRP can activate this pathway. The AR might be either directly activated by 
GRP or indirectly via activation of the MAPK pathway (Culig, 1998). This kind 
of androgen independent activation of the AR, for instance by neuropeptides 
like GRP, IGF-1 (Chan, 1998) or cytokines like IL-6 cannot be excluded 
(Hobisch, 1998). 
In the PC-346 model, which also demonstrated the temporal down-
regulation in AR expression following androgen deprivation, this mechanism 
of androgen independent activation of the AR may be applicable, as different 
hormone refractory sublines of this model were recently developed (Van 
Weerden, personal communication). Allthough one of these independent (I) 
sublines, PC-3461, has an induced AR mutation that is known as the LNCaP 
mutation (Veldschoite, 1992), the other spontaneous AID sublines have a wild 
type AR. In the lalter cell lines, NE differentiation induced or alternative 
androgen independent activation of the AR might well play an important role. 
Androgen deprived prostate cancer models may initially contain heterogenous 
clones that will eventually result in the outgrowth of progressive androgen 
independent strains, like the independent cell lines after androgen depletion of 
the PC-346 model. We have clearly shown the formation of dormant tumor 
residues that contain both maturating NE cells and androgen sensitive, AR 
positive cells in the in vivo PC-310 model. Development of tumor dormancy 
during hormone therapy may well be the first step in developing hormone 
refractory prostate cancer. The development of hormone refractory prostate 
cancer might be the consequence of (in)direct mitogenic or innervating effects 
of NE differentiation on (dormant) tumor cells, as is believed to be the case in 
lung cancer (Cultitta, 1985; Sorokin, 1997), but this has yet to be proven in 
prostate cancer. In vitro, we have shown that prostate cancer cell lines can be 
stimulated to grow in the absence of androgens by neuropeptides, like GRP. 
However, we have not been able to observe androgen independent growth 
induced by NE growth factors in the PC-310 in vivo model. In conclusion, the 
PC-310 model did not progress as a consequence of induced NE 
differentiation or by expression of the AR in long-term androgen depleted PC-
310 tumor residues. 
Model of possible interactions in hormone deprived prostate 
cancer tumor residues 
Based upon the observations in the PC-310 model system (Chapters 4 
& 5), the in vitro studies (Chapter 3) and combined with data in literature, a 
model is proposed for interactions between the NE prostatic tumor cells with 
both the non-NE, AR positive tumor component on the one hand and with the 
surrounding stromal tissue compartment on the other under long-term 
androgen deprived circumstances (figure 2). Typical products of NE cells, like 
GRP, 5-HT, VIP, CT, PAMP and other related products like PAM and CgA 
may be secreted either constitutively or via the regulated secretory pathway 
(RSP). These secreted products will be partly transported from the tumor area 
by the blood stream to exert their growth modulating activity systemically. The 
secreted products can most likely exert local activity, which may be either 
autocrine or paracrine. For this kind of interactions, it is necessary that the 
non-NE cells express receptors for the secreted growth factors. Several 
stUdies have shown that prostatic tumor cells can express receptors for GRP, 
CT, VIP, 5-HT and other growth factors (Fischer, 1992; Reile, 1994; Shah, 
1994; Aprikian, 1996; Zamora, 1996; Wasilenko, 1997; Aprikian, 1998). So 
far, we did not consider the presence of such receptors. Receptor expression 
stUdies in both clinical prostate cancers and in the available human xenograft 
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models are mandatory, however. Paracrine interaction may result in 
stimulation of the non-NE, AR positive epithelial cells, e.g by GRP, VIP, and 
CT, as has been shown in a study of in vitro prostate cancer cell lines 
(Chapter 3). This stimulatory role of bombesin or other members of the GRP 
family in prostate cancer growth has already been shown by others (Aprikian, 
1998). In lung cancer, the positive relation of NE cell maturation with 
mitogenesis and innervation has further been shown by Sorokin et al 
(Sorokin, 1997). Other products of NE cells, like bFGF, PAMP and VEGF, 
may have a paracrine effect on stromal fibroblasts and the endothelial 
compartment. Vice versa, stromal fibroblasts can produce growth factors, like 
EGF, TGF-alpha and -beta, and PTHrP, which may playa role in progression 
of prostate cancer (Cunha, 1994; Desruisseau, 1996; Lee, 1996; Culig, 
1997a; Kooistra, 1997; Yang, 1997; Lamm, 1998). The relationship between 
the three main cell components present in the prostatic tumor residues could 
be seen as a cellular triangle, if indeed fibroblastic growth can be induced by 
NE growth factors. In this cellular triangle, fibroblast-derived growth factors, 
like EGF, TGF-a and -p and PTHrP can act on both the NE and the non-NE 
epithelial cells (Cramer, 1996; Peehl, 1996a; Peehl, 1997). Continuous activity 
of this cellular triangle might eventually lead to prostate cancer progression. 
Alternatively, cytokines supplied via the blood, like IL-1alpha/beta and IL-6, 
hormonal peptides or growth factors, like IGF-1 may also affect the prostatic 
tumor residues, e.g. by tumor maintenance or induction of proliferation. In 
theory, the proposed model may offer an explanation for the growth of non-NE 
tumor cells in the absence of androgens. Now, we have to test this in 
xenografts in vivo and in vitro if this is really true. 
Functional implication of NE cells in the progression of prostate 
cancer 
This thesis represents the experimental data of both in vivo, i.e. in 
human prostate cancer xenografts, and in vitro studies on the kinetics and the 
possible role of tumor cells with neuroendocrine (NE) differentiation in 
prostate cancer during androgen deprivation. In addition, the NE related 
markers, PAMP and PAM were studied in experimental models as well as 
evaluated for their prognostic significance in clinical prostate cancer 
specimens with long-term fallow-up. NE cells normally represent a relatively 
small part of the prostatic epithelium and are well recognized by their 
frequently displayed dendritic processes which may extend to neighbouring 
tumor cells (di-Sant'Agnese, 1992b). NE differentiated cells are found in 70% 
of all clinical prostate cancer specimens. In our laboratory two experimental 
androgen dependent, NE differentiated in vivo models, PC-295 and PC-310, 
were available. 
Since androgen deprivation in clinical prostate cancer (Van de 
Voorde, 1994; Guate, 1997; Jiborn, 1998) and in human xenografts ((Noordzij, 
1996), this thesis) have shown to result in induced NE differentiation, the role 
of NE tumor cells in the progression of androgen responsive prostate cancer 
to hormone refractory tumors remains a major topic of discussion. From most 
clinical studies on the prognostic value of NE differentiation it has been shown 
that CgA expression does not have a prognostic value. However, patients 
treated with TURP had a better prognosis when they did not have a high 
expression of CgA in the TURP specimen. Our results from the expression of 
new NE markers revealed a tendency towards higher tumor stage and more 
clinical progression in the higher PAM expressing tumors. In conclusion, our 
data cannot define a role of NE cells in progression of prostate cancer from 
the androgen dependent stage to the hormone refractory stage. 
Concluding Remarks 
Androgen deprivation of the human prostate cancer xenograft models, 
PC-295 and PC310 induces proliferation independent NE differentiation. 
Long-term androgen deprivation of the PC-310 model results in a 
process of NE cell maturation, leading to the sequential production of both 
peptide hormones via a regulated secretory pathway as well as the secretion 
of grow1h modulating neuropeptides. 
The temporal down-regulation of AR expression under androgen 
deprivation in the PC-31 0 model as well as in PC-346, PC-82, PC-329 reflects 
the AR expression pattern found in clinical specimens of regressed prostate 
cancer, under endocrine therapy. This indicates that these models reflect (in 
part) the behaviour of clinical prostate cancer 
Induction of NE differentiation and subsequent NE cell maturation in 
the PC-310 model after long-term, i.e. 6 months, androgen deprivation does 
not lead to the initiation of androgen independent grow1h. Thus, our data did 
not provide evidence that NE differentiation plays an important if any role in 
progression of prostate cancer. However, referring to the clinical situation, the 
time between initiation of hormonal treatment and final clinical progression in 
prostate cancer patients ranges from 12 to 36 months. Thus, in periods of 
androgen deprivation longer than that of 6 months studied for PC-310 until 
now, there is still a long traject in which NE cells might playa relevant role in 
progression of prostate cancer. In addition, it cannot be excluded that our 
xenograft models are not the most appropriate tool to study transition to 
androgen independence under influence of neurosecretory products. 
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Future directions for NE related prostate cancer research 
The PC-310 model did not show progression as a consequence of 
induced NE differentiation or by expression of the AR in long-term androgen 
depleted PC-310 tumor residues. Rather, proliferation was completely 
inhibited and the volumes of the long-term androgen deprived tumor residues 
seem to be stable. Thus, one might even argue that induction of NE 
differentiation in prostatic tumors could be a way to stop androgen dependent 
tumors from uncontrolled growth. Induction of NE differentiation in androgen 
dependent tumors like the PC-310 model could then result in growth arrest, 
tumor regression and less tumor burden for the patient. Following this, it might 
be of interest to develop alternative strategies to induce NE differentiation in 
prostate cancer. Besides androgen deprivation, there are numerous other 
methods to induce NE differentiation in prostate cancer, for example by 
application of dibutyryl-cyclicAMP, phenylacetate, vitamin A and D. At the 
department of Urology, we have available both the in vitro models as well as 
in vivo xenograft models to study treatment of prostate cancer with different 
concentrations of these agents in time. The detailed kinetic studies that were 
performed in the PC-310 model provided knowledge of a complete set of NE 
markers, including CgA and the time related markers of the RSP which can 
now be used for characterization of the degree of induced NE differentiation 
by these substances. 
As CgA and AR did not colocalize in any PC-310 tumor cell studied, the 
presence of the AR positive cells in prostatic tumor residues adjacent to 
induced NE differentiated cells should not be neglected. The fact that the AR 
is expressed in 50% of the residual tumor cells makes the PC-310 model a 
useful model to study the upregulation of the AR sensitive pathway after the 
temporal decrease which might eventually lead to tumor progression. As we 
did not observe progression in the PC-310 model during six months of 
androgen deprivation, it may be possible that the AR positive PC-310 tumor 
cells lack the molecular pathways to stimulate the AR sensitive pathway. 
Adaptation of the AR sensitive pathway to the androgen deprived situation 
might also require longer periods of androgen deprivation than six months. 
The production of specific neuroactive substances, like 5-HT and GRP, 
occurred rather late during NE cell maturation. Such specific products of fully 
maturated NE cells might be essential to induce growth of AR positive PC-310 
tumor cells. Androgen withdrawal experiments in the PC-310 model system 
should be performed that exceed six months to study potential long-term 
effects of NE cell maturation on induction of androgen independent growth. 
In view of prostate cancer progression, three androgen dependent 
xenograft models are at our disposal displaying different properties of 
hormonally treated clinical prostate cancer, i.e. progression of AR positive 
tumors (PC-346), induction of NE differentiated tumor residUes (PC-310) and 
formation of androgen sensitive, AR positive, tumor residues (PC-82). The 
tumor cells in the PC-346 model, which develop into androgen independent 
cells should be characterized in detail. By using the androgen dependent 
models in co-transplantation studies, i.e. transplantation of a mixed cell 
population of two xenograft models, we might be able to initiate progression of 
the two growth arrested models, PC-310 and PC-82. Detailed kinetic studies 
with comparable long-term androgen deprivation as has been done for PC-
310 (Chapter 4) should be performed with PC-82 and PC-346 bearing mice to 
study the behavior of these tumors during long-term androgen deprivation. 
Androgen withdrawal in all three tumor models induces a temporal decrease 
in AR expression. In PC-82 and PC-310, p27hlP, a cell cycle growth arrest 
marker, is highly expressed and MIB-1 expression decreases rapidly to zero, 
whereas in the PC-346 model a low level of proliferation continued after 
androgen deprivation. If the induction of NE differentiation in PC-310 does 
play a role in inducing progression, we might find androgen independent 
growth during co-transplantation of PC-82 and/or PC-346 with PC-310 under 
androgen deprived conditions. In all experimental designs expression of 
different cell cycle markers, AR, CgA, different NE growth modulating 
peptides, proliferative markers, and factors involved in the MAPK pathway are 
relevant to be studied. 
The induction of NE differentiation by androgen deprivation and the 
mitogenic products released after long-term depletion indicate the possibility 
of MAPK activity induction in neuropeptide receptor positive tumor cells. Long-
term mitogenic and growth inhibiting studies in the PC-346, PC-310 and PC-
82 xenograft models should be performed under androgen deprived 
conditions. Therefore, these tumors should carefully be studied for the 
presence of neuropeptide receptors. Both in vivo and if possible in vitro 
studies will yield information as to whether NE growth factors can playa role 
in prostatic tumor residues by initiating growth induction of the AR positive 
non-NE cells. Large groups of tumor bearing mice should be studied for 
growth modulating effects by different concentrations of GRP and other 
neuropeptides under androgen deprived conditions and over different periods 
of time. 
Clinically, a large study could be performed on prostate cancer patients 
that are undergoing hormonal treatment followed by either a consecutive 
radical prostatectomy or not. The main objective of this study is to examine 
whether NE differentiation is induced, whether NE growth factors are 
produced and whether these growth factors can playa role in clinical prostate 
cancer progression. Tumor mass and level of NE differentiation can be 
determined by measuring plasma levels of PSA and CgA. The relation 
between AR expression, induction of NE differentiation and subsequent 
expression of late evolving NE markers like 5-HT and GRP should be studied 
as well as the presence of receptors for NE growth factors on residual tumor 
cells. Patients should be followed for tumor progression, disease related 
death with respect to differences in therapy and in relation to the induced 
levels of NE differentiation. 
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Summary 
Assessing growth modulatory effects of neuropeptides in prostate 
cancer models in vitro and in vivo, and studying the kinetics of induction of 
NE differentiation upon androgen withdrawal in human prostate cancer 
xenografts and in vitro cell lines has contributed to a better understanding of 
the role of NE cells in androgen deprived prostate cancer. 
Experimental work described in Chapter 3 demonstrated that cell 
proliferation of the prostatic cancer cell lines, LNCaP, DU-145, PC-3 and PC-
346C under the condition of androgen depletion can be modulated by 
neuropeptides, like serotonin, gastrin releasing peptide (GRP), calcitonin 
and vasoactive intestinal peptide which are known to be produced by 
neuroendocrine cells. The way the four neuropeptides affected cell growth 
differed from one cell line to the other irrespective of their androgen 
dependent status. Although androgen independent PC-3 cells did not 
respond to exogenously added GRP, results of incubation with the anti-GRP 
monoclonal antibody 2A 11 (MoAb 2A 11) did show that PC-3 proliferation is 
strongly dependent on GRP as 3H-thymidine incorporation dropped by 50%. 
Probably, GRP is produced endogenously by this prostate cancer cell line. 
MoAb 2A 11 is a strong and specific inhibitor of GRP-induced proliferation, 
e.g. in GRP producing cell lines, in prostate cancer, as was shown before for 
small cell lung cancer cell lines. In conclusion, GRP is a potent NE growth 
factor for prostate cancer cell lines that acts specifically under androgen 
deprived conditions via induction of the second messenger cAMP in both 
androgen independent (DU-145, PC-3) and androgen dependent (PC-346C) 
cells. 
We established FGC-DCC, an androgen independent derivative of 
LNCaP after long-term androgen deprivation. The parental LNCaP and 
FGC-DCC subline show a clear difference in their androgen responsiveness 
status, which showed the charateristic biphasic relation for DHT in LNCaP 
whereas FGC-DCC cells did not respond to increasing DHT concentrations, 
indicating that FGC-DCC cells grow androgen independently. The FGC-DCC 
cells have a neuronal appearance, produce low levels of P8A and show an 
induction of BcI-2 expression shortly after androgen withdrawal. Neither the 
LNCaP nor the FGC-DCC cell line showed any expression of the NE marker 
CgA or a significantly increased expression of basal 8gll1 or N8E levels. In 
spite of their characteristic neuronal morphology, FGC-DCC is not a NE-
differentiated cell line. like for the PC-3 cells, MoAb 2A 11 decreased 
proliferation of FGC-DCC cells. FGC-DCC cells possibly have adjusted to an 
autocrine growth pattern after androgen suppression, by producing growth 
factors like GRP endogenously. 
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Studying NE differentiated in vivo models like PC-295 and PC-310 has 
contributed to implicating new functions for NE differentiation in clinical 
prostate cancer. In Chapter 2, we showed the effects of short-term androgen 
deprivation in the completely androgen dependent xenograft model PC-295. 
Upon androgen withdrawal, proliferation and PSA serum levels decreased 
rapidly to zero. AR expression is downregulated and there is a strong 
induction of apoptosis, which resulted in near complete regression of the 
tumor volume. Induction of NE differentiation was a proliferation independent 
process and independent of tumor volume changes. After longer periods of 
androgen deprivation, the PC-295 model could no longer grow in the 
presence or absence of androgens. 
In Chapters 4 and 5 we have shown that the hormone depletion of the 
PC-310 model resulted in induction of apoptosis and p27",P1 expression, 
decreased proliferation and PSA serum levels, and temporal down 
regulation of the androgen receptor (AR). Like in the PC-295 xenograft, 
proliferation independent induction of NE differentiation was observed in PC-
310 from 5 days post-castration on. This was shown by increased 
expression of CgA and by the time related induction of the secretogranins, 
7B2 and Sglll and the processing enzymes, PC1, PC2 and PAM, factors all 
belonging to the regulated secretory pathway (RSP). The time dependent 
induction of these markers in the PC-310 NE cells showed that they possess 
an active RSP and demonstrate the maturation inside the secretory 
granules. Additionally, the serum CgA levels were clearly increased post-
castration, which shows that the PC-310 NE cells can actually secrete 
neuropeptides and secretogranins. 
When we looked at the behavior of the PC-310 model during long-term 
castration with regard to NE cell differentiation and maturation, the 
production of growth regulatory peptides or hormones and the expression of 
the androgen receptor, we found additional markers for the maturation of the 
NE cells. NE growth factors, like 5-HT and GRP are expressed after a 
relatively long period of androgen deprivation. Expression of GRP and 5-HT 
was initially found in a small part of the NE cells at 14 and 21 days post-
castration, but became evidently expressed 154 days post-castration. PAM 
expression is also induced in the NE cells at 84 and 154 days post-
castration. This late NE specific expression points at a direct role in 
amidation of neuropeptides during the maturation of NE cells. The 
expression of VEGF co-localized in the NE cells and was induced shortly 
after the expression of CgA and Sgili. 
The in vivo PC-310 xenograft model regresses after androgen 
deprivation, but not as strong as the PC-295 model. Between 14 and 21 
days, the tumor volume is stabilized at 30-40 % of the initial tumor volume. 
During longer periods of androgen deprivation the tumor residues remains 
constant and the PC-310 model has become dormant. In these dormant 
tumors there are two main cell types, which are the AR positive cells and the 
NE cells. Both cell types may playa role in the formation of the PC-310 
tumor residues. On the one hand, the AR positive cells remain androgen 
sensitive as shown by tumor regrowth upon androgen reconstitution. On the 
other hand, these non-NE AR postive cells might be the tumor cells that 
escape androgen wtihdrawal by means of different hypothetical pathways, 
through mutations of the AR, altered specificity of the AR or ligand 
independent activation of the AR sensitive pathway. 
Chapter 6 shows expression patterns of the NE markers, PAM and 
PAMP in in vivo studies of the experimental PC-310 model as well as in 
clinical prostate cancer patients. Induction of both markers clearly correlated 
with induction of NE differentiation in the PC-310 model. In a group of 
immunohistochemically evaluated specimens of prostate cancer patients, no 
strong correlation of PAM and PAMP expression was observed with either 
tumor stage nor with clinical progression, although there was a tendency 
towards higher expression of PAM and PAMP in late stage tumors, i.e. at 
higher gleason sum scores. 
With the in vitro studies androgen independent grow1h of prostatic 
cancer cell lines was shown to be induced either by growth modulating 
neuropeptides or by androgen deprivation of an androgen dependent cell 
line (LNCaP) which lead to the development of an androgen independently 
growing cell line (FGC-DCC). 
Induction of NE cell differentiation and maturation in the PC-310 model 
by androgen deprivation does not lead to androgen independent grow1h. Our 
data did not provide evidence that NE cell differentiation plays an important if 
any role in progression of prostate cancer. However, the time between 
initiation of hormonal treatment and clinical progression in prostate cancer 
ranges from 12 to 36 months. Thus, androgen deprivation of the PC-310 
model for periods longer than 6 months might still yield a role of NE cell 
differentiation in prostate cancer progression. 
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Samenvatting 
In dit proefschrift staat de rol van neuroendocriene (NE) cel 
differentiatie in prostaatkanker centraal. NE cellen zijn aanwezig in norma Ie 
prostaatklierbuizen en in veel prostaatkankers. Producten die door deze 
cell en worden uitgescheiden, ook wei neuropeptiden genaamd, kunnen 
mogelijk de groei van nabij gelegen non-NE prostaatkankercellen 
moduleren. Voor het bestuderen van de groeimodulerende effecten van 
neuropeptiden en het bestuderen van NE differentiatie werd gebruik 
gemaakt van veschillende experimentele prostaaltumormodellen. Deze 
modellen omvalten enerzijds prostaatkankercellen die gekweekt worden in 
weefselkweek flesjes (in vitro onderzoek) en anderzijds androgeen-
afhankelijke humane prostaattumoren die onderhuids groeien in 
immuundeficiente muizen (in vivo onderzoek). Het zowel in vitro en in vivo 
vaststellen van de groeimodulerende effecten van neuropeptiden in 
prostaatkankermodellen en de studies naar de kinetiek van het induceren 
van NE differentiatie heeft bijgedragen tot een beter beg rip van de rol van 
NE cell en in prostaatkanker na androgeen deprivatie. 
Experimenteel werk beschreven in hoofstuk 3 laat zien dat proliferatie 
van prostaatkankercellijnen, LNCaP, DU-145, PC-3 en PC-346C 
gemoduleerd kan worden door neuropeptides, nl. serotonine (5-HT), 
bombesine (GRP), calcitonine (CT) en vasoactief intestinaal peptide (VIP) 
onder condities van androgeen deprivatie. De manier waarop de 
neuropeptides de celgroei beinvloeden veschilt tussen de 4 ceillijnen 
onafhankelijk van de status van androgeengevoeligheid. Monoclonaal 
antibody 2A 11 (MoAb 2A 11) is een specifieke remmer van door GRP-
geinduceerde proliferatie zoals studies in kleincellige longkankercellijnen 
hebben aangetoond. Hoewel de androgeen-onafhankelijke cellijn PC-3 niet 
reageert op exogeen toegevoegd GRP, tonen incubaties met het anti-GRP 
MoAb 2A11 aan dat proliferatie van PC-3 afhankelijk is van GRP. Hieruit kan 
afgeleid worden dat GRP wordt geproduceerd door deze 
prostaatkankercellijn. Concluderend kan gezegd worden, dat GRP in 
potentie een NE groeifactor is voor prostaatkankercellijnen welke specifiek 
werkt via intracellulaire inductie van cAMP in zowel androgeen-
onafhankelijke (DU-145, PC-3) als androgeen-afhankelijke (PC-346C) 
prostaatkankercellen. 
Een androgeen-onafhankelijke cellijn, FGC-DCC is ontstaan door 
langdurige androgeen deprivatie van kweken van LNCaP cellen. LNCaP en 
FGC-DCC cellen vertonen een groot verschil in androgeengevoeligheid. 
Zoals eerder beschreven toont LNCaP de karateristieke bi-fasische 
groeicurve voor DHT, terwijl FGC-DCC cellen niet reageren op toenemende 
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DHT concentraties, hetgeen aangeeft dat FGC-DCC cellen onafhankelijk 
van androgenen groeien. Morfologisch lijken FGC-DCC cellen op 
zenuwcellen, ze produceren in tegenstelling tot de oorspronkelijke LNCaP 
geringe hoeveelheden prostaat specifiek antigeen (P8A) en vertonen Bcl-2 
expressie na androgeen onUrekking. Noch LNCaP, noch FGC-DCC cellen 
laten expressie zien van de NE specifieke marker chromogranine A (CgA) of 
een significante toename van de basale niveaus van secretogranine III 
(8glll) of neuron specifiek enolase (N8E), ondanks hun karakteristiek 
neuron ale uiterlijk. Evenals in PC-3 cellen, is MoAb 2A 11 in staat om de 
proliferatie van FGC-DCC cellen te remmen. Mogelijk hebben FGC-DCC 
cellen na androgeen deprivatie het vermogen tot autocriene groeistimulatie, 
door endogene productie van groeifactoren zoals GRP. 
Het bestuderen van NE gedifferentieerde in vivo modellen als PC-295 
en PC-310 heeft bijgedragen tot een verdere opheldering van mogelijke 
functies van NE differentiatie in klinische prostaatkanker. In hoofdstuk 2 
worden de effecten beschreven van kortdurige androgeen onUrekking in het 
prostaatkanker xenotransplantatie model PC-295, dat voor groei volledig 
afhankelijk is van androgenen. Proliferatie en P8A serum niveau's dalen 
snel tot nul na androgeen deprivatie. Androgeen receptor (AR) expressie is 
sterk verlaagd en er is een aanzienlijke inductie van geprogrammeerde 
celdood of apoptose. Dit resulteert in een bijna complete regressie van de 
tumor. De inductie van NE differentiatie bleek een proliferatie onafhankelijk 
proces. Hergroei van PC-295 model is niet induceerbaar in aan- of 
afwezigheid van androgenen na langdurige periodes van androgeen 
deprivatie. Oftewel, in dit model zijn NE cellen niet in staat om de tumor te 
doen groeien in afwezigheid van androgenen. 
Hoofdstukken 4 en 5 omvaUen gegevens die laten zien dat hormoon 
deprivatie in het PC-310 model resulteert in inductie van apoptose en cel 
cyclus blokkade, aangetoond door verhoogde p27k;P1 expressie, een afname 
van proliferatie en P8A serum niveaus, en een tijdelijke verlaagde AR 
expressie. Evenals in PC-295 wordt in het PC310 model een proliferatie 
onafhankelijke inductie van NE differentiatie waargenomen vanaf 5 dagen 
na androgeen deprivatie. Dit werd duidelijk aan de hand van toegenoemen 
CgA expressie en, in verloop van de tijd, een inductie van achtereenvolgens 
de secretogranines, 7B2 en 8glll, de prohormoon enzymen, prohomoon 
convertase 1 en 2 (PC1, PC2) en het peptidyl-glycine alfa-amiderend mono 
oxygenase (PAM). Deze laatste factoren zijn geassocieerd met de 
gereguleerde secretie route (R8P). De tijdsafhankelijke inductie van deze 
specifieke markers in NE cellen van het PC-310 model laat zien dat die 
cellen over een actieve R8P beschikken en demonstreren het rijpingsproces 
binnen de secretoire granulas. Overigens werden in de xenotransplantaat 
dragende muizen ook sterk toegenomen CgA serum niveaus waargenomen 
hetgeen erop duidt dat NE cellen in het PC-310 model neuropeptiden en 
secretogranines uit kunnen scheiden. 
Vervolgens werd gekeken naar het gedrag van het PC-310 model 
gedurende langdurige androgeen deprivatie. Dit werd bestudeerd met 
betrekking tot NE cel differentiatie en rijping, de productie van 
groeimodulerende peptiden of hormonen, en de expressie van de AR. Er 
bleken additionele specifieke markers voor rijpende NE cellen te zijn. 
Vasculair endothelium groeifactor (VEGF) kwam in NE cell en tot expressie 
en werd ge'induceerd kort na de expressie van CgA en 8glli. NE 
groeifactoren, zoals 5-HT en GRP komen pas tot expressie na een relatief 
lange periode van androgeen deprivatie. De expressie van GRP en 5-HT 
was aanvankelijk na 14 en 21 dagen beperkt tot enkele NE cellen, maar 
kwam met name sterk tot expressie na langere period en van androgeen 
deprivatie (154 dagen). Ook PAM kwam specifiek en relatief laat (84 en 154 
dagen na androgeen deprivalie) tot expressie in NE cellen. Deze relalief late 
NE specifieke PAM expressie leek te duiden op een directe rol van PAM in 
de amidatie van neuropeptiden gedurende de rijping van NE cell en. 
Hoewel in vivo PC-310 xenotransplantatie tumoren in regressie gaan 
na androgeen deprivatie, geldt dit in veel mindere mate als voor het PC-295 
model. Tussen 14 en 21 dagen na androgeen deprivatie stabiliseert het 
tumor volume zich rond 30-40 % van het begin volume. Gedurende langere 
perioden van androgeen deprivatie blijlt het volume van de tumorresiduen 
constant. In deze 'slapende' (dormant) tumoren komen twee tumorceltypes 
v~~r. Oil zijn de AR positieve cell en en de NE cellen. Aan de ene kant blijven 
de resterende AR positieve cellen androgeen gevoelig, zoals blijkt uit tumor 
hergroei na opnieuw toedienen van androgenen. Aan de andere kant 
kunnen deze niet-NE, AR postieve cellen de tumorcellen zijn welke 
ontsnappen aan langdurige androgeen deprivatie, Hieraan kunnen 
verschillende mechanismen ten grondslag Iiggen: door mutaties van de AR, 
veranderde specificileit van de AR of androgeen onafhankelijke activatie van 
AR afhankelijke groeistimulatie. 
Hoofdstuk 6 beschrijlt de expressie patronen van twee NE markers, 
PAM en proadrenomedulline-N-terminaal peptide (PAMP) in zowel in vivo 
studies van het experimentele PC-310 model alswel in tumoren van 
prostaatkankerpatienten. In het PC-310 model komt het expressiepatroon na 
inductie van be ide markers overeen met die van NE differentiatie gebaseerd 
op CgA expressie na androgeen deprivatie. In een groep tumoren van 
prostaatkankerpatienten vinden we geen sterke correlatie van PAM en 
PAMP expressie met hetzij tumorstadium of klinische progressie. Er Iijkt een 
tendens te zijn voor hogere expressie van PAM en PAMP in slechter 
gedifferentieerde prostaattumoren. 
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Uit de in vitro studies bJijkt dat androgeen onafhankelijke groei van 
prostaatkankercellijnen ge'(nduceerd kan worden door enerzijds 
groeimodulerende neuropeptides en anderzijds door androgeen deprivatie 
van een androgeen afhankelijke cellijn (LNCaP) hetgeen leidt tot de 
ontwikkeJing van een androgeen onafhankeJijk groeiende cellijn (FGC-DCC). 
Inductie van NE eel differentiatie en het daarop volgende rijpingsproces 
in het PC-310 model door androgeen deprivatie leidt niet tot androgeen 
onafhankeJijke groei van dit model. Uit de huidige stu die is niet gebleken dat 
NE eel differentiatie een directe rol speelt in progressie van prostaatkanker. 
Echter, de tijd die verstrijkt tussen start van hormonale behandeJi~g en 
kJinische progressie bij prostaatkankerpatienten varieert van 12 tot 36 
maanden. Dus androgen onttrekking van het PC-310 model gedurende 
perioden langer dan de 6 maanden die tot op heden werden bestudeerd zou 
alsnog kunnen leiden tot progressie van deze tumor als gevolg van 
androgeen-onafhankeJijke groei. In dat geval kan een mogeJijke rol van NE 
cellen in progressie van prostaatkanker in meer detail worden bestudeerd. 
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